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Among patients presenting acutely with ischaemic stroke who are being considered 
for intravenous thrombolysis, prompt brain imaging is used to exclude contra-
indications to treatment (chiefly haemorrhagic stroke or other conditions mimicking 
stroke) rather than to identify which patients are more or less likely to benefit from 
thrombolysis. For example, it is unclear whether the presence or absence of arterial 
obstruction on imaging should be used to guide thrombolysis treatment decisions.  
In this thesis I explore methods of imaging arterial patency among patients 
presenting acutely with ischaemic stroke and look for associations between these 
early imaging findings, response to intravenous thrombolysis and functional outcome 
six-months after stroke onset. I primarily use data from the Third International Stroke 
Trial (IST-3), the largest ever randomised-controlled trial testing the use of 
intravenous alteplase for the acute treatment of ischaemic stroke.  
I begin by summarising the main features of stroke, covering techniques for imaging 
the brain and for imaging arterial patency, and post-stroke outcomes. Next I describe 
two literature reviews which I compiled to increase my understanding of the topic 
with particular reference to imaging arterial patency. This is followed by a summary 
of IST-3. Then I describe the general methods I used to address my thesis aims 
exploring relationships between imaging characteristics of arterial patency, treatment 
with intravenous alteplase and functional outcome after ischaemic stroke.  
Specifically, I investigated the following imaging features: 
 The hyperattenuating artery sign (HAS), which is a non-contrast enhanced 
CT finding thought to be indicative of acute arterial obstruction by thrombus 
or embolus 
 Arterial patency or obstruction as demonstrated using contrast enhanced CT 
and MR angiographic imaging.  
In addition to providing better characterisation of the HAS and a better 
understanding of how angiography helps to assess ischaemic stroke patients, I found 
that arterial obstruction (however this is identified on imaging) is associated with 
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more severe stroke at baseline and worse functional outcome six months after stroke. 
I also prove that intravenous alteplase is effective in the presence of arterial 
obstruction, counter to a widely held concern that it may not be effective in this 
context. Most of my work has been published in peer reviewed journals.  
My work should give front line clinicians greater confidence to use intravenous 
alteplase for the treatment of ischaemic stroke associated with arterial obstruction on 
imaging, but more work is needed to better understand the implications of apparently 
normal arterial patency on imaging among patients with ischaemic stroke. 
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The main aims and objectives of the work contained within this thesis are to: 
1) Quantify the prevalence and observer reliability of the Hyperattenuating Artery Sign 
(HAS) on CT performed for the initial imaging assessment of patients with suspected 
ischaemic stroke 
2) Determine how intravenous alteplase affects HAS and whether the presence or 
absence of HAS influences the response to intravenous alteplase and outcome and 
whether the characteristics of HAS such as attenuation, location and extent are 
important 
3) Calculate the sensitivity and specificity of HAS for arterial obstruction  
4) Quantify observer reliability for the assessment of CT Angiography (CTA) performed 
routinely as part of the initial CT imaging assessment of patients presenting with 
ischaemic stroke  
5) Determine if the addition of CTA to standard plain CT improves ischaemic stroke 
detection, and prognosis prediction, by CT when performed as part of the initial 
imaging assessment and determine how much extra time is needed to perform CTA in 
this context 
6) Determine whether the presence or absence of arterial obstruction on angiography 
performed acutely after ischaemic stroke influences the response to intravenous 
alteplase and outcome and whether characteristics of obstruction such as location, 
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Chapter 1 Introduction and Background 
 
1.1 Aetiology of Stroke 
Stroke is a medical emergency which is caused by disruption of blood supply to the 
brain and leads to a focal neurological deficit. There are two major causes of blood 
supply disruption. The majority of strokes are ischaemic (approximately 80%) and 
most of these relate to interruption of arterial blood flow to the brain; ischaemic 
stroke secondary to venous insufficiency is much less common.  Haemorrhagic 
stroke accounts for the remaining 20% and denotes bleeding into the brain (to be 
differentiated from bleeding around the brain, i.e. subarachnoid haemorrhage).   
The aetiologies of ischaemic and haemorrhagic stroke are usually quite different, but 
ischaemic strokes are often complicated by secondary haemorrhagic transformation.  
In general, large artery ischaemic stroke occurs in the presence of an intra-arterial 
thrombus or embolus.  Occlusive atherosclerotic vascular disease represents the 
major underlying pathology.  This can be further divided into cardioembolic (for 
example, cardiac emboli arising secondary to atrial fibrillation or valvular heart 
disease) and atherothromboembolic causes (thrombus or embolus developing from 
atheromatous plaques of the extra and/or intracranial arteries). Hypertension, 
hypercholesterolaemia, diabetes and smoking act as major risk factors for the 
development of atherosclerotic disease.  Haemorrhagic stroke can occur secondary to 
an underlying vascular abnormality such as aneurysm, amyloid angiopathy or venous 
sinus thrombosis or in the presence of medicinal anticoagulation (e.g. warfarin); 
hypertension is also a major risk factor for haemorrhagic stroke.  Less commonly, 
both ischaemic and haemorrhagic stroke can occur secondary to a variety of 
neurological diseases including vasculitis, CADASIL (Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), 
Moyamoya syndrome, Sneddon’s syndrome, MELAS (Mitochondrial 
Encephalomyopathy Lactic Acidosis and Stroke-like episodes). 
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1.2 Stroke Prevalence 
Stroke is a major health concern worldwide but it is a particular problem in less 
developed countries where there are increased risk factors (including vascular risk 
factors and exposure to pollution
1;2
).  But even in developed nations stroke remains a 
significant concern among our increasingly aged populations.  Recent figures from 
the World Health Organization show that in the UK, cerebrovascular disease 
(predominantly stroke but includes subarachnoid haemorrhage from aneurysmal 
rupture) causes approximately 10.6% of all deaths and has a death rate of 45.6 per 
100,000 of population.  Table 1-1 compares world rankings for death rate (lower 
death rates at the top) from cerebrovascular disease for selected countries, the UK is 
placed 34th; the worldwide median death rate is 101.8 per 100,000 of population.
3
 
Table 1-1 Comparison of global death rates from cerebrovascular disease (predominantly 
stroke) for selected countries 
Rank Country 
Death Rate per 
100,000 Population 
1 Seychelles 25.0 
2 Canada 25.7 
3 Switzerland 26.5 
4 Israel 26.6 
5 Monaco 27.8 
6 France 27.9 
7 United States 30.4 
8 Bahrain 30.8 
9 Austria 31.3 
10 Australia 32.6 
 
18 Ireland 36.0 
 
22 Germany 37.5 
 
26 Italy 41.4 
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28 Japan 42.2 
 
34 United Kingdom 45.6 
 
101 India 108.0 
 
168 China 156.5 
 
190 Russian Federation 228.0 
 
1.3 Clinical Presentation of Stroke 
Disruption of intracranial blood supply in stroke reduces delivery of oxygen and 
other essential nutrients, particularly glucose, to brain cells. Deprived of oxygen and 
glucose, neural tissue ceases to function almost immediately leading to loss of 
normal body functionality. Due to the standardised routes of blood supply to the 
human brain and the commonality of certain aetiologies (especially acute middle 
cerebral artery occlusion), the loss of neural function in stroke often results in facial 
and/or limb paresis and sensory loss, deficits in cognition and problems 
understanding and producing speech, but clinical presentation is variable (see Table 
1-2). Cell death follows shortly thereafter, potentially within minutes of the 
disruption to blood supply; cell death can be postponed or avoided if there are 
alternative routes for blood delivery - i.e. as collateral supply - but such vascular 
redundancy may only offer a temporary reprieve. Treatments for stroke therefore, 
aim to restore the primary blood supply before neuronal cells die and deficits in body 
functionality become permanent. 
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Table 1-2 Clinical presentation of stroke 
Ischaemic Stroke 
Middle Cerebral Artery 
(MCA) occlusion 
Total occlusion: 
 Hemiparesis (arm > leg) 
 Hemisensory loss 
 Aphasia (if dominant hemisphere) 
 Conjugate eye deviation 
 Hemianopia 
Partial (branch) occlusion: 
 Upper branch occlusion – hemiparesis, hemisensory 
loss, expressive dysphasia 
 Lower branch occlusion – receptive dysphasia 
 Small cortical branch occlusion – isolated cortical 
signs 
 Striatocapsular – motor and sensory loss 
Anterior Cerebral Artery 
(ACA) occlusion 
 Hemiparesis (leg > arm) 
 Executive dysfunction 
 Disinhibition 
 Lack of insight 
Posterior Cerebral Artery 
(PCA) occlusion 
 Hemianopia (cortical blindness if bilateral) 
 Memory impairment 
Large vessel cortical 
infarct 
Following occlusion of large cerebral artery branches (i.e. 
MCA, ACA, PCA), the following cortical symptoms & signs 
are common:  






 Lateral medullary syndrome 




Lacunar infarct Absence of cortical signs with unilateral weakness or sensory 
loss of face and/or limbs, the following are common: 
 Pure motor hemiparesis 
 Sensorimotor hemiparesis 
 Pure sensory stroke 
 Ataxic hemiparesis 
Borderzone ischaemia Following a global fall in perfusion pressure (e.g. during 
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cardiac arrest), the regions between major arterial territories 
can be ischaemic. Symptoms & signs include: 
 Behavioural abnormality 
 Memory impairment/ amnesia 
 Complex visual abnormalities 
Transient Ischaemic Attack 
(TIA) 
Can present like and precede any of the other ischaemic stroke 
syndromes listed above but common TIA symptoms include: 




 Facial or tongue numbness  
 Diplopia 
Haemorrhagic Stroke 
Cerebral haemorrhage Often described as deep (basal ganglia and thalamus) or lobar. 
Deep: 
 Hemiparesis 
 Hemisensory loss 
 Conjugate eye deviation 
Lobar: 
 Hemiparesis 












 Unilateral ataxia 
Adapted from Clinical Neurology – 4
th
 Ed. JW Scadding & NA Losseff. Hodder Arnold 2012 
 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
1 – Introduction & Background 6 
1.4 Brain Imaging 
 
Need for early imaging after stroke onset 
To allow for the prompt delivery of appropriate treatment, it is important to make a 
rapid and accurate diagnosis of stroke type as soon as possible following symptom 
onset - imaging is necessary to differentiate ischaemia from haemorrhage. Although 
it is perhaps more accurate to state that CT imaging in early stroke is primarily used 
to exclude haemorrhage and non-vascular causes of stroke (i.e. structural stroke 
mimics such as encephalitis, acute demyelination, meningitis, abscess, subdural 
haematoma or other space occupying lesion) rather than confirm the presence of 
infarction. Haemorrhage (or a structural lesion) is a contra-indication to intravenous 
thrombolysis but the absence of a visible infarct is not.   
CT versus MRI 
CT scanning without contrast enhancement (hereafter referred to as non-contrast CT) 
has become the primary imaging modality (rather than MRI) in the initial assessment 
of acute stroke for several reasons: 
1. CT is widely available whereas MRI is not, especially out-of-hours4 
2. On modern equipment, a non-contrast brain CT can be performed in seconds 
while even a few basic MRI sequences can take several minutes 
3. Due to the inherent differences in machine structure and function, CT makes 
it easier to manage an unstable patient during scanning and CT is better 
tolerated by those who suffer claustrophobia 
4. A proportion of older patients have cardiac pacemakers or other contra-
indications to MR imaging 
5. As a means to answer the basic imaging question, of whether a stroke is 
ischaemic, haemorrhagic or due to a non-vascular cause, CT is very accurate 
for identifying haemorrhage and non-vascular causes.
5;6
 
Other benefits of CT 
In addition to differentiating ischaemic from haemorrhagic stroke, non-contrast CT 
also provides some information on the presence of arterial obstruction (intra-arterial 
hyperattenuation, see 1.6.1) and on the extent of ischaemia (loss of grey-white matter 
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differentiation, hypoattenuation of brain tissue, evidence of swelling), Figure 1-1, 
especially when medium to large areas are affected; small volume ischaemia in the 
early stages of stroke can however be more difficult to detect particularly for those 
with less experience of doing so and especially if insufficient time is allowed for 
assessment.
7;8
  Finally, non-contrast CT provides valuable information on the 
remainder of the imaged brain.  For example, the identification of background 
leukoaraiosis has been shown in meta-analysis of case series and observational 
studies (there is limited randomised-controlled trial data), to increase the risk of 
haemorrhage following treatment with thrombolysis
9
 while an unexpected subacute 
infarct, i.e. a silent infarct that occurred several days prior to the presenting clinical 
deterioration,
10
 would represent a contra-indication to the use of intravenous 
thrombolysis. 
Figure 1-1 Brain tissue changes of early ischaemic stroke identifiable on non-contrast CT 
 
Footnote: Left image was obtained within a few hours of stroke symptom onset (hyperacute). Note 
that the right basal ganglia and insular cortex are difficult to identify (boxed area). 
Right image was obtained at 24 hours after stroke symptom onset (subacute) in a different patient with 
a similar distribution of ischaemic lesion. 
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Benefits of MRI 
MRI is used for assessing acute stroke in many centres.  Ideally, MRI in stroke 
includes at least four sequences, namely T2 weighted, diffusion-weighted imaging 
(DWI), T2* (or an alternative haem sensitive sequence) and FLAIR.  In this context, 
MRI is usually most appropriate in patients with mild stroke since these minimum 
four sequences will require approximately 15 minutes of in-scanner time for the 
patient using standard modern equipment, and this will increase if other sequences, 
e.g. T1 weighted, time-of-flight angiography, are applied.  In some series, patients 
with moderate or severe stroke were unable to complete imaging in up to 45% of 
examinations.
11
  Depending on availability, MRI may be used instead of non-contrast 
CT but only if blood-sensitive sequences like T2*, SWI, SWAN are used – MRI 
without these is not able to differentiate acute haemorrhage reliably; both CT and 
MRI are excellent at differentiating acute ischaemia from haemorrhage (and for 
excluding other structural abnormalities that may present as stroke) in the first five 
days after stroke if suitable MRI sequences are used.  Allowing for the 
aforementioned limitations of MRI, it also has certain advantages over non-contrast 
CT.  The main advantage of MRI in acute stroke relates specifically to the use of 
diffusion-weighted imaging which can provide very clear evidence of the extent of 
parenchymal ischaemia and/or infarction within minutes of stroke onset and can do 
so with greater sensitively than non-contrast CT.
12-14
  Early parenchymal changes are 
appreciated as increased restriction in the normal diffusivity of intracellular water 
(i.e. restricted diffusion – high signal on DWI sequences and correspondingly low on 
ADC maps), Figure 1-2.  It should be noted that DWI provides most benefit in 
patients with small volume infarct (like the example provided) since these infarcts 
are more likely to be overlooked using non-contrast CT; large volume infarcts are 
usually readily apparent on both modalities.  Unfortunately, is has been demonstrated 
in an observational study of over 200 patients that, for various reasons,
15
 DWI 
changes may not be apparent in up to 33% of those with minor stroke.
16
  Changes on 
the other standard MRI sequences (i.e. increased T2 signal within affected tissues, 
best seen on FLAIR) occur later with the development of parenchymal oedema and 
are therefore seen in a similar time course (and with no greater sensitivity) than the 
changes described above for non-contrast CT.  This time difference between DWI 
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and other MRI sequences has been used to estimate the time of ischaemic stroke 
onset by assessing for a DWI-FLAIR mismatch.  It has been shown that while DWI 
changes can be identified within minutes of stroke onset, in a large proportion of 
patients, FLAIR changes may not be apparent until several hours from onset.  
Patients with large areas of mismatch are therefore deemed to have had a recent 
onset time of stroke and could potentially be eligible for intravenous thrombolysis 
even if an absolute stroke onset time is not available.
17;18
  This concept is currently 
being tested in the WAKE-UP randomised-controlled trial.
19
 
Figure 1-2 Diffusion weighted imaging (DWI) showing early infarct on MRI 
 
Footnote: DWI (left) and corresponding ADC map (right) confirming small focus of abnormal 
diffusion restriction within the left thalamus. 
 
1.5 Imaging Intracranial Arterial Patency 
 
1.5.1 Hyperattenuating artery sign (HAS) on non-contrast CT 
In 1983, an article by Gács and colleagues documented several cases of vascular 
hyperattenuation identified on non-contrast CT performed acutely after stroke. The 
authors correctly postulated that this appearance represented acute thrombus or 
embolus within intracranial arteries.
20
 The hyperattenuating artery sign (HAS) 
provides indirect evidence of arterial obstruction.          
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As discussed above, non-contrast CT is usually performed as first line imaging 
immediately after stroke onset predominantly to exclude haemorrhage or a structural 
stroke mimic. While evidence of parenchymal ischaemia can be difficult to identify 
in these very early stages on CT, HAS are usually recognised more readily, see 
Figure 1-3.
7;8
    
Figure 1-3 HAS visible on two different non-contrast CT scans (arrows) 
 
 
1.5.2 Susceptibility sign and flow voids on MRI 
Indirect evidence of arterial obstruction can also be observed in standard MRI 
sequences of the brain.  
MRI works by transmitting radio frequency energy into magnetised tissues then 
detecting returned radiofrequency signals derived as the tissue returns to its pre-
excitation state; the frequency of returned energy varies by tissue type and position 
within the scanner allowing for an accurate image representation of the body to be 
created. Inherent in this model is the requirement that tissue remains in the same 
location during excitation and relaxation. Flowing blood therefore does not return 
sufficient signal on standard MRI sequences (compare with time of flight 
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angiography, see 1.6.3) since many of the excited molecules in blood have left the 
image plane before relaxation begins.  Thus ‘flow voids’ are demonstrated within 
normal arteries, and to a lesser extent within veins (slower flowing venous blood 
may well remain within the image plane for long enough). Comparatively if there is 
an arterial obstruction, this static tissue will return an MRI signal and the normal 
flow void will be absent. 
In addition, if acute arterial obstruction is caused by blood clot (thrombus) rather 
than embolus (which may not consist of blood products) some unique MRI features 
of clotting blood can be appreciated. First, at certain stages in the development and 
subsequent dissolution of blood clot, it becomes paramagnetic and causes an artefact 
on the MR images by disrupting the homogeneity of the local magnetic field. 
Second, blood clot returns a high signal on T1 imaging during certain stages in its 
development (see Figure 1-4), and very few other things can return a high signal on 
standard T1 weighted spin echo acquisitions (e.g. fat, proteinaceous material, 
gadolinium). In the correct clinical context then, if either susceptibility artefact or T1 
hyperintensity are identified within a relevant artery these could be convincing 
indicators of recent thrombus. 
  
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
1 – Introduction & Background 12 
Figure 1-4 Sequence of changing imaging appearances for aging blood on MRI 
                       






Catheter angiography  
By placing a catheter into proximal intracranial arteries and directly infusing a radio-
opaque contrast medium, high resolution, three-dimensional radiographic vascular 
imaging can be obtained. This remains the gold-standard for assessing arterial (and 
venous) flow in real time.  It provides excellent information on vascular anatomy, 
vessel patency and extent of collateral supply (including the length of time that it 
takes and the direction travelled by contrast if it bypasses an occlusion).  Catheter 
angiography is however an invasive procedure that comes with its own risks.  
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Neurologic complications of any type occur in up to 3% of stroke cases while 
permanent disability or death is reported in less than 1%.
22-24
   
CT and MR angiography (CTA & MRA) 
CT and MRI offer a means of obtaining minimally invasive and non-invasive 
angiography.  Minimally invasive indicates that the patient will require only an 
intravenous injection of a contrast agent (CT or MRI), usually via an arm vein.  Non-
invasive implies that no contrast is given to the patient; angiographic images are 
obtained by harnessing features of moving blood (MRI only).  Angiography 
performed with contrast generally provides more robust imaging than angiography 
without contrast since the former is less likely to be affected by imaging artefacts.  In 
an acute setting however, it can be difficult to obtain the baseline renal status or 
allergy profile of a stroke patient.  In addition, many stroke patients will be 
dehydrated at presentation which can further exacerbate the problem.  In these 
scenarios, intravenous contrast may be contraindicated.  Non-contrast time-of-flight 
MR imaging (saturates or removes signal from stationary tissue to isolate the small 
signal returned from flowing blood entering the imaging plane
25
) provides an 
alternative option, but as alluded to, this approach is potentially limited by imaging 
artefact.  Figure 1-5 displays contrast enhanced CT angiography and compares MR 
time of flight angiography with contrast enhanced MR angiography.   
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Figure 1-5 Comparison of CT and MR angiography techniques performed in the same 
patient 
 
Footnote: Upper panel compares contrast enhanced CT (a) and contrast enhanced MR (b) 
angiography of the circle of Willis. 
Lower panel compares time-of-flight (c) and contrast enhanced (d) MR angiography of the major 
arteries in the neck. Note multiple imaging artefacts within the time-of-flight sequence (arrows) which 
are not visible on the contrast enhanced images.  
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1.6 Treatment of Stroke 
 
Development of stroke treatments 
Advances in care over the last 20 years have greatly improved the outcome for stroke 
patients with less mortality and a greater number of patients ultimately achieving 
independence.  Amongst several possible changes, three factors are largely 
responsible for this improvement.  First was the emergence of dedicated stroke units 
which offer both acute and rehabilitative care for the various and variable needs of 
stroke patients;
26
 prior to this, stroke patients were cared for on general medical 
wards.  Second was the introduction of intravenous thrombolysis which represented 
the first effective treatment for acute ischaemic stroke
27
 (aspirin has a very modest 
effect).
28
  Third is a better understanding among the general public at large, thanks in 
part to the FAST (Face, Arm, Speech, Time) mass media campaign
29
 that stroke 
represents a potentially treatable medical emergency
30
; a ‘brain attack!’  Despite 
these advances however, many stroke survivors remain disabled; in general around 
one third of stroke patients die, one third remain disabled long term and one third 
regain or retain their independence. Stroke related disability has enormous 
implications and costs for both the patient and for society as a whole. It is estimated 
that stroke costs the UK economy around £9 billion per year.  Around 49% of this is 
billed directly to the NHS (health and social care), 27% is for the cost of informal 





Intravenous thrombolysis is now established as an effective treatment for acute 
ischaemic stroke and acts by disrupting and dissolving occlusive thrombus or 
embolus and thereby restoring arterial blood flow to the brain.
32-44
  A recently 
updated systematic review and meta-analysis incorporated data from the 12 major 
randomised-controlled trials performed to date that tested intravenous alteplase 
(recombinant tissue plasminogen activator, rt-PA). In 7012 patients randomised over 
a 20 year period, this meta-analysis showed that those treated with alteplase within 
six hours of stroke were significantly more likely to be alive and independent at 
follow up (46.3% versus 42.1%, respectively, p=0.001).  This is despite evidence that 
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there is an increase in early death rate secondary to haemorrhage for those treated 
with alteplase (8.9% versus 6.4%, respectively, p=0.0003).  Furthermore, the power 
of this thrombolytic effect declines with time and greatest benefit is achieved if 
treatment begins within the first 3 hours from ischaemic stroke onset (among treated 
patients, 40.7% alive and independent <3 hours versus 31.7% >3 hours, p<0.0001).
45
  
The steep time dependency of thrombolytic effect on good outcome was similarly 
identified in a subsequent patient level data meta-analysis including nine of the major 
trials (n=6756) which showed greater proportional benefits for those treated earlier.
46
 
Importantly, approximately 10 years of observational data from the SITS register 
(Safe Implementation of Thrombolysis in Stroke) which monitors alteplase use in 
routine clinical practice across Europe has shown, in nearly 30,000 patients that 
intravenous alteplase can be used safely in this context.  SITS data show comparable 
rates of haemorrhage, death and good outcome among stroke patients treated with 
intravenous alteplase within the first 3 hours (n=25,279) and those treated between 3 
to 4.5 hours (n=4056); even those treated ‘off-licence’, i.e. between 4.5 and 6 hours 
from stroke onset (n=283) did not show a significant increase in the rates of poor 
outcome, though the authors acknowledge the limitations of this latter comparison.
47-
50
  Presently, there is no evidence to support the use of intravenous thrombolysis 
therapy beyond 6 hours of ischaemic stroke onset and the license in most countries 
only extends to 4.5 hours after stroke (3 hours in the USA). Trials are ongoing to find 
out if the time window can be extended and in which patients. 
Mechanical thrombectomy 
Endovascular retrieval of intra-arterial clot (mechanical thrombectomy or 
embolectomy) offers an effective means to restore blood flow to the brain after 
ischaemic stroke secondary to proximal, large vessel arterial occlusion.  A recent 
series of clinical trials compared mechanical thrombectomy plus intravenous 
thrombolysis to intravenous thrombolysis alone for the early treatment of ischaemic 
stroke. At the time of writing, eleven randomised-controlled trials have been 
completed and six of the eight trials published since 2015 have each independently 
demonstrated (on primary end point analysis) that endovascular thrombectomy in 
addition to intravenous thrombolysis improves functional outcome compared with 
intravenous thrombolysis alone.
51-61
 In meta-analysis of ten of these trials including 
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2925 patients, those treated with endovascular thrombectomy had a significantly 
higher chance of achieving a good outcome (modified Rankin score ≤2, see 1.7.2) 
compared to patients treated with intravenous thrombolysis alone: risk ratio 1.37 
(95% confidence interval 1.14-1.64). This means that for every 1000 patients treated 
with mechanical thrombectomy rather than intravenous thrombolysis alone, 123 
extra patients achieved a good outcome.
62
  
Other medical treatments 
The treatment for haemorrhagic stroke is currently primarily supportive unless there 
is a specific underlying cause such as an aneurysm.  
A large number of trials for agents that might improve medicinal thrombolysis or 
offer neuroprotection in both ischaemic and haemorrhagic stroke have been and 
continue to be tested.  As yet, no such agents have been convincingly identified. 
 
1.7 Outcome after Stroke 
 
1.7.1 Short-term outcomes 
As noted above, the clinical stroke syndrome with which a patient presents to 
hospital can be partially, or even completely reversible. This will occur if blood 
supply to brain is restored, either spontaneously or following treatment, before 
ischaemia becomes infarction (that is before brain cells die). Reversible ischaemia 
causes stunning rather than death of neurons.  
Also, it has been demonstrated that early and sustained arterial recanalisation is 
related to better early and late outcomes in stroke
63;64
 presumably due to return of 
normal arterial perfusion leading to greater neuronal recovery, less cell death and less 
secondary haemorrhage. 
Transient ischaemic attack 
If a presenting neurological deficit spontaneously resolves within 24 hours of onset, 
by definition this is a transient ischaemic attack, or TIA, rather than a stroke. TIAs 
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are often a precursor to an ischaemic stroke and their appearance usually prompts a 
thorough assessment for and treatment of vascular risk factors in the affected patient. 
For example: 
 Encouragement to stop smoking 
 Control of blood pressure, diabetes and cholesterol levels  
 Oral anti-platelet therapy 
 Treatment for atrial fibrillation 
 Treatment for right-to-left cardiac shunt 
 Carotid endarterectomy surgery 
Haemorrhagic transformation of infarct 
Following infarction there is likely to be disruption to the blood-brain barrier and 
damage to the capillary bed supplying the region. If there is some residual arterial 
blood supply, or more likely blood supply has been restored following treatment, 
haemorrhage into the area of infarct can occur.  
If this haemorrhage is of small volume, does not extend beyond the margins of 
infarct and does not worsen local swelling or change the severity of stroke, it is 
termed petechial haemorrhage and the clinical implications of this change are likely 
to be minimal (see Figure 1-6). Ongoing post-stroke care may not change in the face 
of petechial haemorrhage, e.g. even antiplatelet therapy may continue. 
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If however, haemorrhage into an infarct is more significant, extends beyond the 
margins of the original injury and the mass effect from this haemorrhage causes new 
shifts in brain position and thereby worsening symptoms, it is termed symptomatic 
intracranial haemorrhage (SICH – sometimes the term symptomatic intracerebral 
haemorrhage is used synonymously but the former term is preferred and more often 
correct since it also encapsulates the brainstem and cerebellum. Note however that 
SICH is sometimes also used to denote spontaneous intracranial haemorrhage), see 
Fig 1-7. SICH is likely to significantly change post-stroke care for that patient, e.g. 
cessation of antiplatelet therapy, possibly the need for surgery. In addition, SICH is 
associated with worse long and short term outcomes.
65
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Hydrocephalus after haemorrhagic stroke 
Extension of haemorrhage from brain parenchyma into the CSF-filled ventricular 
system can occur after primary haemorrhagic stroke or after significant haemorrhagic 
transformation of infarct. The end result is the same; haemorrhage obstructs normal 
CSF flow and drainage through the arachnoid villi resulting in accumulation of CSF, 
termed hydrocephalus (see Figure 1-7). This causes an increase in intracranial 
pressure and worsening of the patient’s clinical status, often reducing conscious 
level. In severe cases if left untreated, hydrocephalus can be fatal. 
Figure 1-7 Large volume haemorrhage into an area of recent infarct and adjacent lateral 
ventricle associated with hydrocephalus and worsening of the patient’s symptoms 
 
  
Malignant middle cerebral artery syndrome 
When a large volume of brain is infarcted (commonly, but not exclusively the entire 
middle cerebral artery – MCA – territory) this leads to a correspondingly greater 
volume of post-infarct swelling secondary to oedema. Swollen brain can then 
displace and compress adjacent normal brain, worsening the patient’s status. This is a 
particular problem for younger patients since there is minimal redundant space 
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around the brain to allow for expansion and the skull is a solid, fixed volume. Older 
patients are less at risk of malignant swelling syndromes if previous, age-related 
global volume loss of brain has occurred, the extra intracranial space created is 
protective. Figure 1-8 demonstrates a malignant MCA syndrome in a young patient. 
Figure 1-8 Malignant MCA syndrome in a young patient  
 
Footnote: Sequential non-contrast CT images taken at baseline, 1 and 6 days after ischaemic stroke 
onset. Craniectomy was performed between the latter two images to relieve raised intracranial 
pressure following entire right MCA territory infarct. In the final image infarcted and swollen brain 
herniates through the skull defect. 
 
Randomised trials of surgical intervention by hemicraniectomy for patients at risk of 
significant swelling after ischaemic stroke have shown mixed results; while there is a 
significant reduction in mortality following hemicraniectomy, there is also an 




1.7.2 Long-term outcomes 
For those patients that retain a neurological deficit more than 24 hours after stroke 
onset, post-stroke rehabilitative therapy can help to minimise long term disability by 
encouraging the patient to relearn particular activities. For example, how to articulate 
speech or to recover some mobility. Younger patients with greater potential for 
neuroplasticity may have the most to gain from neuro-rehabilitation.
67-69
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Stroke trials investigating the impact of intravenous thrombolysis or more recently, 
endovascular thrombectomy have usually assessed the patient’s functional status at 
three or six months after stroke onset to allow for a ‘final’ stable post-stroke outcome 
to become evident.  
The modified Rankin Scale (mRS) has been most commonly used to assess 3-6 
month outcome in stroke trials.
70-72
  mRS is graded 0-6: 
0. No symptoms. 
1. No significant disability. Able to carry out all usual activities despite some 
symptoms. 
2. Slight disability. Able to look after own affairs without assistance, but 
unable to carry out all previous activities. 
3. Moderate disability. Requires some help, but able to walk unassisted. 
4. Moderately severe disability. Unable to attend to own bodily needs without 
assistance, and unable to walk unassisted. 
5. Severe disability. Requires constant nursing care and attention, bedridden, 
incontinent. 
6. Dead. 
Traditionally, trial patients said to have derived benefit from treatment were those 
without or with only minimal disability (mRS 0-1 or 0-2) who retained their 
independence. Thus analysis of results was based on converting mRS into a simple 
dichotomy comparing patients with ‘good’ versus ‘bad’ outcomes. Straightforward 
statistical testing is required in this type of analysis, e.g. a two by two table and chi-
squared (χ
2
) statistics; see Table 1-3 for an example using imaginary stroke trial data.  
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Table 1-3 Example data from imaginary stroke trial comparing treatment allocation with 
outcome as a dichotomy 
 
Treatment Allocation 
IV Alteplase Control 
3-Month 
Outcome 
mRS 0-2 45 35 
mRS 3-6 30 40 
Footnote: mRS = modified Rankin Scale. n=150 
χ
2
 = 2.7, p = 0.102, i.e. despite an extra 10 patients achieving a good outcome following treatment 
with intravenous thrombolysis (in treatment allocation groups which are matched for size), the 
treatment effect on outcome in this analysis is non-significant. 
 
However, this approach fails to take account of trial patients who moved along the 
mRS scale but did not cross the line of dichotomy, i.e. it has the effect of smoothing 
data since seven mRS groups become two. Conceivably many patients enrolled in 
trials who did not cross the line would nevertheless demonstrate improved or 
worsened outcomes (depending on direction of travel) as a consequence of their 
treatment allocation in the trial. Figure 1-9 uses the same imaginary stroke trial data 
but displays all mRS levels as stacked horizontal bar graphs.  Figures of this type are 
commonly used to report stroke trial results (sometimes termed Grotta bars)
73
 as they 
highlight that multilevel scalar shifts occur in such datasets. Unfortunately, more 
complex statistics are required to assess stepwise shifts over multiple levels, e.g. 
ordinal regression analysis.
74
 The benefit of such analyses is that with a greater 
number of data points per treatment allocation group (7 rather than 2), the results are 
more powerful for the same number of included patients.
75
 Note that from Table 1-3 
to Figure 1-9, in my imaginary dataset, the result of the latter analysis is significantly 
in favour of treatment when data are analysed using the more statistically powerful 
regression technique incorporating all data points (i.e. non-smoothed data). 
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Figure 1-9 Example data from imaginary stroke trial comparing treatment allocation with 
outcome 
 
Footnote: Result of ordinal regression analysis with mRS (modified Rankin Scale) as the dependent 
variable, n=150: Odds ratio for improved outcome with alteplase versus control (shift toward the left) 
= 2.25 (95% confidence interval = 1.27-4.00), p=0.006. 
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Chapter 2 Literature Reviews 
 
In the early stages of my MD research project, I undertook two reviews to investigate 
the major topics for consideration in my thesis: 
I. Systematic review of the hyperattenuated artery sign (HAS) in ischaemic 
stroke with meta-analysis of HAS prevalence data 
II. Narrative review of CT and MR angiography (CTA and MRA, respectively) 
performed acutely in the assessment of ischaemic stroke 
These reviews sought to refine the aims of my thesis and to direct and inform 
subsequent analyses designed to address those aims. 
 
2.1 Systematic Review of Prior HAS Research 






I performed concurrent searches on the Embase and Medline databases using the 
strategy outlined in Figure 2-1.  Keywords pertaining to the three topic areas of CT, 
ischaemic stroke and hyperattenuating arteries (in any intracranial location) were 
combined within each topic area using the Boolean operator OR.  I combined results 
from these three topic area searches using the Boolean operator AND.  Since 
hyperattenuating arteries in stroke were first described in the early 1980s,
1;2
 I 
included all reports from 1980 to the date at the time of search (October 2012).  I 
hand searched and cross checked the reference lists from returned citations 
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(especially review articles) to identify any further relevant work that may have been 
overlooked by the searches. 
Figure 2-1 Search strategy for systematic review of prior HAS research 
 
 
Inclusion and exclusion criteria 
First I screened titles and abstracts. For efficiency, I sought only peer reviewed 
original research articles published in English. Results published only in abstract, 
review articles, editorials and case studies were not included. Articles had to contain 
original data on intracranial hyperattenuated arteries identified on CT in the course of 
investigating stroke.  
To be widely inclusive, I imposed no further exclusion criteria (i.e. I did not use 
quality criteria to determine eligibility) and I included all types of HAS research. I 
then subclassified articles into four topics based on their commonality in the search 
output: 
 Prevalence/ identification of HAS 
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 Pathological composition of HAS 
 Correlation with angiography 
 Clinical implications of HAS (on stroke severity and response to 
thrombolysis) 
Meta-analysis of HAS prevalence 
To derive an overall prevalence for HAS in ischaemic stroke, I included only 
absolute numbers for HAS presence within individual study populations. However, I 
did not examine differences between these study populations. I collected data in a 
spreadsheet and calculated sum totals for the numerator and denominator for each 
study prior to calculation of the overall prevalence. 
Literature review 
I did not otherwise meta-analyse articles identified in my systematic review but all 
relevant citations are included below in a narrative literature review exploring the 
status of published HAS research at the outset of my MD project.  
 
2.1.2 Results of search 
My searches identified 1609 unique citations from which 206 were selected after 
abstract screening for further reading and 101 were ultimately included in the review, 
see Fig 2-2. The main reasons for exclusion from the review were: studies comparing 
MRI findings to CT hyperattenuation; review articles (including pictorial), editorials 
or letters adding no new data to the field; case studies describing unusual findings 
that were not relevant to the declared HAS topics for review. Most of the articles 
represented observational studies (86/101 = 85%), there was very little data from 
randomised-controlled stroke trials (7 articles derived from 4 trials).
3-9
 Most of the 
observational studies were conducted retrospectively in single centres and included 
fewer than 100 patients. I identified only 2 large multicentre observational 
datasets
10;11
 and only 1 systematic review which investigated early CT findings 
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Figure 2-2 Flow chart for systematic review showing numbers of articles identified and 
selection of reports for inclusion 
 
 
The 101 citations identified after systematic review contributed to the predetermined 
HAS topics as follows in Table 2-1. Note that many articles contributed to more than 
one topic.   
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Table 2-1 Contribution of articles to each of the HAS research topic areas 
HAS Research Topic n (% of 101 
identified) 
Prevalence/ identification of HAS 54 (53.5) 
Pathological composition of HAS 7 (6.9) 
Correlation with angiography 21 (20.8) 
Clinical implications of HAS – Stroke severity & outcome 52 (51.5) 
Clinical implications of HAS – Response to thrombolysis 27 (26.7) 
 
Meta-analysis of HAS prevalence in the published literature 
Among 54 articles providing data on HAS prevalence, I identified a wide range of 
values (7-88%) which may reflect variability in the included study populations; the 
overall prevalence from over 20,000 scans was 21.2%, Table 2-2.  Figure 2-3 
demonstrates that there was greater variability in published prevalence for studies 
with fewer than 100 patients. 
Table 2-2 Published prevalence of HAS 
First Author of Publication 
(Year) 
Prevalence, n (%) 
Tomsick (1989)
13
 6/50 (12.0) 
Schuknecht (1990)
14
 28/121 (23.1) 
Bastianello (1991)
15
 18/36 (50.0) 
Ricci* (1991)
16
 14/90 (15.6) 
Leys (1992)
17
 73/272 (26.8) 
Tomsick (1992)
18
 19/55 (34.5) 
Wolpert (1993)
19





 25/53 (47.0) 
Moulin (1996)
21
 22/100 (22.0) 
Tomsick (1996)
22
 18/55 (33.0) 
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Büttner (1997)
23
 11/95 (11.6) 
Barber (1999)
24
 5/17 (29.0) 
Dávalos (1999)
4
 195/615 (31.7) 
Manelfe (1999)
5
 107/620 (17.7) 
Scott (1999)
25
 7/39 (18.0) 
Fiorelli (2000)
26
 41/158 (26.0) 
Flacke (2000)
27
 6/23 (26.0) 
Barber (2001)
28
 16/100 (16.0) 
Berge (2001)
29
 32/449 (7.0) 
Mendizabal (2001)
30
 4/36 (11.0) 
Gadda* (2002)
31
 19/32 (59.3) 
Somford (2002)
32
 42/186 (22.6) 
Koga (2003)
33
 27/112 (26.0) 
Leary* (2003)
34
 12/50 (24.0) 
Aronovich (2004)
35
 20/150 (13.3) 
Barber (2004)
36
 25/100 (25.0) 
Gadda (2005)
37
 33/49 (67.3) 
Kim* (2005)
38
 45/51 (88.0) 
Mandava (2005)
39
 14/18 (78.0) 
Krings (2006)
40
 17/48 (35.4) 
Qureshi (2006)
8
 91/616 (15.0) 
Tei (2006)
41
 52/166 (31.3) 
Poniatowska (2007)
42
 45/125 (35.7) 
Kim (2008)
43
 46/78 (59.0) 
Nichols (2008)
44
 79/604 (13.0) 
Ozdemir* (2008)
45
 25/71 (35.0) 
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Tartaglia (2008)
46
 64/130 (49.0) 
Abul-Kasim* (2009)
47
 39/121 (32.0) 
Aries (2009)
48
 104/384 (27.0) 
Goldmakher (2009)
49
 12/95 (12.6) 
Kharitonova (2009)
11
 1905/10023 (19.0) 
Kobayashi (2009)
9
 206/510 (40.0) 
Jensen (2010)
50
 11/24 (46.0) 
Nedeltchev* (2010)
51
 40/245 (16.3) 
van Overbeek (2010)
52
 72/247 (29.1) 
Tan (2010)
53
  31/126 (24.6) 
Ambrosius (2011)
54
 12/55 (21.8) 
Fitzsimmons* (2011)
55
 22/120 (18.3) 
Paciaroni (2011)
56
 148/1010 (14.7) 
Guo (2012)
57
 9/30 (30.0) 
Lingegowda (2012)
58
 12/41 (29.3) 
Paliwal (2012)
59
 109/226 (48.2) 
Sakamoto** (2012)
60
 8/50 (16.0) 
Strbian* (2012)
61
 233/1319 (17.7) 
Sum Totals (Overall Prevalence) 4292/20256 (21.2) 
Footnote: *Several results were presented, not all are listed here. ** Excluded 17 patients with 
primarily haemorrhagic stroke. 
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Figure 2-3 Bar chart ordering the 54 studies included in the HAS prevalence analysis by sample size 
 
Footnote: HAS = Hyperattenuated Artery Sign. Studies with matching sample size are grouped. Dotted line represents overall prevalence of HAS, 21.2%. 
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2.1.3 Narrative literature review of HAS 
In the following sections I provide an overview of the HAS literature summarising 
the remainder of the articles identified in my systematic review and grouped by the 
subcategories described above in Table 2-1. Note that I did not undertake any further 
meta-analyses with the data from these articles.  
   
Variability in the identification of HAS 
The location of HAS may determine how often it is detected. Most of the early case 
studies describing HAS related to hyperattenuation within one of the middle cerebral 
arteries (MCA),
2;62-64
 which is arguably one of the easier locations to identify HAS 
given that the main MCA trunk lies roughly in parallel with the standard axial plane 




Several papers describe HAS as a transient phenomenon
5;15;17;21;52;62;68;69
 more 
frequently found early in the process of acute stroke.
29;50
 However one article noted 
that HAS prevalence increased from 3 to 6 to 9 to 12 hours after stroke onset.
42
 
These results imply that there is a peak time soon after stroke onset when HAS is 
most likely to be identified. This may relate to the normal temporal development and 
subsequent breakdown (natural or treatment related) of the thrombus or embolus that 
gives rise to the appearance of HAS.    
Several other factors might also account for the described variance in HAS 
prevalence.  Significantly improved results have been reported where thin slice CT 
data were used.  Kim et. al. compared 5 mm slice data with that from 1.25 mm or 1 
mm slices (defined as thin slice) for detecting HAS.  The prevalence of HAS with 
thin slice CT was 88% versus 32% for images based on 5 mm slices.
38
  Other authors 
have also shown that intravascular thrombus can be identified more readily with thin 
slice CT.
31;37;70;71
 Similarly, prevalence is increased if larger, more proximal vessels 
are examined, i.e. likely to represent a greater volume of thrombus in positive 
cases.
33
 Instinctively it makes sense that a greater clot load is more likely to be 
identified on CT.
72
 Notwithstanding, the basilar artery is uniquely recognised as a 
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difficult vessel to assess on non-contrast CT due to bony artefact within the posterior 
fossa and the lack of a paired vessel for comparison.
67
  
False positive HAS can be produced by non-thrombotic or embolic causes. Vessel 
wall calcification, raised haematocrit, arterial dissection, circulating intravascular 
contrast agents (residual iodinated contrast in patient with renal failure, bromine as a 
treatment for epilepsy, cocaine) and reduced density within the surrounding brain 
parenchyma have all been reported.
73-78
   
Several of these reported problems relate to subjective assessment of vessel 
hyperattenuation, i.e. the vessel appears bright to the human eye.  In addition, they 
make no allowance for whether the finding is generalised or isolated to a single 
vessel.  Koo and colleagues attempted to ascertain criteria for validating an 
apparently dense intracranial vessel.  They found that an absolute attenuation greater 
than 43 HU or a ratio (with matched contralateral vessel – more dense:less dense) 
greater than 1.2 might be used to define ‘true’ hyperattenuation as defined by an 
expert reader.  The ratio of affected vessel to adjacent brain parenchyma was not 
found to be useful as a discriminator of true intravascular hyperattenuation.
79
  An 
intravascular attenuation >40 HU has also been independently identified as an 
optimal cut-off for defining intra-arterial hyperattenaution.
54;67
 It is important to 
correct attenuation measures for background intravascular attenuation.
47;80
 An added 
benefit of taking into account attenuation within the contralateral vessel is that it also 
controls for decreases in background intravascular attenuation (e.g. in states of 
anaemia); this may allow for more subtle hyperattenuation to be appreciated.   
Finally, it is worth noting that bilateral MCA hyperattenuation related to 
bihemispheric stroke has been reported.
81
  While this rarity would clearly obviate use 
of the contralateral vessel as a measure of normality, this case nevertheless 
demonstrates the need for correlation between radiological and clinical findings. 
Pathological composition of HAS 
Several research articles sought to determine the pathological composition of 
thrombus or embolus in stroke and to relate this to differences in attenuation that 
might be appreciated on CT.   
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A linear relationship between the attenuation of blood and haematocrit has been 
described.
82
  Ischaemic strokes can be caused by either erythrocyte rich or platelet 
rich thrombus, termed red and white clots, respectively.
83
  In addition, histochemical 
differences are appreciated between thrombi that form locally and those that proceed 
to embolisation.
84
  Clots retrieved from patients following acute ischaemic stroke 
demonstrate a variable mixture of red cells, platelets and fibrin.
85
 Mixed or fibrin rich 
clots are most common while pure red clots are rare and it has been postulated that 
these may only occur in stagnant blood following primary occlusion by a mixed or 
fibrin rich clot.
86;87
  Phantom studies have demonstrated that clot composition 
directly affects attenuation.  As with circulating whole blood, higher erythrocyte 
levels lead to a higher CT measurable attenuation.  In one study using phantoms, 
over a time range of 6-144 hours, white thrombi demonstrated HU of 16-24, mixed 
measured 22-52 HU, while red thrombi measured 69-76 HU.
88
 
Koo et. al. and other authors published mean attenuation values within affected 
vessels in the range 46 to 89 HU
14;55;79
 while another study comparing CT and MR 
findings to the pathology of retrieved clot found a mean attenuation of 61 HU in 
cases where HAS was present; hyperattenuated clots were more likely to be red cell 
dominant or mixed and to have a higher red cell content compared with clots that did 
not demonstrate a HAS (47% versus 22%).
87
 Similarly, Sakamoto and colleagues 
found that HAS on CT and susceptibility artefact on MRI were highly consistently 
identified in the same individuals, i.e. both signs were usually synchronously either 
present or absent. Given that susceptibility artefact is an indicator of haem, this 
finding also implies HAS are red cell dominant.
60
 Finally, some authors have 
provided data suggesting that HAS is more likely after stroke secondary to 
cardioembolism rather than large artery atherosclerosis which may have implications 
for the differences in underlying clot composition but these data are subjective due to 
the nature of estimating stroke aetiology.
56;89
 
That only a proportion of thrombi contain enough red cells to be registered as high 
attenuation on CT might also help to account for some of the variability of published 
prevalence results for HAS described above. 
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Correlation with angiography 
Catheter angiography remains the gold standard for assessment of intracranial 
vascular anatomy and arterial patency.  Early studies validated the HAS using 
catheter angiography and confirmed the presence of cerebral artery occlusion in 
arterial segments with intravascular hyperattenuation.  In these studies correlation 
was often 100%, i.e. a hyperattenuating vessel almost always correlated with an 
angiographically detected occlusion but conversely, an occlusion on catheter 
angiography was not always related to the finding of a hyperattenuated vessel on 
CT.
14;15;18;34
 Hyperattenuating vessels have also been shown to signify vascular 
occlusion as determined with CTA.
43;90-92
   
To establish the potential value of HAS in routine practice, it is important to quantify 
the sensitivity and specificity of HAS for the identification of true arterial occlusion. 
Reported numbers for sensitivity, specificity, positive predictive (PPV) and negative 
predictive values (NPV) varied across 16 studies where these figures were reported 
and they did not always use the same angiography gold 
standard.
16;17;19;20;27;34;36;38;40;45;47;49;58;60;67;93
  Sensitivity ranged from 26% to 100% 
(median 44.5%), i.e. fewer than half of acute stroke patients with intravascular 
thrombus had an identifiable HAS.  Specificity was often reported as 100% but 
estimates ranged from 51% to 100% (median 100%), i.e. an identifiable HAS was 
highly likely to relate to an acute stroke.  PPV was estimated within the range 32 to 
100% (median 100%) while NPV was reported from 15 to 100% (median 63.1%), 
i.e. similar to sensitivity and specificity findings, the presence of the sign was likely 
to relate to stroke but its absence did not exclude stroke. The use of thin-slice CT has 
been shown to improve rates of sensitivity, specificity, PPV and NPV; two studies 
reported values of 100% for all measures when thin-slice CT was used.
38;47
 It is also 
worth noting that in several of the studies reporting accuracy data for HAS, there was 
apparently no direct assessment of vascular patency, i.e. neither catheter or CT 
angiography was used to confirm arterial occlusion in the presence of an apparent 
HAS. Instead, several authors used clinical outcomes (confirmed stroke or death) to 
imply that an apparent HAS was a genuine finding which calls the validity of these 
results into question.
16;17;20;40;47
 For completeness, these studies have been included in 
the summary ranges quoted above.  
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Clinical implications 
Stroke severity and outcome: A large body of early work demonstrated on 
univariate analyses an association between the presence of HAS and increased stroke 
severity
50
 and that both short and longer term poor outcome including an increased 
rate of death,
20
 were more frequent in patients with HAS.
12;16;22;23;32;41;45;94-98
   HAS is 
related to larger volume infarcts
17-19;22;23;29;40;54;56;98
 that demonstrate earlier - CT 
identifiable - changes in brain parenchyma,
15;21
 particularly if the HAS resides within 
a proximal vessel.
28;32;37;55
  van Overbeek et. al. reported that striatocapsular infarcts 
due to MCA occlusion (which may present with a clinical syndrome 
indistinguishable from a lacunar stroke) are more likely if HAS within the middle 
cerebral artery has resolved by 24 hours.  In their study, patients for whom HAS 
persisted were more likely to suffer additional cortical infarction.
52
 Comparatively, 
reversal of the sign has been related to better clinical outcomes.
39;59;99
  At the time of 
writing, in the largest published cohort of patients with HAS (1905 from the Safe 
Implementation of Thrombolysis in Stroke, SITS, register), Kharitonova and 
colleagues found that HAS patients had a more severe stroke both at presentation and 
up to three months later and were less likely to regain independence.
11
 Very similar 
results are also reported in other large cohorts such as the European Cooperative 
Acute Stroke Study 1 – ECASS1, a double blind, randomised, multi-centre trial with 
620 patients.
5
   
Several authors have demonstrated, using regression analyses, that associations 
between HAS and poor clinical outcomes occur independently of other clinical and 
demographic factors such as patient age and sex, stroke severity at baseline. 
48;49;53;54;56;61;100
  This includes data from the National Institute of Neurological 
Disorders and Stroke – NINDS intravenous thrombolysis stroke trial (placebo 
controlled, randomised, double-blind, multicentre) which showed that intravascular 
thrombus identified on CT was an independent predictor of both clinical 
deterioration within 24 hours of stroke onset and also poor 3-month outcome.
3;6;8
  
Conversely, Mustanoja et. al. demonstrated in their large cohort of 957 patients that 
absence of HAS at baseline predicted a good three month outcome
101
 and Paliwal et. 
al. showed that persistence of HAS on follow-up CT (22-36 hours after the first) was 
independently associated with a poor three month outcome.
59
  Meanwhile, Dávalos 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
2 - Literature Reviews 46 
and colleagues found that HAS independently predicted an early progression of 
stroke severity – defined as deterioration within 24 hours
4
 while Berge et. al. found 
independent associations between HAS and parenchymal haemorrhage and death.
29
  
This latter association with mortality was also demonstrated by both Zorzon and 
Kharitonova.
11;102
 One large study recently demonstrated an independent association 
between HAS and increasing severity of cerebral oedema.
103
  However, despite 
significant correlations on univariate analysis in most cases, not all studies that 
performed regression testing of their data found HAS to be independently associated 
with prognosis.
5;17;26;27;30;41;46;51;96;104
 Some of these results were summarised in a 
systematic review that nevertheless found clinical outcomes in stroke to be 
significantly worse in the presence of HAS (cumulative odds ratio 2.09, 95%CI 1.47-
2.96).
12
   
In summary, these results are consistent with the observation that increased arterial 
clot burden is associated with poorer outcomes after ischaemic stroke and imply that 
visible clot is likely to be of a higher volume than one which is not visible on CT.
43
  
Larger volume clots are probably more likely to occlude the primary vessel and more 
likely to extend to distal branches and collaterals. Larger volume clots might take 
longer to dissipate - whether occurring naturally or secondary to treatment
99;105
 - 
thereby increasing the duration of any distal ischaemia and reducing the chance of a 
full recovery.   
Response to thrombolysis: Patients with ischaemic stroke secondary to small, 
distally sited clots may respond best to intravenous thrombolysis.
106-109
  Wolpert et. 
al. found that while recanalisation following intravenous thrombolysis was more 
likely in distal occlusions rather than proximal, recanalisation was not related to the 
presence, or absence, of a HAS.
19
  Several retrospective studies have demonstrated 
that HAS is not significantly associated with outcomes following intravenous 
thrombolysis.
30;46
 Secondary analysis of the NINDS data showed that while HAS 
was independently associated with outcomes, the sign was not itself a predictor of 
response to intravenous thrombolysis.
3
  Patients with HAS treated with intravenous 
thrombolysis had increased frequency of recanalisation and reduced infarct volumes 
at 24 hours.
8;44
  Data from ECASS1 also demonstrated that patients with HAS 
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receiving intravenous thrombolysis had significantly better clinical outcomes than 
those given placebo.
5
  Kharitonova and colleagues have shown that following 
thrombolysis, 48% of patients in their large SITS cohort demonstrated clearance of 
HAS within 36 hours.  Patients within their cohort for whom the sign had 
disappeared following thrombolysis suffered a less severe stroke and had better long-
term outcomes.
110
 Interestingly, two groups found that clots with lower attenuation 
on CT were more resistant to intravenous thrombolysis
80;89
 and postulated that this 
relates to the underlying pathological composition where erythrocyte rich clots, 
which are known to be more sensitive to thrombolytics,
111;112
 are of higher 
attenuation.  While this correlates well with the pathological evidence presented 
above, it is somewhat at odds with the cumulative evidence presented here; HAS is 
associated with more severe strokes but the effect on post-thrombolysis outcomes is 
not directly related to the presence or absence of the sign despite pathological 
evidence that HAS should be more sensitive to intravenous thrombolysis.  This 
apparent contradiction might be explained by consideration of the CT data that is 
utilised in most of these studies.  As noted above, CT slice thickness is associated 
with HAS detection, with thin slice data providing better results.  The true prevalence 
and sensitivity rates of HAS therefore are likely to be much higher than is currently 
widely described, i.e. nearer 100%.
38
  It may be that the increased effectiveness of 
intravenous thrombolysis on hyperattenuating clots is masked by the limited 
detection rate of HAS in those studies where only large, central HAS (the type that 
reportedly do not respond well to intravenous thrombolysis
99
) are included.  The 
repeated observation that patients with HAS do, nevertheless, respond to intravenous 
thrombolysis would seem to solidify this supposition.
5;8;110;113
  
A number of non-randomised prospective observational studies have investigated the 
effectiveness of thrombolytics delivered intra-arterially. Two of these studies 
described more favourable outcomes for HAS patients following intra-arterial 
delivery of thrombolytics when compared with the same delivered 
intravenously.
114;115
  In contrast, Ozdemir et. al. found no difference in the long term 
outcomes for HAS patients treated with intravenous compared to intra-arterial 
thrombolysis.
45
  Similarly, Arnold et. al. did not find HAS to be an independent 
predictor of 3-month functional outcome but did identify HAS as an independent 
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predictor of recanalisation among patients with proven basilar artery occlusion 
treated with intra-arterial thrombolysis.
116
 Data from the PROACT study (a 
randomised trial investigating the efficacy of intra-arterial thrombolysis), found that 
HAS patients demonstrated less of a response to intra-arterial therapy compared to 
those without the sign but this finding was not significant; the trial was likely 
underpowered to detect an interaction between intra-arterial thrombolysis and HAS.
7
  
Subsequent work by Barreto and colleagues, found intra-arterial therapy to be less 
effective with larger volume clots.
117
 Given my previous suggestion that clot size 
may relate to whether or not HAS is visible, there is a risk of bias in these HAS 
versus intra-arterial thrombolysis data.    
An increased rate of haemorrhage after thrombolysis might be anticipated in patients 
with HAS given the associations between HAS, a higher likelihood of proximally 
sited larger volume thrombus, worse stroke severity and outcome. Indeed, some 
small studies have found HAS to be associated with an increased risk of intracranial 
haemorrhage following treatment with intravenous thrombolysis.
33;118
  Similarly, in a 
large multicentre review including data from 1205 patients, Tanne et. al. found more 
asymptomatic haemorrhage in those with HAS but no significant difference in the 
risk of symptomatic haemorrhage.
10
  However, analysis of RCT data from the 
NINDS showed no significant relationship between the use of intravenous 
thrombolysis and intracranial haemorrhage,
8
 a finding that has also been 
demonstrated elsewhere.
48;55;113
  Similarly, neither Kharitonova et. al. nor Marti-
Fabregas et. al. found HAS to be an independent predictor of symptomatic 
intracranial haemorrhage in their large datasets following treatment with intravenous 
thrombolysis when defined using the SITS classification: parenchymal haemorrhage 
within 36 hours of treatment accompanied by a decrease in the baseline NIHSS score 
of ≥4 points or death within 24 hours of thrombolysis.
11;119
  Conversely, HAS was 
independently predictive of symptomatic haemorrhage in Kharitonova’s cohort if a 
broader definition (as described in previous randomised-controlled trials) was used: 
any haemorrhage on follow up imaging combined with an NIHSS decrease of one 
point or death before day seven.  The authors postulated that this difference was 
related to the increased severity of strokes seen with HAS however, given that 
baseline NIHSS was also included in their regression model (i.e. the results were 
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adjusted for stroke severity), this explanation does not adequately rebuff the 
importance of their former finding.
11
  Subsequent work by Strbian and colleagues 
concluded that this broader definition of symptomatic haemorrhage does drive a 
larger contribution to worse outcomes when compared to the SITS definition.
120
  
Notwithstanding, Strbian and colleagues recently developed the SEDAN score for 
predicting symptomatic intracranial haemorrhage after intravenous thrombolysis and 
they identified intra-arterial hyperattenuation as one of the predictor variables for 
SEDAN.
121
 Given these mixed results, it is not clear if haemorrhage is more likely 
among all HAS patients following intravenous thrombolysis. Whether haemorrhage 
subsequently affects outcomes in this cohort has been inadequately defined.   
 
2.1.4 What remained unclear after HAS systematic review 
Published evidence demonstrates a wide variability in the prevalence of HAS among 
patients with CT brain imaging performed soon after stroke onset, but it is probably 
more common than at first supposed, particularly within the early phase of stroke 
evolution. In addition, the sign is naturally transient. More frequent use of thin slice 
CT in the hyperacute assessment of stroke is likely to reveal HAS more reliably and 
in a greater number of patients, especially if HAS involves smaller vessels more 
distally sited. It will be important to assess reader reliability for the identification of 
HAS. Measurement of intravascular attenuation of clot assessed objectively may 
improve the identification of HAS and give insights into the pathological 
composition and potentially, the aetiological origin of HAS.  
Comparative angiography data suggest that the presence of HAS is highly specific 
for arterial occlusion but is less sensitive, perhaps in part due to the natural 
variability in clot composition and the technical variability in HAS identification. 
However, the estimates of sensitivity and specificity of HAS for detecting arterial 
obstruction are highly variable and several studies did not use angiography to 
confirm arterial occlusion.  
Much of the published data on HAS indicates that it is associated with worse stroke 
severity at baseline and poorer post-stroke outcomes both in the short and longer 
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term.  Whether these relationships are independent of other stroke severity and 
outcome variables remains unclear. Some evidence suggests that reversal or 
persistence of HAS is important for outcome but this has not been tested rigorously.  
It is likely that HAS represents that proportion of thrombus, rich in erythrocytes, that 
is most sensitive to thrombolysis.  It appears that patients with HAS do gain benefit 
from intravenous thrombolysis but with a greater underlying clot volume than 
patients without the sign, it is perhaps erroneous to compare the two cohorts directly, 
at least without the benefit of thin-slice CT data. There is limited randomised-
controlled trial data to assess whether the presence versus absence of HAS, its 
location and extent and its measurable attenuation value are associated with or 
predictive of response to intravenous thrombolysis. The contingent risk of post-
thrombolytic haemorrhage in patients with versus without HAS remains 
controversial.  
Limitations of this analysis 
I had intended to perform a comprehensive systematic review of the HAS literature 
and to undertake a full meta-analysis. However, initial searches rapidly established 
that the broad scope of the topic and the amount of literature to be reviewed meant 
that this aspect of the project was not feasible. In order to complete the more rigorous 
original research sections of my work described in the chapters that follow, I 
restricted my investigation of prior HAS research to a largely narrative review.   
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2.2 Review of CT and MR Angiography use in Stroke 
This review was commissioned by the British Journal of Radiology (BJR) in July 
2013. The remit was to cover ‘imaging of acute stroke prior to treatment’, including 
‘current practice and evolving techniques’ (advanced imaging).  A large part of the 
review therefore discussed CTA and MRA in this context and is included below in a 
slightly adapted format. This narrative review was not based on a systematic 
literature search. 
The final peer-reviewed published article, which also includes a discussion of non-
contrast CT and CT/MR perfusion studies, is included as Appendix 3 (see Chapter 
11.3.1): 
Mair G and Wardlaw JM. Imaging of acute stroke prior to 
treatment: Current practice and evolving techniques. British 
Journal of Radiology 2014;87:20140216 
 
2.2.1 CTA & MRA for acute assessment of ischaemic stroke 
CTA and/or MRA are used increasingly to assess arterial patency in patients with 
ischaemic stroke in addition to plain CT or MR brain tissue imaging. Two US based 
studies examined a nationwide dataset that captures 15% of all US hospitalisations 
from over 600 hospitals. From 2006 to 2011, both studies showed an increase in the 
use of CTA for assessing ischaemic stroke acutely. This was true for all ischaemic 
stroke patients (3.8% had CTA in 2006 versus 9.1% in 2010)
122
 and for ischaemic 
stroke patients treated with intravenous thrombolysis (18% had CTA in 2008 versus 
20% in 2011).
123
 This trend for CTA use is likely to have increased further recently 
following a new recommendation from the American Heart and American Stroke 
Associations on endovascular intervention following ischaemic stroke
124
 which are 
based on the recent highly positive results from several trials of endovascular therapy 
(see 1.4).
125
 The new guideline states that:  
“Patients should receive endovascular therapy with a stent 
retriever if they meet all the following criteria [a.. b..] c. 
Causative occlusion of the ICA or proximal MCA [d.. e..].” 
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However, it is not explicitly stated how the presence of this occlusion should be 
determined. 
CTA/MRA versus catheter angiography 
Angiography performed with either CT or MRI is known to provide very accurate 
information of arterial flow when compared with the gold standard, catheter 
angiography.
90;91;126-129
  The major limitation is that a standard CTA or MRA obtains 
imaging over a short time period (in the case of CT, this is only a few seconds) and 
therefore provides no information on the speed or direction of blood flow 
(information that can be especially important if collateral supply is being assessed).  
To incorporate this, four-dimensional CTA and MRA have been developed. These 
techniques reimage the field of interest at several time points following the injection 
of contrast or initiation of the stimulatory radio-frequency pulse.  The resultant 




Grading CTA or MRA 
CT and MR angiography in stroke are commonly assessed using either the 
Thrombolysis in Cerebral Infarction (TICI) score or the Mori scale.
133;134
  Both 
scales were however originally developed for the assessment of catheter 
angiography. When properly applied, these scales assess distal tissue perfusion in 
addition to focal arterial luminal narrowing and were developed to be used both in 
the initial assessment of an arterial occlusion and also to measure the extent of 
recanalisation following treatment, i.e. several different components of tissue blood 
supply are being conflated into one scoring system.  Comparatively, standard CTA 
and MRA only allow interpretation of luminal narrowing or focal occlusion (unless 
they are performed in four-dimensions as described above) and therefore the standard 
catheter angiography scores are not wholly appropriate in this context.
135
  Many of 
the studies that have used these scales for assessing CTA or MRA have therefore 
used modified (and non-standardised) versions.
136
  Consequently, it is difficult to 
assess the wider application of angiography rating scales from the available 
literature; as recommended in a recent consensus group statement, greater 
standardisation is required.
137
  The Acute Stroke Imaging Research Roadmap II aims 
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to do exactly that and has suggested use of their modified TICI scale for studies 
assessing CT and MR angiography.
138
 
Additional data with CTA or MRA 
A major benefit of performing angiography with CT or MRI rather than via an intra-
arterial catheter is the additional brain parenchymal imaging that can simultaneously 
obtained.  For a few extra minutes in the scanner, CTA may be preceded by a non-
contrast brain CT while MRA may be enhanced with a few basic stroke sequences 
(e.g. FLAIR, DWI, T2*).  In fact, even if angiography sequences were acquired in 
isolation, additional parenchymal information will still be available.  For example, 
when the window settings of CT angiography images are reset to those of a standard 
non-contrast brain, a simple ‘perfusion’ study is achieved.  Such use of the CTA 
source images (CTA-SI) has been shown to enhance the interpretation of non-
contrast CT and CTA, providing results that are more equivalent to MR imaging in 
stroke by improving the sensitivity of CT for detecting infarct and predicting 
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Figure 2-4 Comparison of visible acute ischaemic changes on standard non-contrast CT and 
CTA-source images 
 
Footnote: CT brain scans performed soon after the onset of severe left MCA territory ischaemia in 
different patients. 
The image on the left is from a standard non-contrast CT; early ischaemic changes in the left MCA 
territory (right side of left image) are very subtle with only loss of normal grey-white matter contrast 
affecting the insular cortex and basal ganglia. 
The image on the right is from a CT angiographic study (note hyperattenuating arterial vessels 
throughout) windowed to best display brain tissue; here, early ischaemic changes in the left MCA 
territory (right side of right image) are comparatively much easier to identify. In addition, reduced 
arterial perfusion can be appreciated on the affected side.  
 
2.2.2 Practicalities of imaging arterial patency in stroke 
It is estimated that during an acute stroke, approximately two million neurons, 14 
billion synapses and 12 km of myelinated fibres are destroyed per minute, i.e. time is 
brain.
143
  Therefore the time required for every intervention or investigation that 
occurs between the acute presentation of a stroke patient and the initiation of 
definitive reperfusion therapy needs to be justified and proven to provide benefit by 
improving outcome, while not causing undue harm.  Inevitably, performing more 
scanning takes more time, increases radiation dose in CT or the risk of aspiration 
while supine in MRI, and reduces oxygen saturation.
144
  Prior to the widespread 
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utilisation of advanced imaging in acute stroke therefore, several factors need to be 
considered.   
Reader reliability 
The first consideration is whether the information from imaging can be consistently 
and repeatedly extracted.  There is variability in the interpretation of non-contrast CT 
for ischaemic stroke, especially in the identification of subtle parenchymal changes 
and potentially among less experienced observers.  A systematic review of inter-
observer agreement for the detection of stroke on non-contrast CT demonstrated 
kappa statistics in the range 0.14-0.78 for the identification of any relevant CT 
finding but the experience level of observers or their number was not clearly stated in 
all cases.
12
  Two more recent observer reliability studies, including large numbers of 
observers (>200) with varying levels of experience and expertise, showed that while 
expert neuroradiologists were more likely than non-neuroradiologists to identify 
subtle stroke signs, the number of years of experience was less important.
145;146
  
Notwithstanding, such reader variability is the baseline upon which more advanced 
imaging techniques will build, i.e. advanced techniques should not significantly 
increase reader variability as this might diminish the value of performing those 
additional techniques in the first place.   
In contrast, there is very little information on the observer reliability of angiographic 
imaging in stroke.  One small study of 17 patients and four observers reported inter-
observer agreement for the identification of arterial occlusion in acute stroke using 
MRA as kappa=0.78.
147
   Another small study assessed the degree of chronic arterial 
stenosis in 25 patients using two observers and found better agreement using MRA 
(kappa=0.78) than CTA (kappa=0.51).
148
 
Technical factors and delay 
Other issues to consider relate to the technical aspects in implementing an advanced 
imaging technique.  These include, a reasonable estimate of the average time each 
additional imaging study is likely to take, a measure of how consistently complex 
imaging is acquired by radiographic staff, the expected increase in radiation exposure 
for CT based modalities, and whether additional hardware or software are required 
for either the creation or interpretation of imaging (i.e. departmental extra costs). 
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Very little data exist to accurately quantify the extra time that is required for 
additional angiographic imaging following non-contrast CT in acute stroke.  In 
general, advocates for these techniques suggest and imply that these extra sequences 
add only a few minutes to the basic imaging requirement, but rarely publish actual 
results.  In reality, staff working in busy imaging centres are likely to have variable 
levels of experience and the efficiency of performing complex imaging is also likely 
to drop when performed out-of-hours.  Additionally, angiographic imaging requires 
more time for image processing and for interpretation.  It has been reported that CT 
angiography requires approximately 15-20 minutes for acquisition and interpretation, 
while a full stroke MR protocol can take more than 20 minutes.
149-152
   
Compared with non-contrast scanning, the acquisition of more complex imaging 
requires greater planning and therefore more opportunity to introduce human error.  
For example, good contrast enhanced angiography requires images to be obtained 
during the peak of the arterial contrast bolus.   
CT radiation dose  
While radiation dose is rarely a concern when assessing acutely unwell patients with 
life threatening pathology, not all of those suffering from an acute stroke can be 
described as such.  The radiosensitive corneas are especially at risk from too much 
radiation as these often lie directly within the x-ray beam when head CT is 
performed and can develop radiation induced cataracts in the medium term.  
Moreover, many stroke patients are of an age where the long term effects of too 
much radiation, i.e. development of a radiation induced malignancy, remains a 
concern.  It should therefore be noted that a non-contrast CT brain requires a median 
total dose (including planning sequences) of approximately 2mSv (inter-quartile 
range 2-3 mSv).  In comparison, a full stroke protocol CT (non-contrast CT, CTA 
and CT perfusion) requires a median dose of 14 mSv (inter-quartile range 9-20 mSv), 
i.e. equivalent to an additional five years of normal background radiation over non-
contrast CT alone.  At these doses, it is estimated that approximately one in every 
2000 patients aged 60 years undergoing a stroke protocol CT will develop a radiation 
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2.2.3 Association between CTA/MRA and acute stroke 
treatment and outcome 
Compared with standard non-contrast imaging, angiography provides extra 
information on the arterial supply to the brain (such as whether there is arterial 
obstruction or occlusion, the location and extent of arterial obstruction/occlusion and 
if there is a collateral supply) but it is less clear whether this information should 
influence management decisions in acute stroke.  It is worth considering how the 
results of CT or MR angiography might alter diagnosis, treatment decisions and 
ultimately, affect clinical outcome. 
Observational studies 
According to a number of non-randomised, single-centre retrospective studies, 
angiographic imaging might improve selection of patients with ischaemic stroke for 
intravenous thrombolysis but some of these results are conflicting and the overall 
picture is non-conclusive. A selection of these results is provided here. In one non-
randomised study of 188 patients with occlusion on CTA, those given intravenous 
thrombolysis were more likely to be independent at six months (35% treated versus 
17% not given thrombolysis, p=0.031).
154
 In two studies comparing proximal versus 
distal MCA occlusions (n=71 and n=225), both studies found proximal occlusion to 
be independently predictive of poor functional outcome at three months.
155;156
 One 
small cohort (n=47) found absence versus presence of occlusion to be an independent 
predictor of independence at day seven (odds ratio, OR=6.8, 95% confidence 
interval, 95%CI=1.3-34.6, p=0.02).
106
 Another analysis comparing those with and 
those without occlusion on CTA (n=168 and n=119, respectively) found no 
difference in three month outcome whether intravenous thrombolysis was given or 
not (p=0.94).
157
 Two non-randomised studies assessed only patients without arterial 
occlusion on imaging. One found better outcomes (OR=3.79, 95%CI=2.04-7.02, 
p<0.01) for those given intravenous thrombolysis (n=103) versus those not treated 
with thrombolysis (n=153)
158
 while the other (n=99) found no association between 
use of intravenous thrombolysis and outcome.
159
 A large (n=654) retrospective 
observational stroke registry  meanwhile observed a non-significant trend for more 
favourable clinical outcome after intravenous thrombolysis in patients with 
intracranial arterial occlusion versus those with no/minimal obstruction in whom it 
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was unclear if intravenous thrombolysis was beneficial or not.
160
 Less extensive 
arterial occlusion/obstruction has been shown to independently predict reperfusion 
following intravenous thrombolysis (OR=1.35, 95%CI=1.14-1.58, p=0.001, 
n=178)
161
 and presumably as a consequence of successful reperfusion, a favourable 
clinical outcome at 90 days (OR=1.56, 95%CI=1.12-2.18, p=0.009, n=85).
162
 While 
in the presence of distal ICA (internal carotid artery) or proximal MCA occlusions, 
poor arterial collateral supply has been shown to predict poor outcome in moderately 
sized (n>200) cohorts and one study showed that multiple scoring methods were 




Very few randomised-controlled trials of intravenous thrombolysis have included 
CTA or MRA to assess whether angiographic findings modify the treatment 
response. A pooled analysis of trials testing desmoteplase (a fibrin specific 
thrombolytic agent derived from vampire bat saliva) - DIAS (Desmoteplase In Acute 
Ischemic Stroke), DIAS-2 and DEDAS (Dose Escalation of Desmoteplase for Acute 
Ischemic Stroke) demonstrated that patients with complete arterial occlusion or 
severe obstruction had better outcomes after desmoteplase rather than placebo, but in 
patients with minimal obstruction or normal arteries, there was no significant 
difference between desmoteplase versus placebo and no significant difference 
between these two groups based on arterial patency (i.e. no interaction between 
arterial patency and thrombolysis).
165
  A post hoc analysis of EPITHET (Echoplanar 
Imaging Thrombolytic Evaluation Trial) demonstrated better outcome amongst 
patients with MCA than ICA occlusion following intravenous alteplase, but they did 




2.2.4 What remained unclear after CT/MR angiography review 
CT and MR angiography are being used more commonly in general clinical practice 
for the assessment of ischaemic stroke.  While these techniques can provide an 
accurate representation of arterial flow to the brain, it is not clear if this knowledge 
improves diagnostic accuracy or how it should influence decisions on the use of 
intravenous thrombolysis for acute ischaemic stroke.   
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Unfortunately, CT and MRI angiography are limited by a lack of standardisation. 
Questions remain over how, when and in whom we should best acquire such imaging 
and how to grade and assess the myriad appearances. We need better data on how 
accurately angiography is scored by readers. It is important to understand more 
clearly the likely delays angiographic techniques will cost the average patient in a 
non-specialist imaging department. Without standardisation it is not possible to 
understand the impact of these technologies on stroke treatment.  Specifically, we 
need to know whether angiographic occlusion or its absence should alter the decision 
to treat with intravenous thrombolysis.  Similarly, it is unclear if the location, 
completeness and longitudinal extent of arterial occlusion need to be considered and 
whether we should also assess collateral supply. Much of this vital information is not 
currently available in a robust form, i.e. there is very little relevant randomised-
controlled trial data to test for treatment interaction between angiographic findings 
and response to thrombolysis.  
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Chapter 3 Third International Stroke Trial (IST-3) 
 
The following details of IST-3 are provided only for context. Most of this work was 
completed before I joined IST-3 as a member of the angiography expert panel.    
 
3.1 Background and Aims of IST-3 
The Third International Stroke Trial (IST-3) was an international multicentre 
prospective randomised open-label blinded endpoint (PROBE) trial that tested 
intravenous thrombolysis (alteplase) versus control for ischaemic stroke presenting 
within 6 hours of symptom onset. IST-3 was devised to become the largest single 
trial of intravenous alteplase for ischaemic stroke.  
The primary measure of outcome was the proportion of patients alive and 
independent at 6 months from randomisation in the alteplase versus control groups.
1
 
At the time of trial planning, there was uncertainty over several specific treatment 
issues which IST-3 aimed to address:
2
 
 Is alteplase of benefit to a wider variety of patients than that defined by 
current approvals, including: 
o Is alteplase effective between 3 and 6 hours from symptom onset? 
o Can alteplase be used safely and effectively in patients older than 80 
years of age? 
 Do early CT imaging features (both those associated with the acute ischaemic 
insult and background chronic changes) predict response to treatment with 
alteplase? 
 Does alteplase affect stroke mortality? 
Various subgroup analyses were therefore also pre-planned in the trial protocol
1
 to 
address these (and other) specific uncertainties, see Table 3-1.  
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Table 3-1 Pre-planned subgroup analyses for IST-3 
Analyses to be performed on the effect of treatment at six months 
among all those allocated alteplase versus control, subdivided by:  
Time from symptom onset (0-3 versus 3-6 hours) 
Age 
Sex 
Clinical stroke syndrome (OCSP classification, see 3.3) 
Presence or absence of atrial fibrillation 
Pre-randomisation brain imaging appearances (extent and severity of 
visible infarct, visible infarct versus not, presence of the dense artery 
sign [HAS], leukoaraiosis, atrophy) 
Use of antiplatelet drugs at time of randomisation 
Stroke severity (NIHSS, see 3.3) 
Blood pressure at randomisation 
Randomisation in a centre with prior experience of using intravenous 
thrombolysis 
Randomisation during the double-blind start-up phase versus 
randomisation during the main (open label) phase 
Footnote: Adapted from the IST-3 main trial protocol.
1
 OCSP = Oxfordshire Community Stroke 
Project. NIHSS = National Institutes of Health Stroke Scale.   
 
In addition, in IST-3 recruitment centres where standard practice included the 
acquisition of ‘advanced’ imaging (i.e. CT or MR angiography and/or perfusion 
imaging) for all patients presenting acutely with stroke, the trial allowed for these 
extra imaging datasets to also be submitted. Advanced imaging would not however 
be used within the main trial analysis. Instead, a pre-specified perfusion and 
angiography imaging sub-study was developed with the explicit aim of determining 
whether CT and MR perfusion or angiographic imaging can be used acutely to 
identify patients with ischaemic stroke more or less likely to benefit from 
intravenous alteplase.
3
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3.2 Ethics, Consent, Trial Registration and Funding 
Ethical approval for IST-3 was granted by the Scotland A Multicentre Research 
Ethics Committee (MREC/99/0/78) and by all national and local ethical committees. 
Written informed consent was obtained for all patients.  In the event of patient 
debility too severe to allow an informed discussion, consent was obtained by proxy 
from family members either in person or over the phone, as appropriate. 
IST-3 was registered with ISRCTN, an open access primary clinical trial registry: 
http://www.isrctn.com/ISRCTN25765518. 
IST-3 was funded from a large number of sources; these are fully documented in 
Appendix 2 (see Chapter 11.2). The IST-3 main trial was primarily funded by the 
UK Medical Research Council (MRC, grant numbers G0400069 and EME 09-800-
15). The IST-3 angiography and perfusion substudy was funded by the National 
Institute for Health Research (NIHR) Efficacy and Mechanisms Evaluation Panel 
(EME 08-43-52). Development of the Systematic Image Review System 2 (SIRS-2, 
an image analysis platform, see 3.4.2) was funded by the Edinburgh MRC Hub for 
Trials Methodology Research (G0800803). 
 
3.3 Recruitment, Randomisation and Data Collection 
IST-3 recruited patients from 156 hospitals in 12 countries. Recruitment for IST-3 
ran from May 2000 to July 2011. Adult patients (18 years or older; importantly, there 
was no upper age limit) with acute stroke of any severity were eligible for 
recruitment into IST-3 when: 
 There was no clear indication for treatment, i.e. they did not meet the 
prevailing license criteria for treatment with intravenous alteplase (first 
licensed for use in the European Union in 2002; administration was initially 
restricted to within 3 hours of stroke onset but this was increased to the 
current 4.5 hours in 2012) 
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 There was no clear contra-indication to treatment  
 Both the treating doctor and patient were uncertain whether or not to give 
treatment to that patient (i.e. the uncertainty principle) 
 Treatment could be started within 6 hours of known stroke onset 
 CT or MR imaging had reliably excluded intracranial haemorrhage or any 
intracranial structural stroke mimic.    
Demographic and baseline clinical data were collected and included: patient age and 
sex, witnessed time and date of stroke onset; time from stroke onset to baseline CT 
or MRI scan; time from stroke onset to randomisation; clinical stroke syndrome as 
defined using the Oxfordshire Community Stroke Project (OCSP) classification, i.e. 
one of - Total Anterior Circulation Infarct (TACI), Partial Anterior Circulation 
Infarct (PACI), Lacunar Circulation Infarct (LACI), or Posterior Circulation Infarct 
(POCI).
4
   
The National Institutes of Health Stroke Scale (NIHSS) was used to assess stroke 
severity at onset: http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf.  NIHSS 
ranges from 0-42 where:  
 0 = No stroke symptoms 
 1-4 = Minor stroke 
 5-15 = Moderate stroke 
 16-20 = Moderate to severe stroke 
 21-42 = Severe stroke 
Patients were randomly allocated to intravenous alteplase (rt-PA, recombinant tissue 
plasminogen activator, 0.9 mg/Kg) or open control.  Treating clinicians used an 
automated telephone or secure online system to enter baseline data and obtain a 
randomised treatment allocation.  Excepting the first 276 patients (initial double-
blinded start-up phase), treatment was given open label, i.e. neither treating clinicians 
nor patients were blinded to treatment allocation. Trial design was changed from 
double-blinded to open label due to cessation in the supply of placebo.  
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Follow-up clinical data were primarily collected at 7 days and 6 months for 
assessment of the primary trial outcome. When patients were uncontactable at any 
time point, efforts were made to determine if they had died. Longer term follow-up 
was carried out at 18 months for all survivors and at 3 years for patients from the UK 
and Scandinavia (Sweden and Norway). Data collected at 7 days included: 
symptomatic intracranial haemorrhage (SICH); recurrent ischaemic stroke; 
neurological deterioration due to brain swelling post infarct; extra-cranial 
haemorrhage and death. At 6 months functional outcome was assessed by the Oxford 
Handicap Scale (OHS) administered by postal questionnaire or telephone interview; 
those conducting telephone interviews were blinded to treatment allocation.
5
  OHS is 
similar to the modified Rankin Scale (mRS, see 1.7.2)
6
 and ranges from 0-6 where: 
 0 = Normal 
 1 = Minor symptoms not restricting lifestyle  
 2 = Minor handicap with some restrictions but independent  
 3 = Moderate handicap, unable to lead a totally independent existence 
 4 = Moderate-severe handicap, unable to live independently but does not 
require constant attention 
 5 = Severe handicap requiring constant attention day and night 
 6 = Death. 
At 18 months from randomisation, OHS was repeated and quality of life was 
measured for survivors using the EuroQol instrument.
7;8
 At 3 years from 
randomisation, survival was assessed in the UK, Norway and Sweden. 
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3.4 Imaging 
 
3.4.1 Imaging protocol 
Prior to recruiting patients into IST-3, receiving centres had to submit test scans to 
ensure their routine image quality was adequate, that the trial imaging protocol 
standards could be met and to test file transfer and image handling processes. All 
imaging was sent to the central trials office for quality control and validation.   
Minimum standards were provided for all imaging acquisition to ensure scans were 
of sufficient quality but without being too restrictive so that most departments did not 
need to change their imaging protocols.  
The IST-3 protocol required that CT scans should cover the entire brain from the 
foramen magnum to the vertex, with maximum slice thickness 4-5mm through the 
posterior fossa and 8-10mm for the cerebral hemispheres, with no slice gap.  Thinner 
slices and spiral scans were also acceptable; given that trial recruitment lasted for11 
years, scanning technology changed considerably during this time and thin-slice CT 
became more common as the trial progressed.   
MRI scans had to include, as a minimum, a gradient echo sequence (T2*) to exclude 
haemorrhage, Diffusion Weighted Imaging (DWI) to identify recent infarct and T1  
& T2/FLAIR to assess for structural abnormality, white matter lesions or old infarcts. 
More specific advisory minimum standards were provided for centres proposing to 
include CT or MR angiography,
3
 Table 3-2.   
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Table 3-2 Advisory minimum standards for a) CT and b) MR angiography acquisition 
a) CT Angiography 
Kvp 100 
mAs 120 
Contrast (volume/type/rate) 50 ml Omnipaque 300 at 4 ml/sec 
Flush (volume/type/rate) 40 ml saline at 4 ml/sec 
Delay 15 secs 
Coverage  Circle of Willis (upwards)  
Slice collimation  0.75 mm 
Pitch 1.25 
 
b) MR Angiography 
Sequence 3D TOF 2 slab HR 
TR (ms) 23 
TE (ms) 2.7 
Flip angle 20° 
Locs / slab 32 
Slice thickness 1.6 
Slice gap 0 
Matrix 320 x 224 
Φ FOV 1 
FOV 16 cm 
Slice orientation Straight axial 
Tscan  5:46 
Footnote: TOF = Time of flight 
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Follow-up brain imaging was obtained for all patients where possible.  It was 
expected that follow-up imaging, either CT or MRI, would be obtained at 24-48 
hours from stroke onset to the same protocol as for baseline imaging. However scans 
performed earlier due to clinical deterioration were also accepted. All brain imaging 
for each patient performed within 7 days of stroke onset was to be sent to the IST-3 
central office. Follow-up imaging was not performed if patients were deemed too 
unwell at the proposed time of scanning. 
 
3.4.2 Image analysis 
All imaging in IST-3 was collected centrally as DICOM (digital imaging and 
communications in medicine) where possible; cut film was collected if digital 
imaging was not available for transfer. Cut film was later redigitised. All imaging 
was then assessed centrally by experts at reviewing brain imaging in stroke.  Expert 
assessment was performed masked to patient demographics, clinical data and any 
other imaging, i.e. those assessing baseline imaging were not given access to follow-
up imaging and vice versa, and for the main IST-3 trial, expert readers were not 
given access to concurrently acquired angiography (or perfusion) data.  For 
assessment of imaging data in the IST-3 angiography substudy, expert readers were 
given simultaneous access to both plain and angiographic imaging when it was 
acquired concurrently. 
Two centralised expert imaging assessment panels, each of ten readers were 
constructed; one for the main IST-3 trial and one for the angiography substudy (see 
Appendix 1, Chapter 11.1.1 and 11.1.2, respectively).  Expert panel assessments of 
imaging for the main trial and for the angiography substudy were performed 
independently.  Imaging assessment for the main trial occurred in line with 
recruitment from the outset of IST-3 until the 27
th
 March 2012. Expert panel 





 July 2013, i.e. there was no overlap, but angiography subgroup plain 
scans were read by both expert panels. 
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All image analysis for IST-3 was performed using an in-house image viewing 
platform compatible with both DICOM and all redigitised imaging, entitled the 
Systematic Image Review System, SIRS. SIRS was developed for IST-3 and tested 
in a prior analysis of CT reader reliability in stroke comprising many readers from 
different international locations.
9;10
 The system was later developed further; SIRS-2 
also allowed for the assessment of angiographic and perfusion imaging in addition to 
standard CT and MR imaging, see: http://sirs2.neuroimage.co.uk/sirs2/. SIRS-2 
allowed readers to review scans online via a standard web browser.  Readers could 
only access those scans which had been allocated to them, i.e. appropriate blinding 
was assured.  SIRS-2 allowed users to display two allocated scans side by side and to 
perform all standard image manipulations (e.g. zoom, pan, scroll), but users could 
not create multiplanar reformats.  Plain CT scans were presented with the following 
default settings but these could be changed to suit user preferences: windowed on 80 
Hounsfield Units (HU) width and centre level of 35-40 HU.   
Questionnaires were developed and validated for the expert assessment of CT and 
MR imaging in IST-3.  These questionnaires included scoring for both acute 
(imaging features representing ischaemia; secondary brain swelling; hyperattenuated 
arteries – HAS; presence, completeness and extent of angiographic obstruction or 
occlusion; arterial collateral status on angiography; brain tissue ‘perfusion’ on CTA 
source images – CTA-SI; haemorrhage) and chronic brain changes (atrophy, 
leukoaraiosis, old stroke lesions, non-stroke lesions); see Appendices 9 and 10 for all 
available CT and MRI scoring options; Chapters 11.4.1 and 11.4.2, respectively.  
Table 3-3 summarises the questions and available selection options relevant to 
assessment of HAS and also CT and MR angiography as the main points of interest 
in this thesis.  The SIRS-2 platform displayed imaging and the appropriate 
questionnaire on the same screen; readers could view imaging and submit their 
interpretation of imaging findings simultaneously (Figure 3-1).  Reported image 
findings were then immediately and securely stored in a central database.  
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Table 3-3 Questions presented to SIRS-2 users for assessing the hyperattenuating artery sign 
on plain CT and for assessing CT/MR angiography   
Question Options 
Is there a hyperattenuated artery on plain CT? Y or N 
Is there an abnormal/occluded artery on 
CTA/MRA? 
Y or N 
Name abnormal artery if ‘Y’ to either of above, 
indicate which artery(ies). List most important 
(largest) abnormal artery first (1) and least 
important (smallest) last (3) if more than one. 
1) ICA 
2) MCA stem 










0) No flow/patency 
1) Minimal flow/patency 
2a) Partial flow/patency <50% of 
expected territory 
2b) Partial flow/patency >50% of 
expected territory 




0) No patency 
1) Minimal patency – some contrast 
penetrates obstruction but no/minimal 
enters distal artery 
2) Patency of <50% of the lumen and 
some filling of branches of the distal 
artery 
3) Patency of >50% of the lumen and 
filling of most branches of the distal 
artery 




From a total score for normal arteries 
of 10, two points are subtracted for 
thrombus found on angiography in the 
supraclinoid ICA and each of the 
proximal and distal halves of the MCA 
trunk. One point is subtracted for 
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thrombus found in the infraclinoid ICA 
and A1 segment and for each affected 
M2 branch. 
In occluded ICA/MCA only: 
Score for collateral status
13
 
A ‘Good’ = entire MCA distal to the 
occluded segment reconstituted with 
contrast 
B ‘Moderate’ =  if some of the MCA 
branches reconstituted within the 
Sylvian fissure 
C ‘Poor’ = if only the distal superficial 
MCA branches reconstituted with 
contrast 
Is there are area on CTA-SI of brain tissue 
contrast enhancement deficit? 
Y or N 
Footnote: This is an abridged version of the IST-3 image scoring proforma; see Appendices 9 and 10 
for the full CT and MRI questionnaires, respectively.  
ICA = Internal Carotid Artery, MCA = Middle Cerebral Artery, PCA = Posterior Cerebral Artery, 
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Figure 3-1 Screenshot from SIRS-2 displaying simultaneous image viewing and image rating 
options for expert readers  
 
 
3.5 Storage and Management of Data 
All clinical and imaging datasets in IST-3 were checked for quality and consistency, 
catalogued and de-identified prior to being entered into final databases for analysis 
and storage.  
De-identification included removal of DICOM headers as appropriate. For each 
patient, identifiable data was replaced with a unique IST-3 participant number 
allocated chronologically from IST30001 as patients were enrolled.  The de-
identification key was stored in a separate database from the main trial data and only 
a few individuals had access to this key. 
All data were stored centrally within University of Edinburgh servers with strict user 
access control and in full compliance with the University of Edinburgh Research 
Data Management Policy: http://www.ed.ac.uk/information-services/about/policies-
and-regulations/research-data-policy. 
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In accordance with the UK MRC recommendations for sharing of individual patient 
level data from publically funded clinical trials,
14
 the IST-3 collaborative group has 
lodged an anonymised version of the clinical dataset (this does not currently include 
DICOM or redigitised imaging but does include expert panel assessments of 
imaging) with Edinburgh DataShare: http://datashare.is.ed.ac.uk/handle/10283/1931. 
This will enable interested bona fide researchers to apply for direct access to IST-3 
data.
15
   
 
3.6 Statistical Analysis Plan 
In order to be completely transparent over data analysis, the IST-3 Collaboration 
published a statistical analysis plan for the trial shortly before the final data set was 
locked, before data analysis commenced and therefore before the IST-3 investigators 
were un-blinded to the results.
16
 By this means there was no risk of introducing 
analysis bias where researchers might, even inadvertently, manipulate the analysis 
strategy to produce the most favourable results.    
Analyses were performed by intention to treat. That is, patients were included in the 
treatment group they were randomised to for all analyses, even if their treatment 
subsequently changed for clinical or technical reasons (for example, if a control 
patient eventually received intravenous alteplase outside of the trial or if there was 
failure to administer intravenous alteplase to a patient allocated to the treatment arm 
of the trial).   
For assessment of the primary measure of outcome (proportion alive and independent 
six months after randomisation), a simple two-by-two analysis (crossing outcome 
dichotomy with treatment allocation) was planned in keeping with previous 
randomised-controlled trials of intravenous alteplase. This analysis was performed 
both with and without adjustment for: patient age; NIHSS; time from stroke onset to 
randomisation; and presence (versus absence) of signs of acute ischaemia on the 
baseline scan. In addition, a further analysis was planned using ordinal logistical 
regression analysis with OHS as the dependent variable.
16
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IST-3 was powered to deliver definitive results on the efficacy of alteplase in this 
context.  The initial recruitment target was 6000; at this level there was 80% power 
to detect a 3% difference. However the recruitment target was reduced to 3100 in 
2007, due to lower recruitment rates than expected; at this level there was 80% 




3.7 Major IST-3 Results and Impact 
In total, IST-3 recruited 3035 patients. The main IST-3 results were published in 
2012. For the primary measure of outcome, a greater proportion of patients were 
alive and independent at six-months in the treatment versus control groups (554/1515 
= 37% versus 534/1520 = 35%, respectively), but this difference was not significant 
(p=0.181). However, when OHS was analysed as a scalar variable rather than 
dichotomously, i.e. using ordinal regression analysis, patients in the treatment group 
had significantly better outcomes; adjusted odds ratio, OR = 1.27 (95% confidence 
interval, 95%CI = 1.10-1.47, p=0.001).
17
   
Secondary analyses showed that while more deaths occurred in the first 7 days 
among patients treated with alteplase compared to controls, there were 
correspondingly fewer deaths in the treatment group over the following 6 months 
such that in total, death rates were the same in both groups (27%).  IST-3 
demonstrated better outcomes for patients treated within 3 hours (OR = 1.64, 95%CI 
= 1.03-2.62) but was underpowered to detect a significant difference in treatment 
effect between patients treated <3 hours versus >3 hours (p value for interaction = 
0.613). Compared with prior trials, IST-3 has a large proportion of patients >80 years 
old (1617/3035 = 53%). Contrary to conventional wisdom at the time, IST-3 showed 




After publication, the main IST-3 results were included in two systematic reviews of 
tabular randomised-controlled trial data of thrombolytics for the treatment of 
ischaemic stroke. The first comprised 12 trials testing intravenous alteplase and 
included 7012 patients (i.e. IST-3 contributed 43% new data).
18
 The second was an 
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update of the Cochrane Collaboration systematic review and comprised 27 trials and 
included 10187 patients (IST-3 contributed 30% new data) testing one of five 
different thrombolytics (urokinase, streptokinase, alteplase, recombinant pro-
urokinase or desmoteplase) delivered either intravenously or intra-arterially.
19
 Both 
reviews reached the same main conclusion: that despite the early risk of 
haemorrhage, thrombolytics were of significant net benefit for the treatment of 
ischaemic stroke and 1) increased the odds of being alive and independent at final 
follow-up (OR = 1.17, 95%CI = 1.06-1.29, p=0.001)
18
 or 2) reduced the odds of 
being dead or dependent 3 to 6 months after stroke (OR = 0.85, 95%CI = 0.78-0.93, 
p=0.0002).
19
   
Longer follow-up of IST-3 patients at both 18 months and 3 years from 
randomisation showed continued benefit for treatment with alteplase. At 18 months, 
the favourable shift in OHS for the treatment group remained significant, i.e. treated 
patients were still more likely to have better functional outcome on ordinal 
regression analysis (adjusted OR = 1.30, 95%CI = 1.10-1.55, p=0.002). In addition 
and perhaps as a consequence, treated patients self-reported a significantly better 
quality of life at 18 months using the EuroQol instrument (adjusted mean difference 
= 0.06, p=0.019).
20
 At 3 years, patients treated with alteplase were less likely to have 




A secondary analysis of the expert panel assessment of IST-3 imaging tested whether 
evidence of early ischaemia or pre-existing structural changes on baseline brain 
imaging affected the response to alteplase and whether there were any associations 
between baseline brain imaging and 6-month outcome.
22
 Although several imaging 
characteristics (tissue hypoattenuation on CT, a large lesion, swelling, a 
hyperattenuated artery, old infarct, atrophy and leukoaraiosis) independently 
predicted symptomatic intracranial haemorrhage and/or poorer outcome in IST-3 
(adjusted for age, NIHSS, time to randomisation and treatment allocation), none of 
the tested imaging characteristics (individually or combined) modified the effect of 
alteplase on symptomatic intracranial haemorrhage risk (p-value 0.082 to 0.568) or 
likelihood of achieving a good functional outcome (p-value 0.237 to 0.960). In other 
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words, the treatment and control groups in IST-3 did not differ significantly in their 
risk of symptomatic haemorrhage or likelihood of a better functional outcome for 
patients with and without any of the specific imaging characteristics assessed.
22
        
 
3.8 IST-3 Data Used Within this Thesis 
Much of the work contained within this thesis is based on analysis of IST-3 patient 
data. In addition to the complete IST-3 trial dataset (n=3035) I also used two 
overlapping subsets: 
1. All IST-3 patients with non-contrast CT performed at baseline (pre-
randomisation) 
2. All IST-3 patients with CT or MR angiography performed at baseline. 
For a small number of IST-3 scans (18 baseline and 55 follow-up), imaging was not 
received centrally and could therefore not be included in any analyses based on 
central expert reads (in these cases, the main trial analysis was based on image 
interpretation provided by local experts). In addition, 50 patients were too unwell 
(13) or had died (37) at the proposed time of follow-up scanning and so never had a 
repeat scan. 
Most centrally reviewed brain imaging in IST-3 was non-contrast CT: at baseline 
2961/3035 (97.6%) scans were non-contrast CT and 56/3035 (1.8%) were MRI; at 
24-48 hour follow-up 2779/2985 (93.1%) scans were non-contrast CT and 151/2985 
(5.1%) were MRI.  In total, 2731 (90.0% of 3035) patients had centrally reviewed 
non-contrast CT performed both at baseline and follow-up. 
IST-3 recruited 300 patients with baseline angiography: most were performed using 
CT (271/300, 90.3%) rather than MRI (29/300, 9.7%). 
Table 3-4 compares demographic and clinical data for the entire IST-3 group 
(n=3035) with the baseline non-contrast CT (n=2961) and angiography (n=300) 
subgroups, respectively.  
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full IST-3 & 
baseline CT 
groups 






full IST-3 & 
angiography 
groups 






0.952 132 (44.0%) 0.119 
Mean Time 
Stroke Onset to 
Baseline Scan, 
minutes (SD) 
164 (73) 163 (73) 0.707 180 (80) <0.0001 
Mean Time 
Stroke Onset to 
Randomisation, 
minutes (SD) 
231(73) 231(73) 0.844 241 (80) 0.019 
Time to Follow-






25 hours   
(24-29) 
0.006 
NIHSS 11 (6-17) 11 (6-18) 0.821 9 (5-17) 0.003 
OHS 4 (2-6) 4 (2-6) 0.850 3 (1-5) 0.001 
Independent at 






0.817 134 (44.7%) 0.001 






0.956 67 (22.3%) 0.063 






0.877 147 (49.0%) 0.738 
Footnote: Results are n (%) or median (interquartile range), unless stated otherwise. NCCT = Non-
contrast CT. SD = Standard Deviation. NIHSS = National Institutes of Health Stroke Scale (baseline). 
OHS = Oxford Handicap Scale (at 6 months). 
 
There were no significant differences between IST-3 patients with non-contrast CT at 
baseline and the full IST-3 group (i.e. including those without centrally assessed 
imaging or MRI at baseline). Patients with non-contrast CT at baseline were well 
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balanced for age, sex, NIHSS and time from stroke onset to scan/randomisation 
between alteplase and control, with no significant differences between groups (Table 
3-5a). 
Patients with angiography had less severe strokes at baseline than those in the full 
IST-3 trial (median NIHSS 9 versus 11 respectively, p=0.003), better six-month 
outcomes (median OHS 3 versus 4 respectively, p=0.001), had baseline scanning 
later (mean 180 minutes versus 164 minutes respectively, p<0.0001) and were 
randomised later after stroke onset (mean 241 minutes versus 231 minutes for the full 
IST-3 trial, p=0.019).  There was no significant difference between patients with 
angiograms versus the full IST-3 trial for patient age, sex or treatment allocation.  
Patients with angiograms were well balanced for age, sex, NIHSS and time from 
stroke onset to scan/randomisation between alteplase and control, with no significant 
differences between groups (Table 3-5b). 
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Table 3-5 Comparison of alteplase and control groups: 
a) IST-3 patients with non-contrast CT at baseline (n=2961) 
 Alteplase  
(n=1484) 




Age, years 81 (72-86) 81 (72-86) 0.639 
Male Sex 718 (48.4%) 709 (48.0%) 0.836 
Mean Time Stroke Onset to 
Baseline Scan, minutes (SD) 
163 (72) 163 (72) 0.773 
Mean Time Stroke Onset to 
Randomisation, minutes (SD) 
231 (73) 231 (72) 0.902 
NIHSS 11 (6-18) 11 (6-17) 0.995 
OHS 3 (2-6) 4 (2-6) 0.072 
 
b) IST-3 patients with CT or MR angiography at baseline (n=300) 
 Alteplase    
(n=147) 




Age, years 81 (73-86) 80 (69-85) 0.274 
Male Sex 63 (42.9%) 69 (45.1%) 0.697 
Mean Time Stroke Onset to 
Baseline Scan, minutes (SD) 
184 (82) 176 (78) 0.344 
Mean Time Stroke Onset to 
Randomisation, minutes (SD) 
243 (82) 238 (79) 0.584 
NIHSS 10 (5-17) 9 (5-16) 0.603 
OHS 3 (1-5) 3 (1-5) 0.726 
Footnote: Results are n (%) or median (interquartile range), unless stated otherwise. SD = Standard 
Deviation. NIHSS = National Institutes of Health Stroke Scale (baseline). OHS = Oxford Handicap 
Scale (at 6 months). 
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Chapter 4 General Methods 
 
4.1 Overview of Analyses Undertaken in Pursuit of 
Thesis Aims 
Most of the work in this thesis focusses on imaging arterial patency using CT rather 
than MRI since CT is far more frequently used in routine practice for the hyperacute 
initial imaging assessment of the brain in stroke and consequently was the 
predominant imaging modality collected in IST-3. 
Work undertaken to address thesis aims was based on both newly collected data and 
assessment of existing data as follows: 
Collection and assessment of new data 
 In IST-3 patients with baseline angiography, I reviewed imaging to identify, 
classify and measure the attenuation of arterial obstructions on plain CT and 
correlated the location and extent of plain CT findings with angiographic 
appearances 
 I derived sensitivity and specificity data of HAS for the identification of 
arterial obstruction from my assessment of IST-3 imaging and compiled these 
results in a systematic review and meta-analysis  
 I arranged a multi-reader CTA observer reliability analysis using 
representative cases from IST-3  
Assessment of existing data 
 I analysed data from the IST-3 expert scan reading panel’s assessment of 
baseline and follow-up CT imaging (see 3.4.2) to investigate the importance 
of HAS in relation to stroke severity, response to intravenous thrombolysis 
and outcome 
 I analysed data from the IST-3 expert scan reading panel’s assessment of 
baseline CT and MR angiography (see 3.4.2) to investigate the importance of 
arterial obstruction and other angiographic appearances in relation to stroke 
severity, response to intravenous thrombolysis and outcome 
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4.1.1 Datasets used 
As described in the previous Chapter (3.8), the following datasets have been used 
throughout in the production of this thesis and are defined here with reference to 
appropriate subchapters. 
Main IST-3 trial data 
This dataset represents all 3035 patients recruited into IST-3 and was used for 
establishing the representation of subgroups (Chapter 3.8). 
Main IST-3 trial non-contrast CT data 
This dataset represents the 2961 patients recruited into IST-3 with non-contrast CT at 
baseline and is used for analyses of HAS (Chapter 5).  
IST-3 angiography subgroup 
This dataset contains 300 patients who had CT or MR angiography routinely 
performed at baseline and is used for the analyses: quantifying the attenuation of 
HAS and other non-hyperattenuating arterial obstructions (Chapter 6); identifying the 
sensitivity and specificity of HAS as a marker of arterial obstruction (Chapter 7); and 
for all analyses of CT and MR angiography (Chapters 8 and 9). 
Full details of these datasets and comparisons between the full trial and subgroups 
are presented in Chapter 3.8. 
 
4.2 New Analysis of IST-3 Imaging 
Image analyses discussed in this section are listed in the chronological order in which 
they were performed by me.  Note that this order does not necessarily match the 
order of the thesis aims or therefore the sequence of the major research chapters of 
the thesis. This choronology was dictated so that at all times, IST-3 data were made 
available to me incrementally as needed to maintain reader blinding (especially for 
treatment allocation of individual patients) and to minimise the chance of introducing 
bias.  The IST-3 data management team handled the provision of data. 
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First, I identified all patients in IST-3 for whom a baseline angiographic study was 
available (ideally performed within 30 minutes of the initial pre-randomisation CT 
scan).  Both CT and MR angiography were deemed acceptable but since HAS is a 
CT sign, pre-randomisation plain imaging needed to include a CT.    
For my analyses, I reviewed all imaging using Digital Jacket (V5.0, DesAcc Inc, 
Terre Haute, IN, USA) DICOM viewing software.  Digital Jacket has a standard 
viewing window upon which basic measurement annotations can be applied (see 
Figure 4-1).  
 
Figure 4-1 Screenshot from Digital Jacket software demonstrating application of intra-
arterial attenuation measurement (Ellipse 1 placed within the main branch of right middle 
cerebral artery) on plain CT 
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I performed my image analysis in a similar manner to that undertaken by the IST-3 
expert panels as described in the previous chapter (3.4.2) and I used the same image 
assessment questionnaires developed for IST-3 (see Appendices 9 and 10, Chapters 
11.4.1 and 11.4.2, respectively) although I selected only those questions relevant to 
my work.  All data were stored in a spreadsheet (Appendix 11, Chapter 11.4.3). 
Non-contrast CT 
I reviewed the pre-randomisation non-contrast CT first in each case.  Using the 
validated IST-3 CT assessment proforma (Appendix 9, Chapter 11.4.1) for 
standardisation, I assessed scans for: the location and extent of any acute ischaemia; 
the location and extent of any HAS; the extent of secondary oedema; the presence of 
other infarcts (old or new); and for the presence and extent of chronic brain changes 
(leukoaraiosis and atrophy).  For each scan, I noted the DICOM stored date and time 
and assessed image quality (good, moderate or poor) based on patient position and 
the presence of any imaging artefacts (e.g. movement or beam hardening artefact).   
I assessed extent of ischaemic change with the IST-3 ischaemia score
1
, ASPECTS 
(Alberta Program Early CT Score),
2
 and the 1/3 MCA concept (that is, to make a 
visual assessment of whether more than one third of the MCA territory is affected by 
ischaemia, this idea was first popularised following a post-hoc analysis of ECASS 
[European Cooperative Acute Stroke Study]
3
); the IST-3 score covers all brain 
regions and ranges from 0 (normal scan) to 4 (very large volume of brain affected), 
see Table 4-1 .  In addition, the IST-3 score contains coding for the location of 
affected brain.  ASPECTS assesses only the middle cerebral artery (MCA) territory 
and normally ranges from 10 (normal) to 0 (entire territory affected); the anterior and 
posterior cerebral artery territories can be added to the standard ASPECTS giving a 
total normal score of 12 covering the entire cerebral hemisphere.  If present, old 
infarcts were also assessed using the IST-3 ischaemia score.    
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Middle Cerebral Artery 
(MCA) Territory  
Small cortical  1 
Basal ganglia (>2 x 2 x 2 cm) 2 
White matter adjacent to lateral ventricle 
(>2 x 2 x 2 cm) 
2 
Anterior or posterior half of peripheral 
MCA territory not involving basal 
ganglia 
2 
Anterior or posterior half of peripheral 
MCA territory involving part of the  
basal ganglia 
3 
Whole of the peripheral MCA territory 3 
Whole of the peripheral MCA territory 
and part of the basal ganglia 
4 
Whole of the MCA territory 4 
Anterior Cerebral Artery 
(ACA) Territory 
Up to half of ACA territory 1 
More than half of ACA territory 2 
Posterior Cerebral Artery 
(PCA) Territory 
Up to half of PCA territory 1 
More than half of PCA territory 3 
MCA territory & up to half of ACA or PCA territories 3/4* 
MCA territory & more than half of ACA or PCA territories 3/4* 
Whole of MCA, ACA and PCA territories 4 
Lacune in basal ganglia, internal capsule, internal borderzone, centrum 
semiovale, thalamus or brainstem 
1 
Anterior or posterior borderzone 1 
Cerebellum 
Small cortical 1 
Less than half of a hemisphere 2 
More than half a hemisphere 3 
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Brainstem 
Small (e.g. less than half of pons) 1 
Extensive (e.g. pons & medulla) 2 
Footnote: MCA = middle cerebral artery. ACA = anterior cerebral artery. PCA = posterior cerebral 
artery. This classification system was also used by the expert panel readers in IST-3. 
* 3 if MCA component 1 or 2, 4 if MCA component 3 or 4. 
 
I identified hyperattenuated arteries by applying the following criteria.  HAS was 
considered to be present when: 
 An intracranial artery was affected 
 Intraluminal attenuation (to differentiate from vessel wall calcification, a 
common finding in the elderly) was clearly greater (i.e. brighter on imaging) 
than equivalent vessels or adjacent brain
4
 
I classified HAS location by selecting the three largest vessels affected from a pre-
defined list: 
 Internal carotid artery (ICA) 
 MCA main stem (horizontal segment on axial imaging, sometimes referred 
to as M1) 
 MCA Sylvian or cortical branches (vertical branches on axial imaging, M2-
M4) 
 Vertebral artery (VA) 
 Basilar artery (BA) 
 Anterior cerebral artery (ACA) 
 Posterior cerebral artery (PCA) 
I assessed brain swelling using a validated scale that ranges from 0 to 6
1
, Figure 4-2: 
 0 = no swelling 
 1 = effacement of the sulci overlying the infarct 
 2 = 1 + minor effacement of adjacent lateral ventricle 
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 3 = 1 + complete effacement of lateral ventricle 
 4 = 1 + effacement of the lateral and third ventricle 
 5 = 4 + shift of the midline away from the side of the ventricle 
 6 = 5 + effacement of the basal cisterns 
 
Figure 4-2 Examples of the different grades of brain swelling as demonstrated on plain CT 
following infarct 
 





I then proceeded to take intra-arterial attenuation measurements from within all HAS 
and in up to three standard locations for each case: a proximal section of both the left 
and right MCAs and within the basilar artery. Where HAS was identified in one of 
the standard locations, only HAS measurements were recorded for that location. In 
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each location, using an attenuation measurement tool, three ellipses were drawn 
taking care to ensure that each ellipse was contained entirely within arterial lumen, 
i.e. to minimise the effect of arterial wall calcification on attenuation measures 
(Figure 4-1).  I did not standardise ellipse dimensions but adapted these for each case 
to ensure best intraluminal fit. Where possible, overlap of the ellipses was avoided.  
Later, I calculated a mean intraluminal attenuation value from the three elliptical 
measurement values for each standard arterial location and for each HAS, if present. 
CT or MR angiography 
I only reviewed angiographic imaging after the corresponding non-contrast CT had 
been completely assessed; i.e. my assessments of HAS were performed blind to 
angiography appearances. In addition, I performed baseline imaging assessment 
blind to follow-up imaging. Several angiography measurement scales were used as 
detailed in the validated IST-3 angiography assessment proforma (Appendix 9 for 
CTA, Chapter 11.4.1 and Appendix 10 for MRA, Chapter 11.4.2) and listed in Table 
3-3, including the IST-3 angiography score, the Thrombolysis in Cerebral Infarction 
(TICI) score, the Clot Burden Score and a collateral status score.
5-8
  CTA source 
image review was also performed as previously described. For each CT angiographic 
scan, I noted the DICOM stored date and time and objectively assessed image quality 
(good, moderate or poor) based on timing of arterial contrast bolus (i.e. not too early 
or too late) and scan coverage (ideally centred on the circle of Willis and of 
significant imaging volume to assess all major intracranial arteries). Later, I 
subtracted the date and time of non-contrast CT from the date and time of CT 
angiography to calculate the extra time required for CT angiography in IST-3.   
If I identified an angiographic obstruction in the absence of HAS, intra-arterial 
attenuation measures were then repeated retrospectively in an identical location on 
non-contrast CT using the technique as described above.  Arterial locations were 
matched by viewing non-contrast CT and angiographic imaging side by side on the 
same screen at equivalent slice locations. 
Follow-up imaging 
I assessed follow-up non-contrast CT or MR imaging in the same manner as for 
baseline imaging but with knowledge of baseline imaging findings, i.e. non-blinded.  
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First, I noted the DICOM stored date and time so that an accurate time from baseline 
to follow-up scan could be calculated.   
In all cases, I noted and scored the presence of subacute ischaemia or new infarct 
using both the IST-3 ischaemia score and ASPECTS.  If haemorrhage was present, 
this was measured and classified (e.g. minor petechial or extensive haemorrhagic 
transformation of infarct, haemorrhage remote from infarct, etc.) as per the validated 
IST-3 scoring options for CT and MRI; Appendix 9 for CT, Chapter 11.4.1 and 
Appendix 10 for MRI, Chapter 11.4.2.   
I noted whether HAS had completely resolved or persisted between baseline and 
follow-up non-contrast CT brain imaging. For patients with persistent HAS on 
follow-up imaging, I repeated intra-arterial attenuation measures as described above. 
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Chapter 5 Hyperattenuating Artery Sign 
In this chapter, I use existing IST-3 data (expert panel assessment of non-contrast CT 
imaging, n=2961) to identify the prevalence of HAS in IST-3 and to quantify HAS 
location and extent. I also use these data to investigate relationships between HAS 
presence, stroke severity at baseline, response to intravenous alteplase and functional 
outcome at six months. 
This chapter addresses Thesis Aims 1) and 2).  
This work is also published in a peer reviewed journal, the final draft of which is 
included as Appendix 4, see Chapter 11.3.2: 
Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, 
Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, 
Sandercock PAG, Lindley RI and Wardlaw JM for the IST-3 
Collaborative Group. Effect of alteplase on the CT 
hyperdense artery sign and outcome after ischemic stroke. 
Neurology 2016;86:1-8 
 
5.1 Methods for Analysis of IST-3 Expert Panel Image 
Assessment Data 
HAS prevalence was calculated by identifying all patients with HAS in any 
intracranial location visible on baseline imaging.  Using the largest vessel affected, 
HAS location was classified as proximal (ICA, main stem MCA, VA, BA) or distal 
(Sylvian branch of MCA, ACA, PCA).  HAS extent was classified by the number of 
contiguous named vessels involved (0, 1, 2 or 3 as per the pre-defined options listed 
previously in Table 3-3).   
Baseline and follow-up scans were compared in those who had non-contrast CT 
performed in both instances.  The absolute change in HAS segment number from -3 
to +3 was calculated (negative numbers indicate shrinkage and positive numbers 
indicate growth of HAS).  This new variable was then used to define post-hoc 
subgroups for patients with HAS as follows: (a) Persisting HAS, i.e. unchanged, (b) 
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Disappearing HAS, i.e. completely disappeared, (c) New HAS, (d) Growing HAS, 
and (e) Shrinking HAS. 
Patients with any evidence of HAS on baseline scan were compared with those 
without HAS at baseline. Associations were sought between the presence, location, 
extent and persistence of HAS, stroke severity at onset (NIHSS), six-month 
functional outcome (OHS) and treatment with alteplase (alteplase versus control).  
  
5.1.1 Statistical testing 
 
Univariate analyses 
Simple t-tests were employed to compare ratios and to compare the means of 
normally distributed continuous data. The medians of non-parametric continuous 
data were compared using a Mann-Whitney U test. Odds ratios, OR (with 95% 
confidence intervals, 95%CI) and chi-square statistics (χ
2
) were used to compare 




 were used to calculate common ORs for dependent 
variables: OHS at six months and change in HAS segment number. 
To stabilise ordinal regression estimates, I used the same approach as the original 
IST-3 analysis of functional outcome, where the more severe grades of OHS (4-6) 
were grouped as one, leaving 5 groups for ordinal analysis (0, 1, 2, 3 and 4-6).
2
 
Similarly, several other variables were stratified: time from stroke onset to baseline 
scan, was grouped into 6 one-hour windows (0-60, 61-120, 121-180, 181-240, 241-
300 and 301-360 minutes); the variable time from baseline scan to follow-up scan 
was grouped into 5 twelve-hour windows (<=12, 13-24, 25-36, 37-48 and >48 
hours); and change in HAS segment number was grouped into three outcomes (fewer 
segments = shrinkage, no change, more segments = growth).   
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Statistical software 
Comprehensive Meta-Analysis software (Biostat, Englewood, NJ, USA) was used to 
compute summary ORs and to perform tests of interaction between treatment groups. 
All other analyses were performed using IBM SPSS Statistics software, version 20.0 
(IBM Corporation, Armonk, NY, USA). 
A p-value <0.05 was considered significant. 
 
5.2 Prevalence, Location and Extent of HAS in IST-3 
 
Prevalence of HAS 
Among 2961 patients in IST-3 with NCCT at baseline, HAS was present in 716 
(24.2%) and absent in 2245 (75.8%) according to the expert panel assessment of 
imaging, Table 5-1.   
Similarly, expert readers independently identified HAS on 531 of 2779 (19.1%) 
NCCT at follow-up (HAS data were not available for 1 follow-up NCCT scan).  
The total number of IST-3 patients with NCCT performed at baseline and follow-up 
was 2731. Of these, 870 patients had HAS on at least one of their scans. 
Location and extent of HAS 
A proximal location for HAS (ICA, horizontal segment of MCA, VA or BA) was 
most common, found in 534 IST-3 patients (74.6% of those with the sign) at 
baseline. HAS exclusively affected a distal vessel in 182 patients (25.4% of those 
with the sign) at baseline. 
Most HAS affected only a single vessel segment at baseline (589, 82.3% of those 
with the sign); having 2 or 3 affected vessel segments was progressively less 
common. 
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Table 5-1 Prevalence, location and extent of HAS in IST-3 on baseline CT  




Prevalence 716 (24.2) 
Location 
Proximal Vessels Only 430/716 (60.1) 
Distal Vessels Only 182/716 (25.4) 
Proximal and Distal Vessels 104/716 (14.5) 
Extent 
1 Segment 589/716 (82.3) 
2 Segments 115/716 (16.1) 
3 Segments 12/716 (1.7) 
Footnote: Results are n (%). 
 
 
5.3 Effect of HAS on Stroke Severity, Six-Month 
Outcome and Response to Intravenous Alteplase 
in IST-3 
 
Comparison of those with and without HAS at baseline 
Patients in IST-3 with HAS on baseline CT were slightly younger than those without 
HAS (median 80 versus 81 years, p=0.003).  Patients with HAS had a more severe 
stroke at baseline (median NIHSS 16 versus 9, p<0.001) and worse six-month 
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Table 5-2 Demographic and clinical data of patients with and without a HAS on baseline CT 
 HAS 
n = 716 
No HAS 
n = 2245 
p-value for 
difference 
Age (median, IQR) 80 years (70-85) 81 years (72-86) 0.003 
Male sex  356 (49.7%) 1071 (47.7%) 0.348 
Stroke onset to baseline 
Scan (mean, SD) 
159 minutes  
(71) 
164 minutes  
(73) 
0.082 
Time to imaging follow-up 
(median, IQR) 
26 hours  
(24-38) 
26 hours  
(24-35) 
0.801 
Baseline NIHSS  
(median, IQR) 
16 (10-20) 9 (6-16) <0.001 
OHS at six months  
(median, IQR) 
5 (3-6) 3 (1-5) <0.001 
Death by six months 263 (36.7%) 534 (23.8%) <0.001 
Treated with alteplase  368 (51.4%) 1116 (49.7%) 0.432 
Footnote: Results represent n (%) unless otherwise stated.  NIHSS = National Institutes of Health 
Stroke Scale.  OHS = Oxford Handicap Scale.  IQR = Interquartile range.  SD = standard deviation.   
 
Figure 5-1 compares OHS distribution between the groups with and without HAS at 
baseline.  There were no significant differences between those with and without HAS 
at baseline for sex distribution (49.7% versus 47.7% male, p=0.348), stroke onset to 
scan time (mean 159 versus 164 minutes, p=0.082), time to follow-up (both 26 




Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
5 - Hyperattenuating Artery Sign 112 
Figure 5-1 Comparison of six-month functional outcome distribution (OHS) for patients with 
and without HAS at baseline 
 
Footnote: OHS = Oxford Handicap Scale 
 
Stroke severity and 6-month outcome were significantly worse if HAS was found 
only in proximal rather than only in distal vessels: median NIHSS 17 (interquartile 
range 11-21) versus 12 (7-17), p<0.001; median OHS 5 (3-6) versus 4 (2-6), 
p<0.001). Similarly, stroke severity and 6-month outcome were significantly worse if 
HAS was more versus less extensive: median NIHSS 17 (13-21) versus 15 (10-20), 
p=0.001; median OHS 5 (4-6) versus 5 (3-6), p=0.008. 
Table 5-3 compares the effect of baseline HAS presence, extent and location on 
outcome in separate multivariable ordinal regression analyses (OHS as the dependent 
variable in each). The presence of HAS was an independent predictor of poor 
outcome; OR=0.66, 95%CI=0.55-0.80, p<0.001. More extensive HAS (1, 2 or 3 
segments) also independently predicted a worse outcome among patients with the 
sign (n=716); OR=0.61, 95%CI=0.39-0.94, p=0.027.  In patients with HAS in only 1 
named arterial segment (n=589), proximal versus distal location was not 
independently associated with outcome, OR=1.17, 95%CI=0.80-1.71, p=0.420.  
These regression analyses are adjusted for the effects of age, NIHSS, time from 
stroke onset to scan and treatment allocation.  
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Table 5-3 Multivariable analyses testing the importance of HAS presence, extent and 
location on six-month outcome 
 
a) Presence of HAS 
OR 95% CI p-value 
 
Age (years) 0.96 0.96-0.97 <0.001 
NIHSS 0.84 0.83-0.85 <0.001 
Stroke onset to baseline scan (hours) 1.07 1.01-1.14 0.018 
HAS present 0.66 0.55-0.80 <0.001 
Alteplase treatment allocation 1.29 1.12-1.50 0.001 
b) Extent of HAS    
Age (years) 0.95 0.94-0.96 <0.001 
NIHSS 0.84 0.82-0.87 <0.001 
Stroke onset to baseline scan (hours) 1.06 0.92-1.22 0.412 
HAS extent (1-3 named segments) 0.61 0.39-0.94 0.027 
Alteplase treatment allocation 1.06 0.76-1.48 0.714 
c) Location of HAS    
Age (years) 0.95 0.94-0.97 <0.001 
NIHSS 0.84 0.81-0.87 <0.001 
Stroke onset to baseline scan (hours) 1.03 0.89-1.20 0.681 
HAS location (proximal or distal) 1.17 0.80-1.71 0.420 
Alteplase treatment allocation 1.15 0.81-1.64 0.442 
Footnote: Ordinal regression analyses with Oxford Handicap Scale (OHS) as the dependent variable 
for each:   
a) All IST-3 patients with CT at baseline (n=2961) 
b) Includes only patients with HAS on baseline CT (n=716) 
c) Includes only patients with HAS in a single arterial segment on baseline CT (n=589) 
OR = Odds ratio (<1 indicates worse outcome). NIHSS = National Institutes of Health Stroke Scale.  
CI = Confidence Interval.   
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Change in HAS between baseline and follow-up CT 
Among 2731 patients with NCCT at baseline and follow-up, 674 had HAS at 
baseline and 2057 did not.  Shrinkage of HAS (fewer affected segments on follow-up 
compared with baseline CT) was more common than HAS growth (including 
development of new HAS) between baseline and follow-up scans in IST-3. Among 
patients with HAS on at least one scan, shrinkage occurred in 388/870 (44.6%), and 
completely disappeared in 349. HAS growth occurred in 237/870 (27.2%) patients 
which includes development of a new HAS in 196 patients at follow-up, i.e. no 
baseline HAS was identified in these patients. There was no change in HAS extent 
between baseline and follow-up NCCT for 245/870 (28.2%) patients, Table 5-4. 
 
Table 5-4 Univariate associations between imaging characteristics of HAS on baseline and 
follow-up CT, stroke severity at baseline and six-month outcome 
Change in HAS from Baseline to 
Follow-up CT 
n NIHSS  Median 
Extent change 
from onset to 
follow-up 
Growth 237 17 (10-21) 5 (3-6) 
Shrinkage 388 15 (9-20)** 4 (2-6)* 
Persistence to 
follow-up 
Persisted 324 17 (13-21) 5 (3-6) 
Disappeared 349 14 (9-19)* 4 (2-6)* 
New HAS at 
follow-up 
Yes 196 16 (10-20) 5 (3-6) 
No 1861 9 (5-15)* 3 (1-5)* 
Footnote: Total numbers in each analysis vary because growth/shrinkage data does not include 
patients where HAS extent remained unchanged between scans.  Total n=2731. 
NIHSS = National Institutes of Health Stroke Scale.  OHS = Oxford Handicap Scale. 
Follow-up CT was only available in 674 of those with and in 2057 of those without HAS at baseline.  
HAS data were not available for one follow-up CT. 
Results are median (inter-quartile range). * p-value for difference <0.001, ** p=0.010. 
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Location and extent of baseline HAS were associated with persistence or 
disappearance of the sign at follow-up on univariate analysis.  Smaller HAS (fewer 
arterial segments affected) were more likely to disappear (297/553 = 53.7%) between 
baseline and follow-up than larger HAS (52/120 = 43.3%), χ
2
 = 4.3, p=0.039.  
Similarly, HAS sited in distal vessels were more likely to disappear (112/166 = 
67.5%) between baseline and follow-up than HAS sited in proximal vessels (185/387 
= 47.8%), χ
2
 = 18.1, p<0.001.  These results are grouped and summarised in Figure 
5-2.  Note that while clearance was less common in the presence of a large and 
proximal HAS, it still occurred in 44% (52/118) of these patients. Small and distal 
HAS cleared in 67% (112/166) of cases. 
 
Figure 5-2 Effect of HAS location and extent on HAS persistence to follow-up 
 
Footnote: Small HAS = single arterial segment. Large HAS = more than one arterial segment. 
Proximal HAS = internal carotid, middle cerebral artery main stem, vertebral and basilar arteries.  
Distal HAS = anterior, middle (sylvian branch) and posterior cerebral arteries. * χ
2
 = 15.5, p<0.001. 
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Stroke severity and 6-month outcome were significantly worse if HAS showed 
growth rather than shrinkage between scans (median NIHSS 17 versus 15, p=0.010, 
median OHS 5 versus 4, p<0.001), if HAS persisted to follow-up rather than 
disappeared (median NIHSS 17 versus 14, p<0.001, median OHS 5 versus 4, 
p<0.001) or if a new HAS developed between scans (median NIHSS 16 versus 9, 
p<0.001, median OHS 5 versus 3, p<0.001), Table 5-4. 
Effect of alteplase on HAS 
The following analyses demonstrate the influence of alteplase on both the persistence 
and any change in the extent of HAS at follow-up and on the development of new 
HAS in the interim between pre-randomisation and follow-up CT.   
On univariate analysis, there were significant associations between alteplase 
treatment and an increased likelihood of both HAS shrinkage (222/440 = 50.5% 
treated with alteplase versus 166/429 = 38.7% controls shrank, χ
2
 = 12.6, p=0.002) 
and HAS disappearance (198/350 = 56.6% treated with alteplase versus 151/323 = 
46.7% of controls disappeared, χ
2
 = 6.5, p=0.011).  In patients treated with alteplase, 
distal versus proximal HAS (65/86 = 75.6% versus 105/198 = 53.0%, respectively, χ
2
 
= 12.7, p=0.001) and single segment versus multi-segment HAS (170/284 = 59.9% 
versus 28/66 = 42.4%, respectively, χ
2
 = 6.6, p=0.010) were more likely to have 
disappeared at follow-up. Among patients without a baseline HAS, fewer who 
received alteplase had developed a new HAS in the interim between baseline and 
follow-up CT, although this difference was not significant (90/1047 = 8.6% versus 
106/1010 = 10.5%, χ
2
 = 2.2, p=0.143), see Table 5-5.   
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Table 5-5 Combined 2x2 tables comparing alteplase treatment allocation with changes in 
the presence of HAS between baseline and follow-up CT 
Hyperattenuating Artery 
Characteristics 
Treated with Alteplase Total 
Yes No 
Extent change from 
baseline to follow-up 
Growth 111 126 237 
Shrinkage 222 166 388 
No Change 107 137 244 
Total 440 429 869 
χ
2
 = 12.6,  p=0.002, OR for HAS shrinkage with treatment = 1.52 (95%CI=1.1-2.1)* 
Persistence to  
Follow-up 
Persisted 152 172 324 
Disappeared 198 151 349 
Total 350 323 673 
χ
2
 = 6.5,  p=0.011, OR for HAS disappearance with treatment = 1.48 (95%CI=1.1-2.0) 
New HAS at  
Follow-up 
Yes 90 106 196 
No 957 904 1861 
Total 1047 1010 2057 
χ
2
 = 2.2, p=0.143,  OR for developing new HAS on treatment = 0.80 (95%CI=0.6-1.1) 
Footnote: OR = Odds Ratio. 95%CI = 95% Confidence Interval. HAS data were not available for one 
follow-up CT. *This OR is calculated only for the groups with either growth or shrinkage, i.e. those 
with no change have been excluded. 
 
For the multivariable analysis testing factors associated with change in HAS segment 
number (dependent variable), alteplase treatment was an independent predictor of 
HAS shrinkage at follow-up (OR 0.77, 95%CI=0.65-0.93, p=0.006) while HAS 
growth was more likely in older patients (OR 1.01, 1.00-1.02, p=0.013).  This result 
is adjusted for the effects of time (between baseline and follow-up scans) and stroke 
severity.  Increased time between scans showed a non-significant trend for HAS 
shrinkage (OR 0.91, p=0.059); Table 5-6.  
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Table 5-6 Ordinal regression analysis for factors associated with change in HAS extent 
(growth or shrinkage) between baseline and follow-up CT scans (n=2730) 






Age 81 (72-86) 
years 
1.01 1.00-1.02 0.013 
NIHSS 11 (6-18) 1.00 0.98-1.01 0.475 




0.91 0.82-1.00 0.059 
Treated with alteplase n = 1397 0.77 0.65-0.93 0.006 
Footnote: NIHSS = National Institutes of Health Stroke Scale. Raw data provided as median (inter-
quartile range) unless otherwise stated. An odds ratio <1 indicates HAS shrinkage, >1 indicates HAS 
growth. n=2730, HAS data were not available for one follow-up CT. 
 
Both proximal and distal HAS were equally likely to shrink following alteplase 
treatment (OR 0.66, 95% CI 0.45–0.98, and OR 0.51, 95% CI 0.26–1.00, 
respectively), with no evidence of an interaction between HAS location and alteplase 
effect (p=0.516), Figure 5-3. HAS affecting a single arterial segment at baseline was 
more likely to shrink following alteplase treatment (OR 0.60, 95% CI = 0.43-0.85), 
but alteplase was not an independent predictor of HAS shrinkage if more than one 
arterial segment was affected at baseline (OR 0.78, 95% CI 0.33–1.86). Nevertheless, 
there was no evidence of an interaction between HAS extent and alteplase effect 
(p=0.580), Figure 5-3. These results are adjusted for patient age, time (between 
baseline and follow-up scans), and stroke severity. 
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Figure 5-3 Ordinal regression analyses for the effect of alteplase treatment on change in HAS extent from baseline to follow-up scan 
 
Footnote: Ordinal regression analyses with change in HAS segment number (shrinkage, no change, growth) as the dependent variable assessing the importance of 
baseline (pre-randomisation) HAS location (proximal = internal carotid artery, middle cerebral artery mainstem, vertebral or basilar arteries; distal = anterior or 
posterior cerebral arteries or sylvian branches of the middle cerebral artery) and HAS extent on the effect of alteplase. 
*Location analysis does not include patients with HAS in both proximal and distal arteries.   
Odds ratio <1 (left of line) indicates HAS shrinkage, >1 (right of line) indicates HAS growth. 
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Effect of alteplase on outcome in those with and without HAS 
The result of ordinal regression analysis for alteplase effect on outcome (OHS as 
dependent variable) is shown in Figure 5-4 for the entire group (n=2961) and for the 
subgroups with and without HAS on baseline CT.  These results are adjusted for 
patient age, time (between baseline and follow-up scans), stroke severity and (for the 
full group only) presence versus absence of HAS. 
Overall, alteplase increased the odds of better functional outcome (OR=1.29, 
95%CI=1.12-1.50, p=0.001), as previously described in the complete IST-3 dataset, 
see Chapter 3.7, but there was no evidence of an interaction with the presence versus 
absence of HAS (p=0.167).   
 
Figure 5-4 Ordinal regression analyses showing odds ratios for the effect of alteplase 
treatment on outcome in the full group and in the subgroups with and without HAS on 
baseline CT.   
 
Footnote: Odds ratio >1 (right of line) indicates better outcome (lower six month OHS).  Results are 
adjusted for the effect of age, time from stroke onset to scan (hours) and National Institutes of Health 
Stroke Scale (NIHSS). 
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5.4 Discussion of HAS Results 
In this analysis of IST-3 data, I have shown that HAS is present in approximately 
25% of patients undergoing non-contrast CT within six hours of acute ischaemic 
stroke.  This is consistent with other published large series using similar scanning 
protocols
3;4
 however prevalence rates in the range 47-59% have been demonstrated 
in smaller studies.
5;6
  I confirmed that patients with HAS have more severe strokes 
and worse six-month outcomes than patients without HAS and that six-month 
outcome is worst when HAS is more extensive and proximally located.  The effect of 
HAS presence on outcome is independent of age, time from stroke onset, stroke 
severity and treatment with intravenous alteplase, i.e. patients with and without HAS 
both benefit similarly from alteplase.  Other authors have demonstrated that HAS 
independently predicts outcome
7-9
 but my work further demonstrates that more 
extensive HAS independently predicts a worse outcome among patients with the 
sign.  I did not demonstrate an independent association between HAS location and 
outcome despite highly significant univariate results as demonstrated elsewhere;
10
 
however, my multivariable analysis of outcome including HAS location is limited by 
the exclusion of those HAS affecting more than one arterial segment (n=127) and is 
therefore likely to be underpowered.  
I provide evidence that intravenous alteplase both reduces the persistence (more 
likely to shrink, or disappear) and limits the formation (less likely to grow) of HAS 
among patients with acute ischaemic stroke compared to patients allocated control.  I 
found that alteplase increases HAS shrinkage/disappearance independent of age, 
baseline stroke severity and time between baseline and follow-up scans.  Moreover, 
these changes occur in both large volume proximal HAS and in smaller, more 
distally sited HAS although clearance is more common in the latter.  These findings 
are important since I, and others,
9;11
 have shown improved outcome for patients 
where HAS shrinks or disappears in the presence of alteplase.  I believe my work is 
the first to demonstrate an association between intravenous alteplase and measurable 
growth/shrinkage of HAS using randomised controlled trial data.  I found no 
evidence that presence or absence of HAS materially altered the benefit of alteplase 
(the favourable shift in six-month OHS) which was seen in patients with and without 
HAS.  The appropriate interpretation is that there is no evidence of a difference in 
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treatment effect between those with and without HAS at baseline and not that 
alteplase has no effect in those with HAS. The multivariable analyses support this 
interpretation since HAS predicts poor outcome in ischaemic stroke, independent of 
alteplase use.  This post-hoc subgroup analysis may be underpowered (95% 
confidence intervals overlap substantially) and must therefore be interpreted with 
caution.  Large patient numbers are likely to be required to detect/exclude a true 
interaction which if present, is likely to be very small.  To understand the apparent 
benefit of alteplase in patients without HAS, the presence of undetected thrombosis 
may be an answer; a recent report of case series demonstrated apparent benefit from 
thrombolysis for patients without arterial obstruction on angiography.
12
 I will explore 
this further in Chapter 9.   
Strengths and limitations 
Firstly, most of the CT scans were not thin-section.  Previous work has demonstrated 
that thrombus detection on CT is affected by slice thickness and that prevalence rates 
for HAS are larger with thin-slice protocols.
13
  It is likely therefore that the baseline 
prevalence of HAS is an underestimate. Variability in the detection of HAS could 
also have led to misclassification of new or disappearing HAS when baseline and 
follow-up scans were compared. I could have verified the changing HAS 
appearances in a subset of these cases. Secondly, HAS was not defined by a specified 
level of attenuation measured by Hounsfield units.  Though image analysis was 
performed centrally by an expert panel of readers, (inter-observer reliability for the 
identification of HAS is dealt with in Chapter 8) these assessments were qualitative 
rather than quantitative to reflect how the scan would be used in routine acute stroke 
care.  A recent small cohort study demonstrated that following intravenous alteplase, 
ischaemic stroke patients with persistent arterial occlusion had significantly lower 
mean attenuation of thrombus compared to those who achieved recanalisation.
14
  I 
will explore the effect of thrombus attenuation on outcome in IST-3 in Chapter 6.  
Thirdly, estimating HAS extent from the number of arterial segments affected is 
relatively crude and could have over or underestimated the true extent of HAS 
especially where HAS crossed segment boundaries. A volumetric measurement 
would have provided numerically continuous data and possibly a more accurate 
assessment of changes in HAS volume.  However, it remains unclear if HAS volume 
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can be measured reliably. The IST-3 method of assessing thrombus extent is feasible 
and therefore relevant to daily practice.  Finally, IST-3 has insufficient power to 
reliably explore interactions between HAS and the effect of alteplase but I found 
little evidence that patients with HAS responded differently to alteplase than those 
without HAS.   
Conclusion 
IST-3 data confirmed significant associations between the presence and extent of 
HAS, increased baseline stroke severity and poor six-month outcomes.  I show 
clearly that alteplase accelerates the disappearance of the HAS.  Furthermore, I found 
no evidence that the improvement in functional outcome following alteplase was 
materially different in the presence or absence of HAS.  Therefore, while the 
presence of HAS is useful to support a diagnosis of acute ischaemic stroke, these 
data suggest that the presence or absence of the sign should not influence decisions 
on whether or not to use intravenous alteplase.  
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Chapter 6 CT Attenuation of Arterial 
Obstruction in Ischaemic Stroke 
In this chapter, I use data from my own assessment of IST-3 imaging of patients with 
non-contrast CT and CT or MR angiography at baseline to calculate the CT 
attenuation within acute arterial obstructions (i.e. thrombus or embolus). Using the 
IST-3 angiography subgroup for this analysis allowed me to calculate the attenuation 
of obstructions that were both visible (i.e. HAS) and not visible on non-contrast CT. I 
use the derived data to investigate relationships between the CT attenuation of acute 
arterial obstructions, response to intravenous alteplase and functional outcome at six 
months. 
This chapter addresses Thesis Aim 2).    
This work is also published in a peer reviewed journal, the complete draft of which is 
included as Appendix 5, see Chapter 11.3.3: 
Mair G, von Kummer R, Lindley RI, Sandercock PAG, 
Wardlaw JM. Effect of X-ray attenuation of arterial 
obstructions on intravenous thrombolysis and outcome after 
ischemic stroke. PLOS ONE 2015;10:e0145683. 
 
6.1 Methods for Assessment of CT Attenuation of 
Arterial Obstructions 
As discussed in Chapter 4.3, I had determined the intra-arterial CT attenuation for all 
arterial obstructions (i.e. obstruction attenuation) at baseline and, if still present, at 
follow-up among patients with CT or MR angiography at baseline in IST-3.  
In addition to analysing the obstruction, I also obtained attenuation measures within 
any equivalent contralateral normal artery (for example, the opposite MCA at an 
equivalent location) and also within the basilar artery.  I therefore measured intra-
arterial density at three intra-cranial locations for most patients. At each location, 
three separate elliptical regions of interest were applied by hand, taking care not to 
include the arterial wall or any surrounding tissue; a mean attenuation value of the 
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three readings was later calculated.  Attenuation measurements were performed 
following x2 magnification of images (Figure 4-1).  The subjective appearance of 
obstruction on non-contrast CT was also noted as either iso-attenuating to normal 
vessels or hyperattenuating (if obstruction appeared more attenuating than adjacent 
or equivalent contralateral arteries but non-calcified). I calculated attenuation ratios 
for each patient to assess obstruction attenuation in relation to normal background 
intra-arterial attenuation as:  
mean obstruction attenuation ÷ mean normal intra-arterial 
vessel attenuation.   
I repeated attenuation measurements, in the same location, on follow-up non-contrast 
CT.  I calculated change in obstruction attenuation as: 
mean follow-up attenuation – mean baseline attenuation 
i.e. a negative difference in obstruction attenuation represented a reduction in 
obstruction attenuation between the two scans. 
As for all patients within the IST-3 angiography subgroup, an IST-3 angiography 
score was also calculated to determine the completeness of arterial obstruction. 
For the present analysis, I identified how many patients within the angiography 
subgroup were included, i.e. angiography patients with measurable obstruction on 
non-contrast CT. Patients were excluded from this analysis if the angiographic 
abnormality was insufficient to allow for attenuation measures to be performed (i.e. 
minor stenosis without a discrete measurable filling defect).  Patients identified for 
this present subgroup analysis (obstruction attenuation subgroup) were compared 
with the full IST-3 group. 
I tested whether change in the attenuation of obstructions from baseline to follow up 
was different for the treatment versus control groups. Whether baseline obstruction 
attenuation affected functional outcome at six months and assessed for interaction 
between obstruction attenuation and treatment with alteplase. 
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6.1.1 Statistical testing 
 
Univariate analyses 
Simple t-tests were employed to compare ratios and to compare the means of 
normally distributed continuous data. The medians of non-parametric continuous 
data were compared using a Mann-Whitney U test. I used Pearson’s correlation 
coefficient, analysis of variance and t-tests to look for associations between baseline 
obstruction HU and clinical characteristics, other imaging appearances and outcome 




 were used to calculate common odds ratios (ORs) for 
OHS at six months as the dependent variable. 
To stabilise ordinal regression estimates, I again used the same approach as the 
original IST-3 analysis of functional outcome, where the more severe grades of OHS 
(4-6) were grouped as one, leaving 5 groups for ordinal analysis (0, 1, 2, 3 and 4-6).
2
  
Similarly, time from stroke onset to baseline scan, was grouped into 6 one-hour 
windows (0-60, 61-120, 121-180, 181-240, 241-300 and 301-360 minutes).   
Statistical software 
Comprehensive Meta-Analysis software (Biostat, Englewood, NJ, USA) was used to 
compute summary ORs and to perform a test of interaction between treatment and 
control groups. 
All other analyses were performed using IBM SPSS Statistics software, version 20.0 
(IBM Corporation, Armonk, NY, USA).   
A p-value <0.05 was considered significant. 
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6.2 Results for the Obstruction Attenuation Subgroup 
From the 300 patients in IST-3 with angiography performed at baseline, I identified 
109 who had both a concurrent non-contrast CT and a measurable angiographic 
abnormality; this subgroup is termed the obstruction attenuation subgroup. 
Compared with the remainder of the full IST-3 group, patients within the obstruction 
attenuation subgroup had significantly more severe strokes at baseline (NIHSS 17 
versus 11 for the full group, p<0.001), with more extensive early brain parenchymal 
changes (ASPECTS 9 versus 10 for the full group, p=0.001) and worse six-month 
functional outcome (OHS 5 versus 4 for the full group, p<0.001) including an 
increased death rate (39% versus 27% for the full group).  Subgroup patients were 
more likely to have a total anterior circulation infarct (TACI 62% versus 42% with 
correspondingly fewer partial anterior, posterior or lacunar type infarcts, p<0.001). In 
addition, there were significantly fewer men in the obstruction attenuation subgroup 
(35% versus 48% in the full group, p=0.004).  There were no significant differences 
in patient age, rate of atrial fibrillation, time from stroke onset to scan, time to 
randomisation or time to imaging follow-up between the obstruction attenuation 
subgroup and the full IST-3 group, Table 6-1. 
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Age (median, IQR) 82 (75-86) 81 (72-86) 0.192 
Male Sex (n, %) 38 (34.9) 1465 (48.3) 0.004 
Clinical Stroke Syndrome (n, %) 
     TACI 
     PACI 
     POCI 
     LACI 














Atrial fibrillation at baseline (n, %) 35 (32.1) 879 (30) 0.644 
Time (mins) from stroke onset to 
baseline CT (mean, SD) 
171 (79)  164 (73)  0.282 
Time (mins) from stroke onset to 
randomisation (mean, SD) 
230 (79)  231 (73)  0.891 
Baseline NIHSS (median, IQR) 17 (11-21) 11 (6-17) <0.001 
Baseline ASPECTS (median, IQR) 9 (6-10) 10 (8-10) 0.001 
Treated with rt-PA (%) 51 (46.8) 1515 (49.9) 0.506 
Time (hours) from baseline to follow-
up CT (median, IQR) 
25 (24-29)  26 (24-36)  0.110 
Six-month OHS (median, IQR) 5 (3-6) 4 (2-6) <0.001 
Independent at six-months (OHS 0-2) 26 (23.9) 1088 (35.8) 0.008 
Dead by six-months (%) 43 (39.4) 815 (26.9) 0.003 
Footnote: TACI = Total Anterior Circulation Infarct. PACI = Partial Anterior Circulation Infarct. 
POCI = Posterior Circulation Infarct. LACI = Lacunar Infarct. NIHSS = National Institutes of Health 
Stroke Scale. ASPECTS = Alberta Stroke Program Early CT Score. OHS = Oxford Handicap Scale.  
IQR = Interquartile Range.  SD = Standard Deviation. 
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Imaging findings 
Table 6-2 demonstrates the results of imaging assessment for the 109 patients in the 
obstruction attenuation subgroup. I identified HAS in 64 patients (59%).  The mean 
CT attenuation within these hyperattenuating obstructions was 51.0 Hounsfield Units 
(HU).  This compares with a mean attenuation of 37.9 HU in iso-attenuating 
obstructions, p<0.001.  Similarly, the mean attenuation within normal vessels (i.e. 
normally flowing blood) was 38.1 HU.  The mean HU ratio of hyperattenuating 
obstructions was 1.38 compared with a mean HU ratio of 0.97 for iso-attenuating 
obstruction, p<0.001.  The majority of patients had obstruction within an ICA (20%) 
or an MCA branch (75%).  In most patients, obstruction was isolated to a single 
named arterial segment (56%); fewer patients had obstruction affecting 2 or 3 arterial 
segments (37% and 7%, respectively).  The mean length of hyperattenuating 
obstructions on non-contrast CT was 19 mm (standard deviation 10 mm). By IST-3 
angiography score, 84% of patients had >50% luminal stenosis (IST-3 angiography 
score 0-2b) and in 44%, there was either complete occlusion or severe luminal 
stenosis (IST-3 angiography score 0-1). 
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Table 6-2 Imaging characteristics of the IST-3 obstruction attenuation subgroup 
Non-contrast CT 






Hyperattenuating obstruction 51.0 (8.3) HU 
Iso-attenuating obstruction 37.9 (10.7) HU 
Normal vessel 38.1 (5.2) HU 
Follow-up hyperattenuating obstruction 45.1 (9.2) HU 
Follow-up iso-attenuating obstruction 38.2 (8.2) HU 
Obstructed: normal 
vessel  attenuation ratio 
(mean, SD) 
Hyperattenuating obstruction 1.38 (0.23) 
Iso-attenuating obstruction 0.97 (0.21) 




Location of arterial 
obstruction (%) 
ICA 22 (20.2) 
MCA mainstem 61 (55.9) 
MCA sylvian branch 21 (19.3) 
ACA 0 
PCA 0 
Vertebral artery 2 (1.8) 
Basilar artery 3 (2.8) 
 
Number of obstructed 
arterial segments (%) 
1 61 (56.0) 
2 40 (36.7) 






0 11 (10.1) 
1 37 (33.9) 
2a 17 (15.6) 
2b 27 (24.8) 
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Footnote: n=109. SD = Standard Deviation.  HU = Hounsfield Units. ICA = Internal Carotid Artery.  
MCA = Middle Cerebral Artery.  ACA = Anterior Cerebral Artery.  PCA = Posterior Cerebral Artery. 
IST-3 angiography scoring: 0 = occluded, 1 = minimal patency (some contrast penetrates obstruction 
but none or only a minimal amount enters distal artery), 2 = patency <50% of the lumen at the point of 
obstruction and a) only partly filling (<half) or b) incomplete filling (but >half) of the major branches 
of the affected artery, 3 = patency >50% of the lumen and filling of most of the branches of the 
affected artery, 4 = normal. 
 
Associations with obstruction attenuation at baseline 
On univariate analysis, there was no significant difference in the mean attenuation of 
baseline arterial obstruction when patients with versus without atrial fibrillation were 
compared (45.9 HU versus 45.5 HU, respectively, p=0.859) or among the different 
clinical stroke subtypes (F = 1.5, p=0.220). Similar non-significant results were 
obtained in all cases if those with hyper- versus iso-attenuating arterial obstructions 
were compared. There was no correlation between the length of the hyperattenuating 
arterial segment and the attenuation of that obstruction (r = 0.03, p=0.825). Similarly, 
the mean attenuation of arterial obstruction at baseline did not differ between those 
with 1 versus those with 2 or 3 obstructed arterial segments (44.8 HU versus 46.6 
HU, respectively, p=0.418). Finally, there was no correlation between the time from 
stroke onset to baseline scan and the attenuation of arterial obstruction on the 
baseline scan (r = 0.13, p=0.203). 
 
Effect of alteplase on obstruction attenuation 
For all attenuation subgroup patients, the median time between baseline and follow-
up non-contrast CT was 25 hours.  At follow-up, the attenuation of hyperattenuating 
obstruction had fallen to mean 45.1 HU while the attenuation of iso-attenuating 
obstruction was essentially unchanged at mean 38.2 HU.  There was a non-
significant (p=0.117) greater reduction of obstruction attenuation between baseline 
and follow-up non-contrast CT for patients treated with alteplase (median reduction 
of 8.0 HU) compared to controls (median reduction of 1.4 HU), Figure 6-1. Similar 
results were obtained if only patients with hyperattenuating obstructions at baseline 
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were included; median reduction of 8.4 HU in those treated with alteplase versus a 
median reduction of 0.5 HU in those allocated control, p = 0.094. 
 
Figure 6-1 Effect of alteplase on change in attenuation of arterial obstruction between 
baseline and follow-up CT 
 
Footnote: A negative change in arterial obstruction HU (Hounsfield Units) between baseline and 
follow-up CT indicates a reduction in attenuation of the obstruction. 
This analysis includes patients with both iso- and hyperattenuating obstructions at baseline. 
There was no significant difference between the groups treated with alteplase (median -8.0 HU, IQR -
12.4 to 2.5) and control (median -1.4 HU, IQR -8.7 to 2.9), p=0.117. 
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Obstruction attenuation and six-month outcome 
There were no significant associations on univariate analysis between the attenuation 
of arterial obstruction at baseline and six-month functional outcome in either the 
alteplase or control groups.  For correlation between obstruction attenuation and six-
month OHS the results were: r =0.03, p=0.851 for those treated with alteplase (n=51) 
and r=0.13, p=0.342 in the control group (n=58).  Comparing baseline arterial 
obstruction attenuation between the patients reaching independence (OHS 0-2) and 
those patients dependent or dead at six months (OHS 3-6), the mean attenuation 
difference was: 0.2 HU, p=0.944 for those treated with alteplase and 1.5 HU, 
p=0.673 in the control group.  In both cases, baseline HU values were non-
significantly higher among patients with poor six months outcome (OHS 3-6). 
Test for interaction between alteplase and obstruction attenuation 
Baseline arterial obstruction attenuation was not an independent predictor of six-
month functional outcome on adjusted multivariable ordinal regression analysis in 
either the alteplase (OR=1.00, 95%CI=0.94-1.07, p=0.911) or control groups 
(OR=0.99, 95%CI=0.93-1.05, p=0.680) and there was no significant difference 
between these results, i.e. no treatment interaction between alteplase and obstruction 
attenuation (p=0.824), Table 6-3. 
Similarly, there was no evidence that baseline arterial obstruction attenuation was an 
independent predictor of outcome in the whole group (n=109) using either the 
quantitative (absolute HU of obstruction, OR=0.99, 95%CI=0.94-1.03, p=0.516) or 
qualitative analyses (hyper- versus iso-attenuating obstruction, OR=0.53, 
95%CI=0.20-1.41, p=0.203) in a model adjusting for treatment allocation, Table 6-4.  
There was a non-significant trend towards poorer outcome among patients with 
hyperattenuating rather than iso-attenuating obstructions. 
For all analyses, replacing absolute arterial obstruction attenuation values with 
obstruction attenuation ratios did not alter the results (data not shown). 
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Table 6-3 Ordinal regression analysis with six-month OHS as the dependent variable for a) 
patients treated with alteplase and b) controls 
a) Treated with alteplase (n = 51) Odds Ratio 95%CI p-value 
Age (years) 0.93 0.89-0.98 0.003 
Time from stroke onset to baseline scan (hours) 0.66 0.38-1.15 0.139 
NIHSS 0.87 0.79-0.97 0.009 
Obstruction attenuation at baseline (HU) 1.00 0.94-1.07 0.911 
Location of arterial obstruction 1.45 0.67-3.15 0.349 
Number of obstructed arterial segments  0.79 0.24-2.61 0.696 
IST-3 angiography score 1.41 0.78-2.52 0.253 
 
b) Control group (n=58) Odds Ratio 95%CI p-value 
Age (years) 0.97 0.92-1.02 0.254 
Time from stroke onset to baseline scan (hours) 1.84 1.00-3.37 0.050 
NIHSS 0.79 0.67-0.92 0.002 
Obstruction attenuation at baseline (HU) 0.99 0.93-1.05 0.680 
Location of arterial obstruction 1.06 0.60-1.90 0.834 
Number of obstructed arterial segments  1.73 0.37-8.05 0.485 
IST-3 angiography score 0.81 0.43-1.55 0.533 
Footnote: 95%CI = 95% Confidence Interval. NIHSS = National Institutes of Health Stroke Scale.  
HU = Hounsfield Units. Odds ratio <1 indicates a worse outcome. 
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Table 6-4 Ordinal regression analysis with six-month OHS as the dependant variable for all 
patients in the obstruction attenuation subgroup; obstruction attenuation is included as a) a 
quantitative continuous variable and b) a qualitative dichotomous variable. 
a) Obstruction attenuation continuous variable Odds Ratio 95%CI p-value 
Age (years) 0.95 0.92-0.98 0.001 
Time from stroke onset to baseline scan (hours) 1.12 0.78-1.62 0.539 
NIHSS 0.85 0.79-0.92 <0.0001 
Obstruction attenuation at baseline (HU) 0.99 0.94-1.03 0.516 
Location of arterial obstruction 1.10 0.73-1.68 0.645 
Number of obstructed arterial segments (1-3)  0.70 0.30-1.62 0.407 
IST-3 angiography score (0-3) 1.03 0.71-1.51 0.865 
Treated with alteplase (versus control) 2.17 0.80-5.91 0.131 
 
b) Obstruction attenuation dichotomous variable Odds Ratio 95%CI p-value 
Age (years) 0.95 0.92-0.98 0.001 
Time from stroke onset to baseline scan (hours) 1.13 0.79-1.63 0.508 
NIHSS 0.86 0.79-0.92 <0.0001 
Hyperattenuating obstruction at baseline           
(versus isoattenuating obstruction) 
0.53 0.20-1.41 0.203 
Location of arterial obstruction 1.12 0.75-1.67 0.589 
Number of obstructed arterial segments (1-3)  0.70 0.30-1.60 0.396 
IST-3 angiography score (0-3) 1.02 0.70-1.49 0.902 
Treated with alteplase (versus control) 2.29 0.85-6.17 0.102 
Footnote: n=109. 95%CI = 95% Confidence Interval. NIHSS = National Institutes of Health Stroke 
Scale.  HU = Hounsfield Units. Odds ratio < 1 indicates a worse outcome. 
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6.3 Discussion of Obstruction Attenuation Results 
These IST-3 subgroup data do not support the hypothesis that baseline x-ray 
attenuation of angiographically-proven intra-arterial obstruction measured on non-
contrast CT is an independent predictor of functional outcome at 6 months.  Age, 
baseline stroke severity and time to treatment are such powerful predictors of 
outcome after ischaemic stroke and response to intravenous alteplase that the 
addition of measured obstruction attenuation does not appear to have any value in 
guiding decisions about treatment with intravenous alteplase.  
The value of measuring obstruction attenuation on CT to select patients for treatment 
has been debated.  Two recent non-randomised studies found no association in 
samples of about 100 patients.
3;4
  Three recent cohort studies have however 
demonstrated with highly consistent results that intravenous thrombolysis more often 
resulted in successful arterial recanalisation in patients with highly attenuating 
arterial obstruction at baseline.  Puig et. al. (n=45) demonstrated a mean relative HU 
(equivalent to mean HU ratio in my analysis) of 1.57 for patients achieving 
recanalisation versus 1.11 for those without recanalisation (p<0.001).
5
  Similarly, 
Moftakhar et. al. (n=90) demonstrated a mean relative HU of 1.58 in patients that 
recanalised versus 1.39 in those that did not (p=0.01).
6
  Finally, Niesten et. al. (n=88) 
demonstrated a mean relative HU of 1.54 in patients that recanalised versus 1.29 in 
those that did not (p<0.001).
7
  With IST-3 data, I was not able to assess 
recanalisation following treatment with intravenous alteplase as follow-up 
angiography was not mandatory in IST-3.  The apparent discrepancy between my 
results and these three cohort studies may indicate that success of recanalisation 
therapy is not the only predictor of outcome.  Indeed the literature assessing 
relationships between obstruction attenuation and success of endovascular 
thrombectomy, has demonstrated that while recanalisation is more likely with 
hyperattenuating obstructions, where reported, this does not translate to a 
proportionally improved functional outcome.
8-12
  In addition, some authors have 
identified significant differences in obstruction attenuation when stroke cohorts are 
stratified by aetiological stroke subtype.  For example, cardioembolic thrombus may 
be more attenuating than atherothrombotic thrombus,
5;13
 but such results have not 
always been replicated
4
 and a large retrospective analysis of over 8000 patients failed 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
6 - CT Attenuation of Arterial Obstruction 140 
to demonstrate an independent association between hyperattenuating obstruction and 
stroke aetiology.
14
 I similarly did not find any association in IST-3 between clinical 
stroke subtype (which may vary with differing underlying aetiologies
15
) or the 
presence of atrial fibrillation and the attenuation of arterial obstruction. 
My analysis assessing the change in obstruction attenuation from baseline to short-
term follow-up CT suggested that the HU of obstruction may reduce more rapidly in 
patients given intravenous alteplase than controls; however, the difference in 
obstruction attenuation between treatment and control groups was non-significant.  
This result is nevertheless consistent with my analysis of HAS in the whole IST-3 
dataset (Chapter 5) which demonstrated that intravenous alteplase accelerates the 
removal of HAS, a known surrogate for intra-arterial thrombus.  I assume a similar 
process of removal is occurring in the obstruction attenuation subgroup but that 
smaller patient numbers in the present analysis have limited the power of this 
assessment.  
Strengths and limitations 
In a large pragmatic multicentre trial like IST-3 there is inevitably some variability in 
scan parameters and protocols but, on the other hand, the study design closely 
represents normal working practice.  Nevertheless, I cannot exclude the possibility 
that x-ray attenuation of thrombus was under-estimated due to partial volume effects 
of thick CT slices for some patients. Similarly, attenuation ratios may have varied 
with the hydration status of patients. We might expect patients to be dehydrated at 
baseline and for this to improve following admission to hospital. Therefore 
circulating blood could be relatively hyperattenuating on baseline versus follow-up 
scans due to differences in haematocrit. However, I did not find that use of 
attenuation ratios rather actual attenuation values materially altered results. IST-3 
angiography was performed only in some centres and may therefore be biased 
toward patients for whom it could convey the greatest perceived benefit.  Though the 
total patient numbers for this assessment are similar to previous work, my analyses 
are underpowered.  Nevertheless, as a randomised-controlled trial, IST-3 provides an 
unbiased assessment of the relationships between the use of intravenous alteplase and 
functional outcome.  I used manually applied regions of interest to measure the 
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attenuation of obstruction.  Other centres have developed automated segmentation 
programs for this task but it remains to be seen whether such an approach improves 
the accuracy of the data collected.  I used standardised and validated methods of 
accessing and scoring imaging with absolute blinding for robust and repeatable data 
collection.     
Conclusion 
These data from a prospective analysis of a large randomised trial do not provide 
evidence that measurement of arterial obstruction x-ray attenuation on CT adds 
useful additional information on prognosis or response to intravenous alteplase in 
patients with ischaemic stroke. 
 
 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
6 - CT Attenuation of Arterial Obstruction 142 
6.4 References for Chapter 6 
 
 (1)  Roozenbeek B, Lingsma HF, Perel P, Edwards P, Roberts I, Murray GD et al. 
The added value of ordinal analysis in clinical trials: an example in traumatic 
brain injury. Crit Care 2011; 15(3):R127. 
 (2)  Sandercock P, Lindley R, Wardlaw J, Whiteley W, Murray G, on behalf of 
the IST3 collaborative group. Statistical analysis plan for the third 
International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. Int J 
Stroke 2012; 7:186-187. 
 (3)  Nam HS, Kim EY, Kim SH, Kim YD, Kim J, Lee HS et al. Prediction of 
thrombus resolution after intravenous thrombolysis assessed by CT-based 
thrombus imaging. Thromb Haemost 2012; 107(4):786-794. 
 (4)  Topcuoglu MA, Arsava EM, Kursun O, Akpinar E, Erbil B. The utility of 
middle cerebral artery clot density and burden assessment by noncontrast 
computed tomography in acute ischemic stroke patients treated with 
thrombolysis. J Stroke Cerebrovasc Dis 2014; 23(2):e85-e91. 
 (5)  Puig J, Pedraza S, Demchuk A, Daunis IE, Termes H, Blasco G et al. 
Quantification of thrombus hounsfield units on noncontrast CT predicts 
stroke subtype and early recanalization after intravenous recombinant tissue 
plasminogen activator. AJNR Am J Neuroradiol 2012; 33(1):90-96. 
 (6)  Moftakhar P, English JD, Cooke DL, Kim WT, Stout C, Smith WS et al. 
Density of thrombus on admission CT predicts revascularization efficacy in 
large vessel occlusion acute ischemic stroke. Stroke 2013; 44(1):243-245. 
 (7)  Niesten JM, van der Schaaf IC, van der Graaf Y, Kappelle LJ, Biessels GJ, 
Horsch AD et al. Predictive value of thrombus attenuation on thin-slice non-
contrast CT for persistent occlusion after intravenous thrombolysis. 
Cerebrovasc Dis 2014; 37(2):116-122. 
 (8)  Froehler MT, Tateshima S, Duckwiler G, Jahan R, Gonzalez N, Vinuela F et 
al. The hyperdense vessel sign on CT predicts successful recanalization with 
the Merci device in acute ischemic stroke. J Neurointerv Surg 2013; 
5(4):289-293. 
 (9)  Yilmaz U, Roth C, Reith W, Papanagiotou P. Thrombus attenuation does not 
predict angiographic results of mechanical thrombectomy with stent 
retrievers. AJNR Am J Neuroradiol 2013; 34(11):2184-2186. 
 (10)  Spiotta AM, Vargas J, Hawk H, Turner R, Chaudry MI, Battenhouse H et al. 
Hounsfield unit value and clot length in the acutely occluded vessel and time 
required to achieve thrombectomy, complications and outcome. J 
Neurointerv Surg 2014; 6(6):423-427. 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
6 - CT Attenuation of Arterial Obstruction 143 
 (11)  Mokin M, Morr S, Natarajan SK, Lin N, Snyder KV, Hopkins LN et al. 
Thrombus density predicts successful recanalization with Solitaire stent 
retriever thrombectomy in acute ischemic stroke. J Neurointerv Surg 2015; 
7(2):104-107. 
 (12)  Zhu G, Michel P, Jovin T, Patrie JT, Xin W, Eskandari A et al. Prediction of 
recanalization in acute stroke patients receiving intravenous and endovascular 
revascularization therapy. Int J Stroke 2015; 10(1):28-36. 
 (13)  Niesten JM, van der Schaaf IC, Biessels GJ, van Otterloo AE, van Seeters T, 
Horsch AD et al. Relationship between thrombus attenuation and different 
stroke subtypes. Neuroradiology 2013; 55(9):1071-1079. 
 (14)  Novotna J, Kadlecova P, Czlonkowska A, Brozman M, Svigelj V, Csiba L et 
al. Hyperdense Cerebral Artery Computed Tomography Sign Is Associated 
with Stroke Severity rather than Stroke Subtype. J Stroke Cerebrovasc Dis 
2014; doi:10.1016/j.jstrokecerebrovasdis.2014.04.034. 
 (15)  Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and 
natural history of clinically identifiable subtypes of cerebral infarction. 
Lancet 1991; 337(8756):1521-1526. 
 
 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
7 - Sensitivity & Specificity of HAS 145 
Chapter 7 Sensitivity and Specificity of HAS 
for Arterial Obstruction 
In this chapter, I use data from my own assessment of IST-3 imaging of patients with 
non-contrast CT and CT or MR angiography at baseline to calculate the sensitivity 
and specificity of HAS for identifying true arterial obstruction or occlusion in 
ischaemic stroke. To broaden the applicability of the results of this analysis, IST-3 
sensitivity and specificity data were then included in a systematic review and meta-
analysis. 
This chapter addresses Thesis Aim 3). 
This work is also published in a peer reviewed journal, the complete draft of which is 
included as Appendix 6, see Chapter 11.3.4: 
Mair G, Boyd EV, Chappell FM, von Kummer R, Lindley 
RI, Sandercock P, Wardlaw JM, The IST-3 Collaborative 
Group. Sensitivity and specificity of the hyperdense artery 
sign for arterial obstruction in acute ischemic stroke. Stroke 
2015;46:102-7. 
 
7.1 Sensitivity and Specificity of HAS in IST-3 
 
7.1.1 Methods 
As discussed in Chapter 4.3, among IST-3 patients with CT or MR angiography at 
baseline, I had identified both HAS on non-contrast CT (where available) and 
angiographic obstruction on the concurrent CTA or MRA scan. First I assessed non-
contrast CT scans for the presence or absence of HAS.  Only thereafter did I assess 
angiography for the presence or absence of arterial obstruction, graded using TICI 
(see Table 3-3); i.e. I identified HAS without knowledge of angiography 
appearances. I was then able to determine when angiographic obstruction correlated 
with HAS, when it did not and vice versa.   
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The following were then calculated:   
 True positive (TP) – When the presence of HAS on non-contrast CT 
correlated with an arterial obstruction on angiography in the same anatomical 
location 
 False positive (FP) – When the presence of an apparent HAS on non-contrast 
CT did not correlate with an arterial obstruction on angiography 
 True negative (TN) – When neither HAS nor arterial obstruction were 
identified  
 False negative (FN) – When arterial obstruction was observed in the absence 
of HAS 
Next, I derived sensitivity and specificity data for this IST-3 subgroup: 
 Sensitivity (%) was calculated as TP / (TP + FN) x 100 
 Specificity (%) was calculated as TN / (TN + FP) x 100 
For completeness, the positive predictive value was calculated as the number of true 
positives divided by the number of positive calls (true positives plus false positives).  
The negative predictive value was calculated as the number of true negatives divided 
by the number of negative calls (true negatives plus false negatives). 
Statistical testing 
Simple t-tests were employed to compare percentages. Chi-square statistics (χ
2
) were 
used to compare categorical data.  Pearson and Spearman’s Rank correlation 
coefficients were used to test for relationships between normally distributed and non-
parametric continuous data, respectively. 
All analyses were performed using IBM SPSS Statistics software, version 20.0 (IBM 
Corporation, Armonk, NY, USA). 
A p-value <0.05 was considered significant. 
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7.1.2 Results 
From the 300 IST-3 patients with angiography performed at baseline, I included 273 
in this analysis to determine the sensitivity and specificity of HAS for true arterial 
obstruction following comparison of non-contrast CT imaging and concurrent CTA 
(n=269) or MRA (n=4). From 29 IST-3 patients with MRI performed at baseline, 25 
had no correlative non-contrast CT (<30 minutes of the MRI) with which to assess 
for HAS. In addition, at the time of performing this research, the IST-3 angiography 
subgroup data was still being compiled and ratified; 2 patients with CTA were added 
to the subgroup with baseline angiography subsequent to my present analyses. For 
completeness, Table 7-1 compares the n=273 subgroup with the entire IST-3 group. 
These results are not materially different to the previously reported comparison 
between the n=300 angiography subgroup and the entire IST-3 group, Table 3-4. 
 
Table 7-1 Baseline clinical and imaging characteristics and six-month outcome for IST-3 
patients included in the sensitivity and specificity analysis 
 IST-3 Patients with 
Baseline CT or MR 





Age (median, IQR) 81 years (71-86) 81 years (72-86) 0.815 
Male Sex  120 (44.0%) 1465 (48.3%) 0.135 
NIHSS (median, IQR) 10 (5-17) 11 (6-17) 0.020 
Hyperdense Artery 69 (25.3%) 716/2961 (24.2%)* 0.687 
OHS (median, IQR) 3 (1-5) 4 (2-6) 0.002 
Independent at 6 Months 
(OHS 0-2) 
120 (44.0%) 1088 (35.8%) 0.003 
Dead by 6 Months 61 (22.3%) 815 (26.9%) 0.078 
Treated with rt-PA  138 (50.5%) 1515 (49.9%) 0.827 
Footnote: Results represent n (%) unless otherwise stated.  NIHSS = National Institutes of Health 
Stroke Scale.  OHS = Oxford Handicap Scale (six-month follow up). IQR = Inter-Quartile Range. 
* From the entire IST-3 group 2961 had non-contrast CT at baseline, the remainder had MRI.  
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From these 273 patients, I identified an abnormal angiogram in 114 patients (42%) 
i.e. at least some luminal stenosis or obstruction (TICI < 3).  I identified HAS in 69 
patients (25%).   
Table 7-2 compares the sensitivity and specificity rates of HAS as an indicator of 
true arterial obstruction using different dichotomies of the TICI angiography scale.  
In general, higher grades of TICI (increasing vessel patency towards normal) were 
associated with greater sensitivity and specificity rates.  At the cut-off level used to 
define an abnormal angiogram (TICI < 3), HAS correctly identified arterial 
obstruction in 62/114 (54%), was falsely positive for angiographic abnormality in 7 
of 69 cases (10%) and falsely negative for angiographic abnormality in 52 of 114 
cases (46%).  As a measure of angiographic abnormality in IST-3 therefore, the 
hyperattenuating artery sign has a sensitivity of 54% (95% Confidence Interval = 45-
64%), a specificity of 96% (92-99%), a positive predictive value of 90% (83-97%) 
and a negative predictive value of 75% (68-81%).  Note that in 90% (56/62) of true 
positive cases, HAS was present in patients with arterial obstruction on angiography 
rather than occlusion (i.e. TICI 1, 2a or 2b).   
 
Table 7-2 Sensitivity and specificity of HAS for identifying arterial obstruction on 
angiography as defined using different angiography grades in IST-3 
Footnote: TICI = Thrombolysis in Cerebral Infarction: 0 = No flow, 1 = Minimal flow, 2a = Partial 
flow <50% of expected territory, 2b = Partial flow >50% of expected territory, 3 = Complete flow.   
Definition of Angiographic 
Abnormality 
Hyperattenuating Artery Sensitivity Specificity 
Yes No 
TICI = 0 6 6 50% 76% 
TICI <= 1 27 18 58% 83% 
TICI <= 2a 12 9 58% 88% 
TICI <= 2b 17 19 54% 96% 
TICI = 3 7 152 - - 
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The relationship between HAS and angiography stratified by stroke severity 
(NIHSS) in IST-3 is shown in Figure 7-1. Note that there were more true positives 
and fewer true negatives as stroke severity increased (χ
2
 = 84, 12 degrees of freedom, 
p<0.001).  There was however little change in false negative or false positive rates 
with increasing stroke severity but all false positive cases had an NIHSS less than 15. 
 
Figure 7-1 Relationship between the presence of a HAS and the results of angiography in 
IST-3 stratified by stroke severity at onset 
 
Footnote: Stroke severity defined using NIHSS (National Institutes of Health Stroke Scale).              
χ
2
 = 84, df = 12, p<0.001  
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Table 7-3 compares the effect of scan, obstruction and patient characteristics on HAS 
sensitivity and specificity. When baseline non-contrast CT scans were dichotomised 
by slice thickness (greater than 3 mm, n=108 or equal to/lesser than 3 mm, n=162), 
HAS was more frequently detected on the thin-slice images but the difference was 
not significant (27% versus 21%, p=0.276).  There was improved sensitivity but not 
specificity on the thin versus thick slices (62% versus 41%, p=0.031 and 98% versus 
92%, p=0.089, respectively).  There was no difference in the prevalence of HAS by 
location of arterial obstruction: proximal, n=91, sensitivity 55% versus distal, n=23, 
sensitivity 52% (p=0.814).  More extensive angiographic obstruction, i.e. involving 
more than one named artery (n=48) versus obstruction of one named artery (n=66) 
did not influence with the sensitivity of HAS (58% versus 52%, p=0.475).  Further 
analyses stratified by time from stroke onset and patient age did not meaningfully 
alter accuracy of the results. 
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Table 7-3 Effect of CT, obstruction and patient characteristics on the sensitivity and 
specificity of HAS in IST-3 
Footnote: n=273. Proximal vessels: internal carotid artery, mainstem of the middle cerebral artery, 
vertebral and basilar arteries. Distal vessels: anterior cerebral artery, sylvian branches of the middle 
cerebral artery and posterior cerebral arteries. For Obstruction Characteristics, there were no false 
positive results as all included patients had genuine obstruction; hence specificity was not calculable.  
 HAS Prevalence, n (%) Sensitivity Specificity 
Non-Contrast CT Scan Characteristics 
CT Slice 
Thickness 
≤ 3 mm 44/162 (27%) 62% 98% 
> 3 mm 23/108 (21%) 41% 92% 




Proximal vessel 50/91 (55%) 55% - 
Distal vessel 12/23 (52%) 52% - 
p-value for difference 0.814 0.814 - 
Extent of 
Obstruction 
1 segment 34/66 (52%) 52% - 
2-3 segments 28/48 (58%) 58% - 




≤ 180 minutes 34/151 (23%) 49% 97% 
> 180 minutes 35/122 (29%) 61% 94% 
p-value for difference 0.245 0.221 0.500 
Age 
≤ 80 years 30/136 (22%) 57% 96% 
> 80 years 39/137 (28%) 53% 96% 
p-value for difference 0.225 0.709 0.977 
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7.2 Systematic Review and Meta-Analysis of HAS 
Sensitivity and Specificity 
 
7.2.1 Methods 
This systematic review and meta-analysis was undertaken in compliance with 





I concurrently searched the Embase and Medline databases using the search strategy 
outlined in Figure 7-2.  Keywords pertaining to the topic areas of hyperattenuating 
arteries (in any intracranial location) and angiography (to include CT, MRI and 
catheter angiography) were combined within each topic area using the Boolean 
operator OR.  Results from these topic area searches were then combined using the 
Boolean operator AND.  As noted in Chapter 2, hyperattenuating arteries in stroke 
were first described in the early 1980s,
2
 therefore all articles from 1980 to the date at 
time of search (September 2013) were included.  Reference lists from the returned 
articles were hand searched and cross checked to identify any further relevant work.   
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Figure 7-2 Search strategy for systematic review of HAS sensitivity and specificity 
 
 
Primary inclusion and exclusion criteria  
I screened abstracts according to the following criteria to determine the final article 
list for subsequent data extraction.  Only peer reviewed original articles published 
entirely in English were included.  Articles had to contain data on ischaemic stroke 
patients assessed for hyperattenuating arteries who underwent invasive or non-
invasive angiography (CT-, MR- or digital subtraction angiography, DSA).   
Secondary exclusion criteria and data extraction 
I performed quality assessment for each article that met primary inclusion criteria 
based on a modified version of the STARD (STAndards for Reporting Diagnostic 
accuracy) 2003 checklist.
3
  This quality assessment checklist is shown in Table 7-4.  
For inclusion in subsequent meta-analysis, all essential criteria had to be met.  
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Articles were also excluded if imaging was not performed within 24 hours of stroke 
onset or if the number of patients undergoing angiography was fewer than 20.  This 
time limit for imaging was chosen to allow inclusion of articles assessing HAS in the 
posterior fossa where longer delays before treatment are often deemed acceptable. 
 
Table 7-4 Quality assessment checklist used as secondary exclusion criteria for entry into 





Prospective with sequential patients 
Randomised 
Inclusion/exclusion criteria provided 
Image acquisition 
details provided 
Scanner used (manufacturer and model, number of detector rows) 
Scan parameters (especially slice thickness) 
Time from stroke onset to imaging 
Time from non-contrast CT to angiography 
Description of image 
analysis 
Details of those analysing images 
Blinded to clinical details and treatment allocation (if any) 
Reproducibility data provided 
Hyperattenuating artery sign defined using previously described 
criteria 
 
Two observers (me and a neuroradiology colleague, Dr Elena V Boyd) 
independently extracted data from included publications to allow calculation of true 
and false positive and negative rates as our primary outcome; data were extrapolated 
from tables and figures where necessary.  We only meta-analysed papers where 
sensitivity or specificity (ideally both) could be calculated. We also recorded time 
from stroke onset to imaging and location and/or extent of angiographic obstruction 
as our secondary outcome.  Extracted data were added to a preconfigured spreadsheet 
(Appendix 11, Chapter 11.4.4).  Disagreements were resolved by consensus. 
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Meta-analysis 
Sensitivity and specificity values were calculated for articles included in the final 
meta-analysis.  Cumulative rates were also obtained using total patient numbers from 
those studies where all relevant data were available.  Sensitivity and specificity were 
calculated as above (7.1.1).   
Sensitivity and specificity results were meta-analysed with a random effects model in 
R2.8.1 (http://cran.r-project.org/), using the DiagMeta function, modelling within-
study variation as a binomial proportion
4
 (joint meta-analysis of sensitivity and 
specificity was not possible due to estimation problems).  
 
7.2.2 Results  
 
Search results 
The flowchart in Figure 7-3 details the results of the systematic database search and 
the final number of articles retained for inclusion in the meta-analysis.   
The database search identified 326 unique articles.  An abstract review excluded the 
majority of these (approximately 75%) for not meeting the primary inclusion 
criterion: must contain original data pertaining to the hyperattenuating artery sign in 
ischaemic stroke patients who underwent angiography.  Most of those excluded 
articles discussed CT hyperattenuation in locations other than intracranial arteries, 
e.g. solid abdominal organs.  The next most common reason for exclusion was 
publication only in abstract (approximately 10%).  Finally, some review articles and 
articles published in languages other than English were also excluded.  
Abstract review identified 31 articles for more in-depth assessment using the 
secondary exclusion criteria.  In addition, five further articles were identified from 
the reference lists of these 31 giving a total of 36 articles for full review.  
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Figure 7-3 Flowchart showing results of systematic search and effect of exclusion criteria 
on final number of articles included in meta-analysis 
 
 
Following application of the secondary exclusion criteria, 16 original articles (total 
n=902) remained for meta-analysis.
5-20
 Of the 20 excluded articles, seven provided 
insufficient raw data, six had fewer than 20 patients with angiography, two failed to 
meet all essential quality criteria (Table 7-4), two were duplicates, in two articles 
patients were imaged beyond 24 hours of stroke onset and one article included non-
ischaemic strokes.   
Quality assessment of articles retained for meta-analysis  
The 16 articles identified in systematic review (n=902, not including IST-3) had a 
median of 52 patients (range 20-105).  The majority of articles included in the meta-
analysis (14/16, 88%) used data that were collected prospectively. None of the final 
16 articles included randomised-controlled trial data.  Only seven articles (44%) 
provided specific inclusion and/or exclusion criteria.       
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Most articles provided scan parameters including time from stroke onset to scan 
(15/16, 94%).  Catheter angiography was the commonest technique (9/16, 56%).  
CTA and MRA were equally common (5/16, 31% and 4/16, 25%, respectively) and 
used almost exclusively since 2003.  Most articles declared explicitly the experience 
level or professional position of those analysing images (14/16, 88%); in total there 
were 24 neuroradiologists and nine neurologists in the range 1-6 observers per article 
(median two).  Image assessors were blinded to other data in 11/16 (69%) articles. In 
12/16 articles a standardised definition for HAS was used.  Reproducibility data for 
HAS were provided in only four articles (median kappa-statistic for the detection of 




Meta-analysis of data from the 16 articles identified after systematic review is 
displayed in Figure 7-4 and Table 7-5.  Both include IST-3 data presented above in 
7.1.2. 
Amongst a total of 1175 patients with angiography including IST-3, 769 had arterial 
obstruction and there were 405 HAS. The random effects summary estimate of 
sensitivity, based on 771 patients (384 true positive plus 387 false negative), was 
52.4% (95% CI 41.2-63.4%).  The random effects summary estimate of specificity, 
based on 493 patients, (468 true negative plus 25 false positive), was 94.9% (92.5-
96.6%).  Four studies with missing data were omitted from specificity analysis, 
Figure 7-4.
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Figure 7-4 Systematic review data for the 16 selected articles and IST-3 
 
Footnote: Data from individual studies included only if at least sensitivity or specificity could be calculated.  Unless stated otherwise, CT slice thickness refers to the 
thickest slices used (i.e. in studies with more than one scanner).  CTA = CT angiography.  MRA = MR angiography. HAS = Hyperattenuating Artery Sign.  TP = True 
positive. TN = True negative.  FP = False positive.  FN = False negative.  CI = Confidence Interval. 
* One patient had both a false positive HAS and a true occlusion without HAS (FN) in contralateral arteries.  As such 39 results are reported from 38 angiograms. 
† Data for proximal and distal middle cerebral artery were presented separately providing assessment of 200 arterial segments from 100 angiograms.   
‡ Thin-slice CT data are presented.  Thick-slice (5mm) data for the same angiography is also available.   
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Table 7-5 presents subgroup analyses assessing the relationships between the 
presence of HAS, the location and extent of arterial obstruction and time from stroke 
onset to scan.  HAS was more common with angiographic obstruction in proximal 
arteries (189/402, 47%) rather than distal (92/247, 37%) and this difference was 
significant (p=0.015).  The number of obstructed arterial segments showed a trend 
for increased rates of HAS (59% if two segments or more were obstructed compared 
with 49% if only one segment was obstructed) but this difference was non-significant 
(p=0.160).  The time from stroke onset to scan was not associated with HAS 
incidence; 27% had HAS if scanned ≤180 minutes from stroke onset versus 25% if 
>180 minutes, p=0.682. Three studies with missing data were excluded from 
analyses of arterial obstruction characteristics and time from stroke onset. 
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Table 7-5 Systematic review data assessing how characteristics of arterial obstruction (location and extent) and time from stroke onset affect the 








Location of Arterial 
Obstruction 
Number of Obstructed 
Arterial Segments 
Time from Stroke Onset to Scan 
Proximal Distal 1 ≥2 ≤180 mins ≥180 mins 
Assouline
17
 2005 39 8/16 (50) 6/7 (86) 11/17 (65) 4/8 (50) - - 
Barber
14
 2004 100 7/25 (28) 11/24 (46) - - - - 
Bastianello
6
 1991 36 12/17 (71) 6/13 (46) - - - - 
Flacke
10
 2000 23 6/10 (60) 0/10 (0) - - - - 
Froehler
20
 * 2013 67 15/20 (75) 23/43 (53) - - - - 
Garg
12
 2004 65 - - - - 1/8 (13) 8/57 (14) 
Kim
15
 † 2005 51 11/38 (29) 7/31 (23) - - - - 
Kim
18
 2008 78 36/56 (64) 10/22 (45) - - - - 
Koga
11
 2003 105 21/63 (33) 6/38 (16) - - - - 
Tomsick
5
 1990 20 4/9 (44) 2/7 (29) 3/10 (30) 3/6 (50) - - 
Tomsick
7
 1992 38 7/14 (50) 5/12 (42) 8/22 (36) 6/7 (86) - - 
von Kummer
9
 1994 53 - - - - 20/43 (47) 5/10 (50) 
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Wolpert
8
 1993 60 12/43 (28) 4/17 (24) - - - - 
IST-3
21
 2012 273 50/91 (55) 12/23 (52) 34/66 (52) 28/48 (58) 34/151 (23) 35/122 (29) 
TOTAL 189/402 (47) 92/247 (37) 56/115 (49) 41/69 (59) 55/202 (27) 48/189 (25) 
p-value for difference  0.015  0.160 0.682 
Footnote: Results represent number of HAS within each total (%).  Data were only included when results were available for both sides of the equation (e.g. proximal 
and distal); three articles had incomplete data and are not included. Unless otherwise stated, proximal arterial locations include internal carotid artery, main-stem of the 
middle cerebral artery (MCA), vertebral and basilar arteries.  Distal arterial locations include sylvian branches of the MCA, and anterior and posterior cerebral arteries.  
* Proximal and distal arteries are defined as internal carotid and middle cerebral arteries, respectively. 
† Thick-slice (5mm) CT data are presented here.  Thin-slice data are also available. 
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Using combined data from the meta-analysis and IST-3, the slice thickness of the 
non-contrast CT used to identify HAS was significantly associated with the 
sensitivity of the sign (Figure 7-5, r = -0.73, p=0.001) but not with specificity of 
HAS.  CT slice thickness was also inversely proportional to the year of article 
publication (r = -0.80, p=0.001, Figure 7-4). 
 
Figure 7-5 Relationship between the sensitivity of a HAS for arterial obstruction and non-
contrast CT slice thickness 
 
Footnote: Closed dots represent IST-3 data (thin-slice ≤3mm, mean 1.65mm; thick-slice 
>3mm, mean 4.5mm).  Open dots represent results from systematic review.   
Two dots have been fractionally altered to reveal identical results (sensitivity = 0.27, slice 
thickness = 10mm).  Correlation is r=-0.73, p=0.001.  
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7.3 Discussion of HAS Sensitivity and Specificity 
In this, the first meta-analysis assessing the accuracy of HAS as a non-contrast CT 
marker of arterial obstruction in acute ischaemic stroke, I have confirmed that HAS 
is highly specific and moderately sensitive for angiographically demonstrated arterial 
obstruction with overall specificity 95% and sensitivity 52%.  IST-3, as the largest 
individual study of HAS sensitivity and specificity, contributes 30% more data 
(273/902 patients, new total 1175) than was previously available.  These results are 
widely applicable and provide substantial confidence that there is very high 
likelihood of arterial obstruction when HAS is present, particularly with more severe 
strokes (there were no false positives in IST-3 with NIHSS >15).  However, absence 
of HAS does not predict normal arterial patency; in acute ischaemic stroke patients 
without HAS, approximately half will have arterial obstruction on angiography. It 
remains to be seen whether the presence (or absence) of acute arterial obstruction is 
important for intravenous thrombolysis treatment decisions, I will address this issue 
in Chapter 9. 
Traditionally, HAS was thought to indicate complete arterial occlusion but data from 
IST-3 suggest that most arterial segments with HAS (90% in IST-3) are not 
completely occluded.  However, with the CTA technique applied in IST-3, I was not 
able to determine flow direction.  It is possible therefore that in some patients, 
contrast agent bypassed the arterial obstruction via retrograde collateral flow.
22
 
Nevertheless, these data still demonstrate that intravenous alteplase should be able to 
reach beyond the obstructed segment and facilitate lysis in the vast majority of cases; 
I explore relationships between the completeness of arterial obstruction on 
angiography and response to intravenous alteplase in Chapter 9.   
My meta-analysis confirmed that HAS is more commonly identified with thinner CT 
slices.  Thinner slices do not increase the specificity of HAS, perhaps as HAS is 
already highly specific for obstruction.
15;23;24
  The mean diameter of intracranial 
arteries is less than 3mm.  A slice thickness above this value, as used in the majority 
of IST-3 patients and most of the other studies reported herein, may impair HAS 
sensitivity (especially in smaller arteries) by volume averaging intra-luminal 
thrombus and surrounding CSF space. Volumetric thin-slice CT is becoming more 
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available; as suggested by the strong and highly significant inverse relationship 
between the year of publication and CT slice thickness in the systematic review.  
Allowing for the rising availability of volumetric CT, HAS sensitivity in current 
routine clinical practice may be higher than I report here.   
Meta-analysis also confirmed that HAS is more likely to be identified within 
proximal rather than distal arteries probably reflecting the larger calibre of proximal 
arteries and therefore the greater volume of thrombus or embolus required to  
obstruct them.
18
  Other factors I tested in meta-analysis (extent of obstruction and 
time from stroke onset) were not significantly related to the frequency of HAS.  
Strengths and limitations 
IST-3 was conducted in many centres so inevitably includes variability in scan 
parameters and protocols.  However, IST-3 represents ‘real world practice’ and, 
combined with the systematic review, provides results that are widely applicable to 
centres assessing acute stroke with a range of CT scanners.  Angiography in IST-3 
was performed in about 10% of centres and may have been influenced by local 
practice, so has limitations.  Nevertheless, IST-3 angiography remains the largest 
complete dataset of its kind, the only one performed in the standardised context of a 
randomised-controlled trial, and increases the available data by almost one-third.  In 
terms of angiographies performed, I found only one larger dataset
25
 but it only 
included patients with a HAS precluding assessment of sensitivity or specificity.   
I used a qualitative measure to identify HAS in IST-3 which reflects routine practice. 
In Chapter 6 I explored whether measuring intra-arterial thrombus density 
quantitatively interacts with treatment response.  
The sensitivity and specificity of HAS changes depending on how angiographic 
‘abnormality’ is defined.  I chose to include any luminal narrowing (TICI <3) as my 
measure of abnormality because this maximised the specificity of the sign without 
unduly undermining HAS sensitivity; a cut-off level at TICI <=2a would have 
maximised sensitivity with a minor reduction in specificity and could arguably have 
been chosen instead.  Another consideration is that my method of dichotomising 
angiography results may have included some patients with chronic atheroma in the 
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‘obstructed’ group. This could erroneously raise the number of false negative HAS 
cases and thereby appear to reduce the sensitivity of HAS. However this is a general 
problem in acute stroke, no other studies that I identified in the literature had 
addressed this point, and I decided that the opposite approach (to only consider 
patients with occluded arteries as abnormal) would have been less accurate by having 
the same effect on HAS specificity but also by excluding patients with genuine non-
dense thrombus/embolus from my analyses entirely. 
By following PRISMA criteria and adopting a STARD checklist, I maintained a high 
quality systematic review and meta-analysis of HAS.  My search identified a large 
number of papers, most not relevant but I assert that evaluating several hundred 
abstracts was preferable to missing relevant work.  Excluding abstract-only and non-
English publications may have reduced the completeness of this analysis and led to 
publication bias, but research published only in abstract provided insufficient raw 
data for the analyses.     
The final 16 articles retained for meta-analysis were of moderate to high quality 
according to my criteria.  In particular, most of the data were collected prospectively 
and the methods were described in sufficient detail to be replicated.  More standard 
definitions for HAS and more consistent reporting of factors such as blinding of 




The high specificity of HAS provides substantial confidence for its use as a surrogate 
marker of angiographic obstruction and to confirm the diagnosis of acute ischaemic 
stroke.  The moderate sensitivity means that absence of HAS cannot be used alone to 
indicate that angiography will be normal.  Sensitivity of HAS is significantly 
improved with thin-slice volumetric CT.  
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Chapter 8 Observer Reliability for the 
Assessment of CTA in Stroke 
In this chapter, I use imaging of IST-3 patients with CT angiography (CTA) at 
baseline to create multi-reader CTA observer reliability analyses. 
This chapter addresses Thesis Aim 4). 
This work is also published in a peer reviewed journal, the complete draft of which is 
included as Appendix 7, see Chapter 11.3.5: 
Mair G, von Kummer R, Adami A, White PM, Adams ME, 
Yan B, Demchuk AM, Farrall AJ, Sellar RJ, Ramaswamy R, 
Mollison D, Boyd EV, Rodrigues MA, Samji K, Baird AJ, 
Cohen G, Sakka E, Palmer J, Perry D, Lindley R, Sandercock 
PAG, Wardlaw JM, The IST-3 Collaborative Group. 
Observer reliability of CT angiography in the assessment of 
acute ischaemic stroke: data from the Third International 
Stroke Trial. Neuroradiology. 2015;57:1–9. 
 
8.1 Methods for Observer Reliability of CTA 
In order to most efficiently test both inter- (same scan, different reader) and intra-
observer reliability (same scan, same reader) for the assessment of CTA performed 
acutely after ischaemic stroke, I performed two tasks: 
1. I selected 15 representative CTA cases from IST-3 and recruited a number of 
expert and non-expert readers to each perform independent rating of all 15 
scans online via SIRS-2 (see 3.4.2). As all of the recruited experts had 
previously served as members of the IST-3 angiography expert panel, a 
number of these scans were rated in an identical fashion by the same 
individual on two separate occasions.  
2. I identified when IST-3 CTA scans had already been formally evaluated on 
more than one occasion and I matched and compared the assessment data 
from each episode. Essentially, this means I collated results from my own 
assessment of IST-3 baseline angiography (see Chapter 4.3) with that of the 
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IST-3 expert panel. On both occasions the same scan reading proforma was 
used, however, the expert panel performed reads online via SIRS-2 while I 
performed reads locally on the server using Digital Jacket (V5.0, DesAcc 
Inc, Terre Haute, IN, USA). As I also previously served as a member of the 
expert panel, a small number of scans were rated by me on two different 
occasions using two different viewing platforms. A secondary benefit of this 
comparison therefore was to evaluate whether choice of viewing platform 
significantly affects the results of image assessment. 
Note that both task 1 and task 2 provided data for both inter- and intra-observer 
analyses. An overview of the different datasets and reader groups available for 
observer reliability analysis is provided in Figure 8-1.  
 
Figure 8-1 Different image reading subgroups from among all patients in IST-3 with 
angiography performed at baseline and how these subgroups were used for inter and intra-
observer analyses. 
 
Footnote: SIRS-2 = Systematic Image Review System 2. 
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For all observer reliability analyses, users were presented only with imaging 
performed concurrently (non-contrast CT and CTA) i.e. readers were blinded to all 
other imaging and to any previous reports for that imaging, to clinical and to 
treatment allocation data. Note therefore that as CTA was always rated in the 
presence of concurrent non-contrast CT, observer reliability data for non-contrast CT 
were automatically compiled in parallel with CTA. The results of both are displayed 
below (Chapter 8.2).   
 
8.1.1 Inter-observer reliability analyses 
As discussed above, inter-observer reliability for the assessment of CTA, was tested 
in two separate analyses: the first used 15 representative CTA cases from IST-3 rated 
by 14 individuals of varying experience, specifically for the purpose of this observer 
reliability analysis (i.e. new data); the second compared ratings that had already been 
collected for the assessment of all baseline CTA in IST-3 from both the expert panel 
and from me.  
Assessment of 15 cases rated by expert and non-expert readers 
Selection of cases: I identified a subgroup of IST-3 patients (n=15) who had both 
non-contrast CT and CTA at baseline. These 15 cases were chosen to represent a 
range of angiographic findings (e.g. presence/absence of arterial obstruction in 
variable locations, clot burden) based on the consensus opinion of three senior 
neuroradiologists, Table 8-1.  In three of these cases, CTA was deemed to be normal. 
In the remaining 12 cases, arterial obstruction of varying severity (TICI 1-2b) was 
identified in an internal carotid artery (n=4), in a middle cerebral artery (n=7), or in 
the basilar artery (n=1).  Clot Burden scores ranged from 1-10.     
Selection of readers: I identified 14 readers comprised of seven (of the original ten) 
expert IST-3 angiography panel members (each with greater than five years of 
experience in assessing CTA in acute stroke – the expert group) and also by seven 
non-expert readers (radiology trainees with less than two years of experience 
assessing CTA – the non-expert group – but this group included some with and some 
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without senior neuroradiology training).  This approach enabled me, with 
approximately two years of experience in the interpretation of CTA, to include 
myself in the non-expert group (radiology trainee) which was most appropriate for 
the present analysis. This is however slightly counter to the fact that I had also 
previously served as a member of the IST-3 expert panel for angiography.  
Scan rating: All 15 cases for this reliability analysis were independently rated by the 
14 readers using SIRS-2 in an identical manner as described in Chapter 3.4.2 for the 
original IST-3 assessment of imaging. These scan ratings (of both non-contrast CT 
and CTA) were performed purely to assess reader reliability and were undertaken in 
addition to, and separate from, scan ratings performed during the main IST-3 trial 
and the IST-3 angiography subgroup analysis. 
First inter-observer analysis: Three distinct inter-observer analyses were performed 
using the 15 cases: 
1. The expert group inter-observer reliability analysis compared seven 
observers, i.e. maximum 315 pairs of readings for each imaging characteristic 
assessed (21 reader pairs x 15 cases).   
2. The non-expert group (n=7) were assessed in a separate but identical analysis 
as for the expert group (maximum 315 pairs of readings).   
3. To ascertain whether additional neuroradiology training might improve the 
inter-observer reliability of non-expert CTA readers, the results of 
neuroradiology specialist trainees (n=3) from within the non-expert group 
were separately examined as a subgroup, i.e. maximum 45 pairs (3 x 15) of 
readings for each imaging characteristic.   
Comparison of IST-3 angiography cases rated by the expert panel and 
by me 
Cases and readers: As discussed in Chapter 3.4.2, all baseline angiography routinely 
acquired for patients recruited into IST-3 was collected and centrally assessed by the 
IST-3 angiography expert panel of 10 readers using the SIRS-2 platform. As 
discussed in Chapter 4.3, baseline angiography in IST-3 was also separately and 
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independently assessed by me at a different time using Digital Jacket software. I did 
not have access to expert panel results during my own assessment of the imaging. 
Scan rating: These two datasets were scored using the same imaging assessment 
proforma (Appendix 9, Chapter 11.4.1) including the scan rating characteristics 
previously discussed (Table 3-3).  
Second inter-observer analysis: I matched and compared CTA ratings for all patients 
assessed by both the IST-3 expert panel using SIRS-2 and by me using Digital Jacket 
software. Where expert panel assessment was also performed by me, these results 
were included in the intra-observer reliability analysis, see Chapter 8.1.2.  
When I assessed IST-3 angiography using Digital Jacket software, central trial office 
validation of angiographic imaging was incomplete. Following central validation, the 
initial classification of some scans (based on information provided by recruiting 
centres) was changed; i.e. the initial scan classification changed from pre-
randomisation (baseline) to post-randomisation and vice versa in a few cases based 
on the time difference between non-contrast CT and angiography (had to be <30 
minutes to be considered baseline). The initial classification of scans which I used to 
direct my own imaging assessment included 269 patients with CTA (compared with 
271 in the final centrally validated classification, see Chapter 3.8). Of these 269, I 
also provided the expert panel assessment for 25 cases (included in the intra-observer 
analyses). There was therefore a maximum of 244 pairs of readings for each imaging 
characteristic assessed in these inter-observer analyses. Note that in each case a 
comparison is being made between my assessments of the imaging versus a variable 
member of the IST-3 expert panel’s assessment of the same imaging. 
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Table 8-1 Consensus opinion of three senior neuroradiologists for CTA results of the 15 cases selected for inter-observer analysis 
Scan CTA Abnormal 
(yes/no) 









(good, moderate, poor) 
CTA-SI Deficit 
(yes/no) 
1 Yes ICA 1 1 7 Poor Yes 
2 No - 3 4 10 Good No 
3 Yes M1 2a 2a 7 Moderate Yes 
4 Yes M1 2b 2b 8 Good Yes 
5 Yes M2 2a 2a 9 Moderate Yes 
6 Yes ICA 2b 3 8 Good Yes 
7 Yes ICA 1 1 1 Good Yes 
8 Yes M1 2b 3 8 Good No 
9 No - 3 4 10 Good No 
10 Yes M1 2a 2a 7 Moderate No 
11 Yes ICA 2b 2b 7 Good Yes 
12 Yes Basilar 2b 3 9 Good Yes 
13 Yes M2 1 1 8 Moderate Yes 
14 Yes M1 2b 2b 8 Good Yes 
15 No - 3 4 10 Good Yes 
Footnote: TICI = Thrombolysis in Cerebral Infarction.  CTA-SI = CT Angiography Source Image. ICA = Internal Carotid Artery.  M1 = Horizontal segment of middle 
cerebral artery.  M2 = Sylvian branch of middle cerebral artery.   
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8.1.2 Intra-observer reliability analyses 
Intra-observer reliability for the assessment of CTA was also tested in two separate 
analyses, as discussed above in Chapter 8.1.1: the first used the 15 representative 
CTA cases specifically selected from IST-3 for reliability analysis; the second used 
25 cases, which were rated twice by me.  
In all cases for intra-observer analysis, the user had no knowledge of their previous 
scan assessment or even, in most cases, that a previous assessment had taken place.  
All paired scan reads for intra-observer analyses were separated in time by at least 
four weeks, but in many cases, up to one year passed between scan reads.   
Assessment of 15 cases rated by expert and non-expert readers 
Each of the 15 IST-3 scans specifically selected for this observer reliability analysis 
had already been independently but otherwise identically (as per 3.4.2) rated by one 
member of the expert panel for the primary IST-3 angiography substudy assessment. 
When the angiography substudy assessment and the rating collected for reliability 
analysis were performed by the same individual, these were matched and compared; 
i.e. maximum 15 pairs of readings for each imaging characteristic assessed. 
Comparison of 300 cases rated by IST-3 expert panel and by me 
While serving as a member of the IST-3 expert panel for angiography, I assessed 25 
baseline CTA cases using SIRS-2. At a different time and without knowledge of case 
specifics, I again assessed these cases as part of my own assessment of IST-3 
angiographic imaging using the Digital Jacket software. Results from these two 
separate scan rating roles were matched and compared, i.e. maximum 25 pairs of 
readings for each imaging characteristic assessed. 
 
8.1.3 Observer reliability of non-contrast CT 
In addition to examining CTA scans, in all cases concurrent non-contrast CT scans 
were simultaneously provided to the readers and rated using the non-contrast CT 
components of the CT rating proforma (Appendix 9, see Chapter 11.4.1); the IST-3 
method for assessing non-contrast CT is discussed more fully in Chapter 4.3.   
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In order to most efficiently use all collected data, the results of these non-contrast CT 
assessments were also examined in an identical manner as for CTA to provide 
observer reliability data for the assessment of non-contrast CT performed acutely 
after ischaemic stroke; this was particularly relevant for the assessment of HAS.   
 
8.1.4 Statistical testing 
All reliability analyses were performed using Krippendorff’s alpha (K-alpha) with 
1000 bootstrap samples for each.  K-alpha results range from -1.0 to +1.0 where +1.0 
equates to perfect agreement, 0.0 means no agreement and -1.0 implies perfect 
disagreement.
1
  I have adopted the Landis and Koch approach for interpreting these 
results: K-alpha 0.00-0.20 = slight agreement, 0.21-0.40 = fair agreement, 0.41-0.60 




Differences in K-alpha between expert and non-expert groups (including between 
neuroradiology specialist trainees and others), between imaging characteristics 
assessed on non-contrast CT and CTA or between assessments performed on 
different image viewing platforms were not tested for significance. 
Statistical software 
All analyses were performed using IBM SPSS Statistics software, version 20.0 (IBM 
Corporation, Armonk, NY, USA).  SPSS does not provide native support for K-
alpha; an appropriate macro was therefore applied, available at: 
http://afhayes.com/spss-sas-and-mplus-macros-and-code.html. This macro 
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8.2 Results for Observer Reliability 
 
Inter-observer reliability analyses for CTA 
Inter-observer reliability analyses for the assessment of CTA among expert and non-
expert readers (n=7 for both groups) are displayed in Table 8-2.  Expert readers had 
moderate to substantial agreement for all CTA measures (K-alpha in range 0.56-
0.70) except identification of a perfusion deficit on CTA source images (CTA-SI, K-
alpha = 0.32).  Non-expert readers had only fair to moderate agreement (K-alpha in 
range 0.25-0.61) for all CTA variables.  However among non-experts, 
neuroradiology specialist trainees’ (n=3) agreement compared more favourably with 
the expert group (K-alpha in range 0.36-0.78).   
Inter-observer reliability results comparing me as a single reader using Digital Jacket 
directly on the local server versus a variable member of the expert panel using SIRS 
via the web, were also generally comparable to the inter-observer results of the 
expert readers using SIRS alone (Table 8-2).    
Inter-observer agreement among experts and non-experts with additional training 
was greatest for assessing whether CTA was ‘normal’ or ‘abnormal’ (i.e. any 
intracranial arterial obstruction or occlusion).  For assessing the extent of 
angiographic abnormality, IST-3 scoring performed better than TICI in all groups 
although the 95% confidence intervals overlap so this difference is unlikely to be 
significant.  Expert reader TICI scores for all 15 cases are presented in Table 8-3. 
Note that while there are some discrepancies, most of the disagreements do not differ 
by more than two scalar points.   
The assessment of CTA collateral supply and the identification of a perfusion deficit 
on CTA-SI scored lowest for inter-observer reliability in all groups.  
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Table 8-2 Observer reliability analyses for CT Angiography among expert and non-expert readers 
 Expert Readers Non Expert Readers 
n=7 n=7 Neuroradiology 
Trainees, n=3 
Single Reader 
Total Stroke Cases 15 Cases 269 Cases 
Inter or Intra-Observer Inter (315 pairs) Intra (15 Pairs) Inter (315 pairs) Inter (45 pairs) Inter (244 pairs) Intra (25 Pairs) 
CTA Abnormal (y/n) 0.70 (0.52-0.85) 0.54 (0.08-1.00) 0.49 (0.32-0.66) 0.78 (0.56-0.94) 0.59 (0.41-0.74) 0.82 (0.55-1.00) 
TICI Score
3





0.66 (0.60-0.70) 0.63 (0.16-0.91) 0.43 (0.32-0.52) 0.72 (0.52-0.87) 0.62 (0.51-0.71) 0.78 (0.58-0.92) 
Clot Burden Score
5





0.56 (0.44-0.67) 0.72 (0.54-0.91) 0.30 (0.14-0.42) 0.36 (0.06-0.64) 0.43 (0.23-0.63) 0.56 (0.17-0.83) 
CTA-SI Deficit (y/n) 0.32 (0.13-0.52) 0.57 (-0.29-1.00) 0.25 (0.07-0.45) 0.60 (0.35-0.80) - - 
Footnote: Both inter and intra-observer results are provided.  Results represent K-alpha (95% confidence interval).  Maximum number of possible result pairs in each 
calculation is provided. 
CTA = CT Angiography. TICI = Thrombolysis in Cerebral Infarction. CTA-SI = CT Angiography Source Images. 
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Table 8-3 Comparison of angiography scores from 15 scans as assessed by 7 members of the 

















1 2a 1 1 2b 0 2b 1 
2 1 0 2b 1 0 0 0 
3 3 3 3 3 3 3 3 
4 2a 0 1 2a 0 0 0 
5 2b 0 3 2b 0 0 1 
6 2b 2b 1 2b 3 2b 3 
7 1 1 1 2b 0 0 1 
8 2b 3 3 3 3 3 3 
9 3 3 3 3 3 3 3 
10 2b 0 0 2b 0 0 0 
11 1 3 3 2b 1 0 3 
12 1 0 0 1 0 0 0 
13 2b 1 2b 2b 0 0 2a 
14 2a 3 3 3 3 3 3 
15 2a 0 0 2a 0 1 2a 
Footnote: K-alpha for this inter-observer analysis (315 pairs of readings) is 0.60 (95%CI = 0.53-
0.66). Angiography scored using TICI = Thrombolysis in Cerebral Infarction: 0= No flow/patency, 1= 
minimal flow/patency, 2a= Partial flow/patency of <50% of expected territory, 2b= Partial 
flow/patency of >50% of expected territory, 3= Complete flow/patency. 
 
Intra-observer reliability analyses for CTA 
My own intra-observer agreement was generally greater (K-alpha in range 0.56-0.86) 
than that of the expert readers (K-alpha in range 0.26-0.72) however the wide 95% 
confidence intervals for intra-observer analysis among the expert readers indicate 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
8 - Observer Reliability of CTA 180 
that these results are underpowered (Table 8-2). Consider also that for the expert 
readers, there were relatively few scan rating pairs for any individual reader.  
These results also indicate that reading the scans using different viewing platforms 
(SIRS-2 versus Digital Jacket) did not adversely affect my own intra-observer 
reliability compared with other expert panel members who used the same viewing 
platform (SIRS-2) on both occasions. 
Reader reliability for CTA versus non-contrast CT  
Table 8-4 presents inter and intra-observer reliability analyses for the expert readers’ 
assessment of non-contrast CT. Most imaging characteristics were well represented 
by the 15 selected cases. These results show fair to moderate agreement for most 
imaging characteristics. Identification and classification of ischaemia (using either 
ASPECTS or the IST-3 Ischaemia score) showed the best agreement (K-alpha 0.56-
0.66 for both inter- and intra-observer analyses).  
Identification of a HAS showed only fair inter-observer agreement but almost perfect 
intra-observer agreement (K-alpha 0.37 and 0.83, respectively). 
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Table 8-4 Results of expert readers’ inter and intra-observer analyses for a range of 
imaging characteristics assessed on non-contrast CT 
 
Footnote: Consensus results represent median (inter-quartile range) or percentage (total n=15). 
Reliability results represent K-alpha (95% confidence interval). Ischaemia defined as loss of grey-
white matter differentiation or parenchymal hypoattenuation. ASPECTS = Alberta Stroke Program 
Early CT Score. Ischaemia Depth = degree of hypoattenuation (0 = none, 1 = grey matter appears 
indistinct from white matter, 2 = grey and/or white matter of lower attenuation than normal white 
matter). HAS = Hyperattenuating Artery Sign. 
 
Figure 8-2 stratifies the expert readers’ inter-observer reliability for all imaging 
characteristics of both non-contrast CT and CTA.  Agreement was generally greater 
for the assessment of CTA features (K-alpha 0.32-0.70) than for non-contrast CT 
features (K-alpha 0.13-0.66) although the ranges were similar.  In addition, four of 




of Three Senior 
Neuroradiologists 
Expert Reader Reliability 
Inter-observer Intra-observer 
Acute features on non-contrast CT 
Ischaemia Yes = 75% 0.66  (0.59-0.75) 0.66 (0.39-0.93) 
ASPECTS
7





2 (1-3) 0.59 (0.51-0.68) 0.61 (0.32-0.84) 
Ischaemia Depth   
(0-2) 
0 = 20% 
1 = 80% 
0.38 (0.24-0.50) 0.54 (0.02-0.90) 
Mass Effect Yes = 62% 0.13 (-0.06-0.30) 0.39 (-0.02-0.80) 
HAS Yes = 67% 0.37 (0.19-0.54) 0.83 (0.58-1.00) 
Chronic features on non-contrast CT 
Atrophy
9
 (0-4) 1 (1-2) 0.32 (0.20-0.43) 0.46 (0.17-0.70) 
Leukoaraiosis
10
 (0-4) 2 (1-3) 0.56 (0.49-0.63) 0.69 (0.34-0.92) 
Previous Stroke Yes = 47% 0.49 (0.32-0.66) 0.47 (0.17-0.78) 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
8 - Observer Reliability of CTA 182 
Figure 8-2 Expert reader inter-observer reliability results for the assessment of imaging characteristics of both non-contrast CT and CTA 
 
Footnote: K-Alpha of 1.0 = perfect agreement, 0.0 = no agreement, -1.0 = perfect disagreement.  *Collateral supply is ranked as Good, Moderate or Poor.  Closed 
circles represent imaging characteristics identified on CTA.  Open circles represent imaging characteristics identified on non-contrast CT.  Ischaemia defined as loss of 
grey-white matter differentiation or parenchymal hypoattenuation. TICI = Thrombolysis in Cerebral Infarction.  ASPECTS = Alberta Stroke Program Early CT Score. 
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8.3 Discussion of Observer Reliability Results 
In this analysis where 14 observers with differing levels of experience, assessed a 
purposive sample of 15 examinations, I show that CTA features have slightly higher 
levels of agreement than non-contrast CT features. Imaging characteristics that are 
likely to have the greatest clinical impact (e.g. the presence and severity of arterial 
occlusion) have the highest inter-observer agreement, both for experienced (K-alpha 
> 0.60) and inexperienced observers. There was less agreement over arterial 
collateral supply and use of CTA-SI to identify perfusion deficits, even among 
experienced observers (K-alpha 0.30-0.60).  Despite being comparatively 
inexperienced, the participating radiology trainees that had undertaken additional 
neuroradiology training (neuroradiology fellows) performed as well as experts in the 
assessment of CTA.  This implies that, with adequate training, CTA can be reliably 
assessed even by readers with less case-based experience.  
Somewhat surprisingly, I found only fair inter-observer agreement for the 
identification of HAS (K-alpha 0.37) but near perfect intra-observer agreement (K-
alpha 0.83; this was the second highest level of agreement for any of the features 
assessed in either inter- or intra-observer analyses). My interpretation of these results 
is that the identification of HAS is highly consistent for individuals but that there 
remains some discrepancy in the definition of what represents a true HAS between 
different observers. 
I also show that my personal inter and intra-observer reliability for assessing CTA 
was consistent with equivalent results from the IST-3 expert panel as a whole. This 
provides confidence that my own results are meaningful and applicable to the work 
but also that my ability to interpret the imaging was not clearly affected by using a 
different image viewing platform. I suspect this latter observation reflects that 
reporting radiologists are routinely required to be adaptable to different viewing 
conditions and given a particular viewing platform will quickly adjust it to suit their 
own needs and preferences. This observation also provides some assurance that if 
radiological imaging assessment for multicentre research projects cannot be 
standardised, variability in image viewing techniques and conditions may be less 
important than previously supposed.        
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The IST3 angiography score is an adaptation of earlier scores (TICI, Mori).
3;11
  It is 
designed to overcome the limitations of using a catheter angiography score for the 
assessment of CTA by primarily assessing residual arterial calibre at the point of 
stenosis and contrast penetration into the major distal vessels only and makes no 
attempt to assess distal tissue perfusion.
4
  The present work represents the first 
external testing of observer reliability for the IST-3 angiography score and it 
compares favourably with TICI. 
To the best of my knowledge, there are only a few previous studies of CTA 
reliability in stroke; all had fewer than seven observers and none tested all the CTA 
characteristics assessed in my analysis.  Knauth et. al. reported an inter-reader 
kappa=0.78 for two readers identifying the correct location of occlusion on CTA in 
acute ischaemic stroke.
12
  Suh et. al. compared TICI versus a modified TICI score 
and found both scales were moderately repeatable (intra-class coefficients, ICC, 0.67 
and 0.73, respectively) across five readers.
13
  IST-3 expert readers did not replicate 
inter- and intra- observer reliability demonstrated by Puetz and colleagues in their 
original report of the Clot Burden Score (six readers, ICC=0.87 and 0.96, 
respectively) despite similar reader numbers.
5
  Similarly, in the original report 
defining their classification of collateral status, Miteff and colleagues demonstrated 
an inter-observer reliability of kappa=0.93 for two observers.
6
  IST-3 expert readers 
did not replicate those findings but our results are more consistent with other 
methods of assessing leptomeningeal flow as demonstrated on systematic review 
(0.49-0.87).
14
  Neither did IST-3 expert readers replicate the results from three recent 
articles, each with four readers that demonstrated improved detection of infarct using 
CTA-SI over non-contrast CT alone: Hopyan et. al. improved reader agreement from 
kappa 0.28-0.44 to 0.34-0.57;
15
 Finlayson et. al. showed an increase in ICC from 
0.83 to 0.88;
16




These studies report a mixture of kappa statistics and ICC and are not directly 
comparable with my K-alpha results; any comparisons should be treated with 
caution.  Nevertheless, kappa, ICC and K-alpha work on the same numerical scale 
and are therefore broadly similar.  Following discussion with a local medical 
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statistician, I opted to use K-alpha for several reasons. Cohen’s Kappa is only 
suitable for assessing two observers rating nominal data, adjusted Kappa techniques 
are required to handle ordinal data or comparisons of more than two observers and 
even then Kappa may not be the most suitable test;
18;19
 I had up to seven observers 
per analysis and a mixture of nominal and ordinal data. K-alpha has been shown to 
provide a more robust measure of observer variance than kappa or ICC and provides 
several advantages to the user; it allows comparisons between any number of 
observers, it can handle categorical and ordinal data, it is less prone to the influences 




Strengths and limitations 
Other strengths of my work include; a greater number of readers than in previous 
studies; calculation of both inter- and intra-observer reliability; use of a robust, 
standardised image analysis platform, previously shown to provide consistent multi-
user reporting;
21-23
 complete blinding of readers to all clinical information and to any 
other scan assessments; and use of representative cases from a multicentre trial 
which increases the generalisability and real world relevance of my results. 
My work also has some limitations.  Firstly, in contrast to previous work
23
 I did not 
formally produce a single reference standard for the ‘correct’ interpretation of the 15 
scans to compare with other readers.  Use of a reference standard would have 
allowed me to assess reader accuracy in addition to reader reliability.  The results in 
Table 8-1 represent the consensus opinion of three senior neuroradiologists but are 
nevertheless still open to interpretation error.  By confirming high observer 
agreement among a group of seven experienced readers, including several senior 
neuroradiologists, I believe that my results are as informative as reader comparisons 
set against any reference standard created from the same data.  I do however 
acknowledge the possibility that the expert readers were reliable in making false 
diagnoses but feel this is highly unlikely. Secondly, several of the characteristics I 
tested in intra-observer analyses are probably underpowered, evidenced by the wide 
confidence intervals. It is possible that if I had used more than 15 representative CTA 
cases, there might have been less variability in the results of these intra-observer 
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analyses. However, I decided upon 15 as this number allowed me to include a wide 
range of imaging characteristics without over-burdening the expert readers. Finally, 
the 15 cases were not deliberately chosen to be representative of the range of 
imaging features identifiable on non-contrast CT which may have affected the levels 
of agreement here. Nevertheless, most variables included a good range of values. 
Conclusion 
Experienced observers report CTA performed for the assessment of acute ischaemic 
stroke with substantial levels of agreement for most imaging characteristics.  Non-
expert readers perform well if given specialist training.  The IST3 angiography score 
is reported as reliably as TICI and has some face validity and practical advantages 
for the assessment of CTA. 
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Chapter 9 CT and MR Angiography in IST-3 
In this chapter, I use two datasets: first, data from my own assessment of IST-3 
imaging of patients with non-contrast CT and concurrent CTA performed at baseline; 
second, existing data from the IST-3 expert panel’s assessment of baseline CTA and 
MRA. These datasets are used to undertake three separate but related analyses 
examining the importance of angiographic imaging as a baseline investigation for 
patients presenting acutely with ischaemic stroke:   
1. Diagnostic and prognostic benefits of adding CTA to routine stroke imaging 
and determination of the extra time needed to add CTA (9.1) 
2. Relationships between CTA/MRA angiography results, response to 
thrombolysis and outcome in IST-3 (9.2) 
3. Meta-analysis of randomised controlled trial data testing for interactions 
between angiography findings, treatment with intravenous thrombolysis and 
outcome after stroke (9.3) 
This chapter addresses Thesis Aims 5) and 6). 
 
The first part of this chapter was presented in two posters at the European Stroke 
Conference in London, 28-31 May 2013. The finalised posters are included as 
Appendices 13 and 14 (Chapter 11.5). 
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Kummer R. Combining CT angiography with non-contrast 
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2013;35(Suppl 3):237 (Abst.15) 
Mair G, Wardlaw JM, Sandercock P, Lindley R, von 
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The second and third parts of this chapter are published in a peer reviewed journal, 
the complete draft of which is included as Appendix 8, see Chapter 11.3.6: 
Mair G, von Kummer R, Adami A, White PM, Adams ME, 
Yan B, Demchuk AM, Farrall AJ, Sellar RJ, Sakka E, Palmer 
J, Perry D, Lindley RI, Sandercock PAG and Wardlaw JM 
and for the IST-3 Collaborative Group. Arterial Obstruction 
on Computed Tomographic or Magnetic Resonance 
Angiography and Response to Intravenous Thrombolytics in 
Ischemic Stroke. Stroke 2017;48:353-360 
 
9.1 Baseline CTA for Improving Stroke Detection and 
Predicting Outcome, Time Needed for CTA  
These analyses were designed to test whether the extra information provided from 
CTA performed acutely after ischaemic stroke can improve a readers’ ability to 
identify relevant imaging features consistent with ischaemic stroke (i.e. whether the 
addition of CTA improves the rate of accurate diagnosis of ischaemic stroke using 
imaging alone) and also whether this extra information from CTA can be used to 
better predict prognosis (baseline stroke severity and six-month functional outcome) 
for a given patient compared with non-contrast CT imaging alone. 
9.1.1 Methods 
As discussed in Chapter 4.3, among IST-3 patients with concurrent non-contrast CT 
and CT angiography at baseline, I had assessed these scans (and the associated 
follow-up scans) for any acute imaging abnormality indicative of ischaemic stroke. 
Relevant abnormality on non-contrast CT included loss of normal grey-white matter 
differentiation, the presence of parenchymal hypoattenuation or a HAS.  Relevant 
abnormality on CTA was arterial obstruction or occlusion. 
Testing effect of CTA results on infarct detection and prognosis 
prediction 
Non-contrast CT and CT angiography (CTA) data were used to determine the 
sensitivity and specificity of different combinations of abnormal imaging 
appearances at baseline for predicting the presence of infarct on 24-48 hour follow-
up imaging.   
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Sensitivity and specificity were calculated for: 
 Acute abnormality of non-contrast CT alone 
 Acute abnormality of CTA alone 
 Acute abnormality of either non-contrast CT or CTA 
 Acute abnormality of both non-contrast CT and CTA 
The sensitivities and specificities of these different combinations of imaging 
abnormality were compared graphically using likelihood ratios to determine whether 
the addition of CTA improved the ability of CT at baseline to predict infarct at 24-48 
hour follow-up. 
Non-contrast CT and CTA data were also used to determine whether adding CT 
angiography to standard non-contrast CT improved the ability of baseline imaging to 
predict clinical stroke severity at onset and functional outcome 6-months after stroke. 
NIHSS and OHS were compared between those with normal baseline imaging and 
the groups with abnormality of non-contrast CT alone and those with abnormality of 
either non-contrast CT or CTA. As before, relevant abnormality on non-contrast CT 
was the presence of acute ischaemia or HAS.  Relevant abnormality on CTA was 
arterial obstruction or occlusion. 
Additional time needed for CTA versus time needed for non-contrast CT 
alone 
Among patients with non-contrast CT and CTA performed at baseline, I recorded the 
date and time of both scans from the DICOM headers. I did not record the scan times 
if non-contrast CT and CTA were clearly performed during separate trips to the 
scanner (e.g. two different studies separated by more than 30 mins). I noted if CT 
perfusion had also been concurrently performed. 
I calculated the time difference in minutes between non-contrast CT and CTA. 
Statistical testing 
After deriving true and false positive and negative results (TP, FP, TN, FN, 
respectively) for the combinations of imaging abnormality described above, I 
calculated sensitivity and specificity as before and as follows: 
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 Sensitivity (%) was calculated as TP / (TP + FN) x 100 
 Specificity (%) was calculated as TN / (TN + FP) x 100 
Decision matrices were derived from sensitivity and specificity data to allow a 
comparison of the diagnostic capabilities of the different non-contrast CT and CTA 
imaging combinations. Chi-square statistics (χ
2




I derived likelihood ratios from sensitivity and specificity data comparing non-
contrast CT with and without the addition of CTA for predicting infarct on follow-up 
imaging by plotting the true versus false positive rates.
2
 Thus a graphical comparison 
of the diagnostic capabilities of different imaging combinations was created. 
Mann-Whitney U testing was used to compare median NIHSS (National Institutes of 
Health Stroke Scale) and OHS (Oxford Handicap Scale, see Chapter 3.3 for both) 
between groups with and without imaging abnormality for the different combinations 
of imaging modality assessed. 
9.1.2 Results 
Non-contrast CT and CTA were performed concurrently at baseline in 271 IST-3 
patients.  Nearly half of these patients (119, 44%) were male with a median age of 81 
years (inter-quartile range, IQR 71-85). Non-contrast CT was performed at median 
170 minutes from stroke onset (IQR 110-252). Follow up non-contrast CT was 
performed within 48 hours for 92%.  
Baseline non-contrast CT was acutely abnormal (ischaemia or HAS) in 36% (95% 
confidence interval, 95%CI 30-42%). CTA was acutely abnormal (arterial 
obstruction or occlusion) in 42% (95%CI 36-48%). Either non-contrast CT or CTA 
were abnormal in 50% (95%CI 44-56%); both were abnormal in 28% (95%CI 23-
33%).  
Sensitivity and specificity of CT and/or CTA to predict infarct on follow-
up imaging 
Table 9-1 displays the sensitivities and specificities for different combinations of 
abnormal non-contrast CT and/or abnormal CTA at baseline to predict infarct on 
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short-term follow-up imaging. Identifying abnormality on either non-contrast CT or 
CTA improved the sensitivity of imaging to predict infarct at follow-up (χ
2
 = 27, 
p<0.001) compared with non-contrast CT alone. Identifying abnormality on both 
non-contrast CT and CTA improved the specificity compared with non-contrast CT 
alone (χ
2
 = 22, p<0.001). Figure 9-1 displays these results graphically as likelihood 
ratios.  
 
Table 9-1 Sensitivity and specificity of various baseline imaging combinations for predicting 
infarct on follow-up imaging 
Imaging identified as abnormal Sensitivity Specificity 
Non-contrast  CT  (NCCT) alone 50% 97% 
CT angiography (CTA) alone 55% 91% 
Either NCCT or CTA* 66% 89% 
Both NCCT and CTA* 40% 100% 
Footnote: * Significantly different from NCCT alone, p<0.001. 
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Figure 9-1 Likelihood ratios comparing non-contrast CT and/or CTA at baseline for predicting infarct at follow-up 
 
Footnote: Sensitivity and specificity of an abnormal (ischaemia or HAS) baseline CT in predicting infarct on follow-up imaging is plotted in red. The slopes of the 
connecting lines represent likelihood ratios for this test. The addition of CT angiography to baseline CT in the acute setting improves either sensitivity or specificity but 
not both. 
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Prediction of stroke severity and outcome using non-contrast CT and/or 
CTA 
Table 9-2 compares median NIHSS and OHS between patients with normal baseline 
imaging and those with abnormality on non-contrast CT alone versus those with 
abnormality on either non-contrast CT or CTA. Identifying imaging abnormality 
predicted more severe stroke and worse outcome for both groups but there was no 
significant difference between abnormal non-contrast CT alone and abnormal non-
contrast CT +/- abnormal CTA for NIHSS or OHS results (p=1.000). Figure 9-2 
shows the similarity of NIHSS distribution between the groups with abnormality on 
non-contrast CT alone versus those with abnormality on non-contrast CT or CTA. 
Figure 9-3 compares the distribution of OHS between these same imaging 
abnormality subgroups.  
 
Table 9-2 Stroke severity and outcome categorised by the findings on non-contrast CT and 
CTA 
Imaging test normal/abnormal NIHSS OHS 
Normal non-contrast CT and CTA  6 2* 
Abnormal non-contrast CT alone 16* 5* 
Abnormal non-contrast CT or CTA  15* 5* 
 
Footnote: NIHSS = National Institutes of Health Stroke Scale (stroke severity). OHS = Oxford 
Handicap Scale (6-month functional outcome). Results are median NIHSS and OHS.                            
* Significantly different from those with no abnormality, p<0.001 
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Footnote: NIHSS = National Institutes of Health Stroke Scale. PRCT = Pre-randomisation CT, i.e. 
baseline non-contrast CT. CTA = CT angiography. 
 
  
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
9 - CT & MR Angiography 197 




Footnote: OHS = Oxford Handicap Scale (0 = Normal, 1 = Minor symptoms, 2 = Minor handicap, 3 
= Moderate handicap, 4 = Moderate to severe handicap, 5 = Severe handicap, 6 = Dead). PRCT = Pre-
randomisation CT, i.e. baseline non-contrast CT. CTA = CT angiography. 
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Time needed for the addition of CTA to standard baseline stroke 
imaging 
As an estimate of the delays incurred by performing CTA at baseline among patients 
presenting acutely with ischaemic stroke, I found that the median time between non-
contrast CT and CTA in IST-3 was 6 minutes (IQR 3-10), n=240. The minimum 
delay incurred through the addition of CTA to standard imaging was 1 minute while 
the greatest delay was 63 minutes, see Figure 9-4. The results were slightly improved 
if patients with concurrent CT perfusion were excluded (n=52): median 5.5 minutes 
(IQR 3-9). 
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9.2 Analysis of IST-3 Expert Panel Assessment of 
Angiography Data  
These analyses were designed to assess the importance of baseline angiography 
findings in IST-3 in relation to baseline stroke severity and functional outcome at six 
months. I also tested angiogram characteristics individually to look for treatment 
interactions between normal versus abnormal angiography findings and response to 
intravenous alteplase. 
9.2.1 Methods 
In these analyses I used existing data from the IST-3 angiography expert panel’s 
assessment of CT or MR angiography when either imaging technique was performed 
at baseline (n=300). The IST-3 expert panel assessment of imaging is discussed more 
fully in Chapter 3.4.2; Table 3-3 lists the angiography scoring options available to 
the IST-3 expert panel while the entire imaging assessment proformas for CT and 
MRI are presented as Appendices 9 and 10 (Chapter 11.4), respectively.   
Angiography was categorised as ‘normal’ or ‘abnormal’ (any arterial occlusion or 
obstruction).  Scan readers recorded the presence, location and severity of all arterial 
obstructions noting the largest affected artery first plus up to two additional 
segments. Locations were ICA (internal carotid artery), MCA (middle cerebral 
artery), ACA (anterior cerebral artery), PCA (posterior cerebral artery), VA 
(vertebral artery) or BA (basilar artery). I grouped affected arterial segments as 
proximal (ICA, main stem MCA, VA, BA) or distal (Sylvian branch of MCA, ACA, 
PCA) in an identical fashion to HAS coding (see Chapter 5.1). 
The main focus of arterial obstruction was coded using a modified version of the 
Thrombolysis in Cerebral Infarction (TICI) and the IST-3 angiography scores.
3;4
  
Both are scalar and range from occlusion (0) through lesser grades of obstruction to 
normal (3 for TICI, 4 for IST-3).  
Readers also coded the Clot Burden Score in patients with anterior circulation (i.e. 
ICA, MCA or ACA) obstruction (subtracts the sum of the number of arterial 
segments affected from 10, where a score of 0 means all segments are affected and a 
score of 10 means no segments are affected.
5
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The collateral vessel supply was recorded for patients with ICA or MCA obstruction; 
categorised as good where the entire MCA distal to obstruction reconstituted with 
contrast, moderate where there was some MCA branch reconstitution or poor if only 
distal superficial branches reconstituted.
6
 
CTA source images (CTA-SI), collected on a single arterial pass (compared with 4-D 
angiography or true perfusion imaging collected over multiple passes) were used as a 
surrogate of arterial perfusion of brain tissue;
7
 CTA-SI were assessed for deficits in 
contrast perfusion (any extent or location), by comparison with adjacent or 
equivalent contralateral brain. 
For each of the angiography characteristics assessed in these analyses, I 
dichotomised the results into subgroups with more obstructed versus more patent 
angiography appearances (i.e. worse versus better appearances, respectively). I then 
used these dichotomies to test for differences in the alteplase treatment effect on 
outcome, i.e. to test for treatment interaction. Dichotomies included: angiography 
‘abnormal’ versus ‘normal’; obstructed arterial segment number 1 versus >1; 
obstruction location proximal versus distal and ICA versus MCA; IST-3 angiography 
score 0-2b versus 3-4, TICI 0-2a versus 2b-3; Clot Burden Score 0-7 versus 8-10; 
Collateral score Good versus Moderate-Poor; CTA-SI perfusion deficit versus no 
deficit.  
Statistical testing 
For univariate analyses testing for associations between angiography results, baseline 
stroke severity (NIHSS) and six month functional outcome (OHS), I used Mann-
Whitney U statistics to compare angiography dichotomies and Spearman’s rank 
coefficient to test for correlation with angiography scales. I used a multifactor 
analysis of variance (ANOVA) to look for interactions between combinations of 
angiographic findings and OHS.  
To test for associations between angiography findings, alteplase versus control and 
outcome, I used multivariable ordinal regression to calculate common odds ratios 
(ORs) with OHS at 6 months as the dependent variable. First I tested the impact of 
different angiography characteristics on outcome individually, controlled for patient 
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age, NIHSS, time from stroke onset to scan, and alteplase treatment allocation (here, 
OR <1 indicates worse outcome with alteplase). I then compared alteplase treatment 
effect on outcome (here, OR <1 favours control) for the aforementioned dichotomies 
(more obstructed versus more patent) of each angiography characteristic 
individually, controlled for patient age, NIHSS, and time from stroke onset to scan 
and tested for treatment interactions by comparing ORs between dichotomies. 
To stabilise ordinal regression estimates, I again used the same approach as the 
original IST-3 analysis of functional outcome, where the more severe grades of OHS 
(4-6) were grouped as one, leaving 5 groups for ordinal analysis (0, 1, 2, 3 and 4-6).
8
  
Similarly, I grouped the variable time from stroke onset to baseline scan, into 6 one-
hour segments (0-60, 61-120, 121-180, 181-240, 241-300 and 301-360 minutes). 
Comprehensive Meta-Analysis software (Biostat, Englewood, NJ, USA) was used to 
perform tests of interaction. All other analyses were performed using IBM SPSS 
Statistics software, version 20.0 (IBM Corporation, Armonk, NY, USA).  
A p-value <0.05 was considered significant. 
9.2.2 IST-3 angiography findings 
In IST-3, angiography was abnormal (obstruction or occlusion) in 146/300 (48.7%) 
patients according to the expert panel (Table 9-3); the ICA (47/146, 32.2%) or the 
MCA mainstem (57/146, 39.0%) were most frequently affected.  For those with 
arterial obstruction/occlusion, >1 arterial segment was affected in approximately half 
(77/146, 52.7%), 2 segments in 54 of 146 (37.0%), and 3 segments in 15 of 146 
(10.3%) patients.  From 288 patients with an IST-3 Angiography score, 104 (36.1%) 
scored 0 to 2b (occluded/moderate-severely obstructed), whereas 184 (63.9%) scored 
3 to 4 (mildly obstructed or normally patent). See Table 9-3 for concurrent TICI 
scores. The median clot burden score was 8 (2 segments affected). Similar 
proportions had good (48/135, 35.6%), moderate (37/135, 27.4%), or poor (50/135, 
37.0%) collateral scores. A perfusion deficit on CTA-SI was identified in 69 of 186 
(37.1%) patients where assessable. 
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Table 9-3 Angiography findings for 300 patients in IST-3 with CTA or MRA at baseline 
Angiography Type 
CTA 271 (90.3) 
MRA 29 (9.7) 




Number of Abnormal Arterial Segments 
(n=146) 
1 77 (52.7) 
2 54 (37.0) 
3 15 (10.3) 
Largest Arterial Segment Affected 
(n=146) 
ICA 47 (32.2) 
MCA Mainstem 57 (39.0) 
MCA Sylvian Branch 31 (21.2) 
Basilar 5 (3.4) 
Vertebral 3 (2.1) 
Other 3 (2.1) 
ACA 0 
PCA 0 
Location of Angiographic Abnormality 
(142) 
Distal Vessel Only 29 (20.4) 
Proximal Vessel Only 63 (44.4) 
Proximal & Distal Vessels 50 (35.2) 
IST-3 Angiography Score (n=288) 
4 155 (53.8) 
3 29 (10.1) 
2b 16 (5.6) 
2a 12 (4.2) 
1 32 (11.1) 
0 44 (15.3) 
TICI Score (n=288) 
3 163 (56.6) 
2b 32 (11.1) 
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2a 17 (5.9) 
1 29 (10.1) 
0 47 (16.3) 
Clot Burden Score (n=278) 
10 154 (55.4) 
9 39 (14.0) 
8 29 (10.4) 
7 14 (5.0) 
6 10 (3.6) 
5 9 (3.2) 
4 8 (2.9) 
3 7 (2.5) 
2 5 (1.8) 
1 2 (0.8) 
0 1 (0.4) 
Collateral Score (n=135) 
Good 48 (35.6) 
Moderate 37 (27.4) 
Poor 50 (37.0) 
CTA-SI Perfusion Deficit (n=186) 69 (37.1) 
 
Footnote:  Numbers represent n (%). Variability in the total patient numbers reflects missing data in 
some categories; clot burden and collateral scores were calculated only with anterior circulation 
obstruction. Obstruction was obscured or too peripheral for calculation of an IST-3 angiography, TICI 
or clot burden score in 12 cases. Not all patients with normal IST-3 angiography scores had normal 
TICI scores and vice versa. CTA = CT Angiography, MRA = MR Angiography, ICA = Internal 
Carotid Artery, MCA = Middle Cerebral Artery, ACA = Anterior Cerebral Artery, PCA = Posterior 
Cerebral Artery, TICI = Thrombolysis in Cerebral Infarction, CTA-SI = CTA Source Images. 
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Angiography, stroke severity and outcome in IST-3  
On univariate analysis, all categories of angiographic abnormality were associated 
with significantly worse baseline stroke severity and poorer 6-month outcome 
(p<0.0001 for most), see Table 9-4. A 3-way ANOVA found no interaction between 
any combination of the effects of TICI, clot burden, and collateral scores on OHS 
(F=0.814; p=0.564), see Table 9-5. 
 
Table 9-4 Univariate associations between angiography findings, stroke severity and 
outcome 
Angiography Measure NIHSS OHS 
Angiography Abnormal (n=146) 





Abnormal Arterial Segment Number (n=146) 0.34* 0.37* 
Abnormal Proximal Artery (n=113) 





IST-3 Angiography Score (n=288) -0.52* -0.34* 
TICI Score (n=288) -0.51* -0.36* 
Clot Burden Score (n=278) -0.56* -0.39* 
Collateral Score (n=135) 0.41* 0.36* 
CTA-SI Deficit (n=69) 






Footnote: Numbers represent median (interquartile range) or Spearman’s correlation. * p<0.0001, ** 
p=0.023, *** p=0.002.  NIHSS = National Institutes of Health Stroke Scale.  OHS = Oxford Handicap 
Scale (six-months).  TICI = Thrombolysis in Cerebral Infarction.  CTA-SI = CTA Source Images. 
Proximal arteries include the internal carotid, middle cerebral mainstem, vertebral and basilar arteries.  
Distal arteries include the sylvian branch of middle cerebral, anterior cerebral and posterior cerebral 
arteries. Variability in the total patient numbers reflects missing data in some categories; Clot Burden 
Score and Collateral Score was not calculated in all cases.  Not all patients with normal IST-3 
angiography score had normal TICI score and vice versa.   
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Table 9-5 Three way analysis of variance for interactions between combinations of 
angiographic findings and six-month functional outcome in IST-3 
Angiographic Finding Combination Degrees of Freedom F p-value 
Clot Burden Score * TICI 18 1.306 0.217 
Clot Burden Score * Collateral Score 9 1.480 0.176 
TICI * Collateral Score 6 1.416 0.223 
Clot Burden Score * TICI * Collateral Score 6 0.814 0.564 
 
Footnote: Due to collinearity between some of the angiographic measures, only one feature assessing 
extent of obstruction (Clot Burden Score rather than arterial segment number) and one feature 
assessing completeness of obstruction (TICI rather than IST-3 angiography score) were included in 
this ANOVA based on the strength of their associations with OHS on univariate analysis (Table 9-4). 
There was also strong collinearity between location and extent of obstruction with very few multi-
segment obstructions sited distally rather than proximally; location of obstruction was therefore also 
excluded from this ANOVA. ANOVA = Analysis of Variance.  OHS = Oxford Handicap Scale.  TICI 
= Thrombolysis in Cerebral Infarction.   
 
In multivariable ordinal regression analysis, controlled for age, NIHSS, time from 
stroke onset to scan and alteplase treatment allocation; having a greater number of 
obstructed arterial segments (OR 0.41; 95%CI 0.22–0.76; p=0.005), a worse clot 
burden score (OR 0.78; 95%CI 0.62–0.97; p=0.026), or poorer collaterals (OR 0.53; 
95%CI 0.32–0.85; p=0.009) were all independent predictors of worse 6-month 
outcome, but not proximal versus distal (or ICA versus MCA) arterial obstruction, or 
the residual arterial calibre at the point of obstruction on IST-3 angiography or TICI 
scores (Table 9-6).  
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Table 9-6 Multivariable ordinal regression analyses testing for independent associations 






Angiography Abnormal vs Normal 
(n=300) 
0.81 0.50-1.32 0.394 
Increased Abnormal Arterial Segment 
Number (n=146) 
0.41 0.22-0.76 0.005 
Abnormal Proximal vs Distal Artery 
(n=142) 
0.45 0.20-1.02 0.055 
Abnormal ICA vs MCA (n=135) 0.85 0.40-1.81 0.679 
Worse IST-3 Angiography Score (n=288) 0.90 0.78-1.04 0.145 
Worse TICI Score (n=288) 0.85 0.71-1.01 0.062 
Worse Clot Burden Score (n=278) 0.84 0.72-0.98 0.023 
Poor Collateral Score (n=135) 0.53 0.32-0.85 0.009 
CTA-SI deficit vs No Deficit (n=186) 0.97 0.50-1.88 0.923 
 
Footnote: An odds ratio <1 indicates a worse outcome. Six-month Oxford Handicap Scale (OHS) was 
the dependent variable for each separate model.  In each case, results were controlled for the effects of 
patient age, time from stroke onset to scan, stroke severity (National Institutes of Health Stroke Scale) 
and treatment allocation.  ICA = Internal Carotid Artery. MCA = Middle Cerebral Artery. CTA-SI = 
CTA Source Images. Variability in the total patient numbers reflects missing data in some categories; 
Clot Burden Score and Collateral Score was not calculated in all cases.  Not all patients with normal 
IST-3 angiography score had normal TICI score and vice versa.   
 
Angiography and effect of intravenous alteplase in IST-3 
I found no significant interactions between any individual angiogram feature and the 
effect of alteplase on 6-month OHS (Figure 9-4). There was a nonsignificant trend 
toward better outcomes after alteplase versus control among patients with obstructed 
(OR 1.86; 95%CI 0.76–4.53; p=0.171) versus patent (OR 0.72; 95%CI 0.42–1.25; 
p=0.241) arteries on the IST-3 angiography score, p=0.075 for interaction (Figure 9-
5 and Figure 9-6). 
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Figure 9-5 Ordinal regression analyses comparing alteplase treatment effect on outcome (OHS as the dependent variable) in patients with more versus 
less normal results for the different angiography characteristics in IST-3 
 
Footnote: Ordinal regression analyses, of the effect of alteplase treatment on outcome (Oxford Handicap Scale [OHS] as the dependent variable) in patients with more 
versus less normal results by different angiography features. Results represent odds ratio of better (right of vertical line) or worse (left of line) 6-month outcome with 
alteplase. Adjusted for age, time from stroke onset to scan, and stroke severity (National Institutes of Health Stroke Scale). ICA = Internal Carotid Artery.  MCA = 
Middle Cerebral Artery.  TICI = Thrombolysis in Cerebral Infarction.  CTA-SI = CTA Source Images.  
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Figure 9-6 Bar charts comparing Oxford Handicap Scale (OHS) distribution for alteplase and control groups in those with (A) and without (B) arterial 
obstruction in IST-3. 
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9.3 Meta-Analysis 
This meta-analysis was designed to set the IST-3 angiography results from Chapter 
9.2 in context and, where possible, to strengthen the dataset through the addition of 
comparable angiography data from other randomised-controlled trials which tested 
intravenous thrombolytics for ischaemic stroke. It was hoped that trends identified in 
IST-3 toward treatment interaction with angiography findings might be replicated 
using data from other trials and that the combined results might show statistically 
significant interactions which could ultimately be used to help guide treatment 
decisions in stroke. 
9.3.1 Methods 
In order to identify relevant trials for meta-analysis I decided against performing a 
systematic review. Rather, I used a recently updated Cochrane Collaboration 
systematic review to identify appropriate trials. This route was chosen for efficiency 
and since Prof Wardlaw, one of my MD project supervisors, was the primary author 
of the Cochrane review in question, its robustness and accuracy had been vouched 
for.   
Identification and collection of relevant trial data 
The Cochrane Collaboration systematic review on Thrombolysis for Acute Ischaemic 
Stroke,
9
 was recently updated in 2014 and includes 27 randomised-controlled trials 
which tested thrombolytics for the acute treatment of ischaemic stroke.  This 
systematic review was used to identify relevant randomised-controlled trials for my 
meta-analysis. I included trials if they had compared intravenous thrombolytics with 
control among patients with ischaemic stroke who had angiography performed at 
baseline. I extracted data directly from the original full-text trial publications. I 
sought results for any of the angiography features already assessed in IST-3 and 
collected both raw data and summary statistics (e.g. odds ratios with 95% confidence 
intervals). Chief investigators were contacted to obtain additional data where 
necessary.  
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Statistical testing 
I calculated adjusted odds ratios (ORs) for the effect of intravenous thrombolytic 
treatment on outcome, by logistic regression, separately in patients with:  
a) Patent versus obstructed arteries; and  
b) ICA versus MCA obstruction location.  
Specifically, I meta-analysed trial data using the random effects model to create 
summary ORs for the effect of intravenous thrombolytics (any formulation or dose) 
on outcome (OHS or mRS at 3-6 months) in:  
a) Patients with occlusion/ severe arterial obstruction (IST-3 angiography score 
0-2b or Thrombolysis In Myocardial Infarction – TIMI
10
 0-1 or 0-2, i.e. 
worse results) versus patent arteries (IST-3 angiography score 3-4 or TIMI 2-
3, i.e. better results); and in a separate analysis 
b) Patients with ICA versus MCA obstruction.  
Finally, I tested for interactions between intravenous thrombolytics and arterial status 
on functional outcome. I tested for between-study heterogeneity using I
2
 statistics. I 
followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-




I used Comprehensive Meta-Analysis software (Biostat, Englewood, NJ, USA) to 
compute summary ORs and to test for interactions. 
 
9.3.2 Results 
From 27 trials included in the Cochrane Collaboration systematic review, baseline 
angiography data were available from four trials of intravenous thrombolytics in 
addition to IST-3, Figure 9-7. Sixteen trials were excluded for absence of 
angiography. Four trials were excluded as intra-arterial rather than intravenous 
thrombolytics were used. One trial was excluded as angiography was performed at 
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follow-up rather than baseline. One trial was excluded as it only recruited patients 
with proximal arterial obstruction. 
The final five trials selected for meta-analysis (total n=591) included two trials of 
intravenous alteplase (288 patients from IST-3 and 87 from EPITHET)
12
 and three 
trials of intravenous desmoteplase (216 patients from DIAS, DIAS-2 and 
DEDAS).
13-15
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Testing interaction between completeness of arterial obstruction and 
response to intravenous thrombolytics 
Patients with severe arterial obstruction or occlusion were significantly more likely 
to have better functional outcome with intravenous thrombolytics versus control (OR 
2.07, 95%CI 1.18-3.64, p=0.011, I
2
 0%) than were patients with patent arteries 
(intravenous thrombolytics versus control, OR 0.88, 95%CI 0.58-1.35, p=0.566, I
2
 
16%), p for interaction 0.017 (Figure 9-8).     
 
Testing interaction between location of arterial obstruction and 
response to intravenous thrombolytics 
For this analysis, data were only available from IST-3 and EPITHET (n = 135 + 54 = 
189). I did not identify any difference in the response to intravenous thrombolytics 
between patients with ICA versus MCA obstruction (ICA obstruction, alteplase 
versus control, OR 0.65, 95% CI 0.06-6.89, p=0.720, I
2
 74%; MCA obstruction, 
alteplase versus control OR 1.92, 95% CI 0.90-4.09, p=0.090, I
2
 0%), p for 
interaction 0.391 (Figure 9-9).   
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Figure 9-8 Meta-analysis of IST-3, EPITHET (alteplase) and the DIAS, DIAS-2 and DEDAS (desmoteplase) trials comparing the effect of intravenous 
thrombolytics on functional outcome between patients with arterial patency versus obstruction 
 
Total patient numbers in each trial are provided, n.  Raw treatment data were unavailable for the Desmoteplase trials. Results represent odds ratio (95% confidence 
interval) of better (right of vertical line) or worse (left of vertical line) outcome after thrombolytics.  Open circles represent patients with arterial patency (test for 
heterogeneity, I
2
 = 0%). Closed circles represent severe arterial obstruction / occlusion (I
2
 = 16%). TIMI = Thrombolysis in Myocardial Infarction.
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Figure 9-9 Meta-analysis of IST-3 and EPITHET comparing the effect of intravenous alteplase on outcome between patients with ICA versus MCA 
obstruction 
 
Footnote: Total patient numbers in each trial are provided, n. Results represent odds ratio (95% confidence interval) of better (right of vertical line) or worse (left of 
vertical line) outcome after thrombolytics.  ICA = Internal Carotid Artery (test for heterogeneity, I
2
 = 74 %).  MCA = Middle Cerebral Artery (I
2
 = 0%). 
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9.4 Discussion on the use of Baseline Angiography in 
the Assessment of Ischaemic Stroke 
 
In this chapter, I have examined three inter-related lines of research to explore 
relationships between the clinical presentation of stroke, findings on angiography 
performed at imaging baseline as soon as possible after symptom onset and the effect 
of intravenous thrombolytic therapy on functional outcome: 
1. I looked at the diagnostic and prognostic benefits (and extra time needed) of 
performing CTA as part of the routine imaging work up of patients presenting 
acutely with stroke. 
2. I used data from the expert panel assessment of imaging in one of the largest 
randomised-controlled trials of intravenous alteplase for ischaemic stroke 
(IST-3) to test for treatment interaction between intravenous alteplase and 
various angiographic imaging characteristics. 
3. I compounded the results of the IST-3 analysis in 2, by setting them in the 
context of a meta-analysis including angiography data from other relevant 
randomised-controlled trials. 
Diagnostic and prognostic benefits of performing CTA at ischaemic 
stroke baseline, additional time needed 
I have demonstrated using IST-3 data that combining CTA with non-contrast CT for 
the baseline imaging assessment of patients with ischaemic stroke significantly 
increases the sensitivity (if either non-contrast CT or CTA are abnormal) or 
specificity (if both non-contrast CT and CTA are abnormal) for predicting the 
presence of infarction on follow-up imaging. While the inclusion of CTA therefore 
increases the number of patients with abnormal imaging, this extra information does 
not alter the prediction of stroke severity or functional outcome at six-months over 
non-contrast CT alone. 
Patients recruited in IST-3 after CTA or MRA were randomised and treated, on 
average, ten minutes later after stroke onset than were those with only plain scans 
(see Table 3-4). By comparing the DICOM recorded time of non-contrast CT and 
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CTA in patients where these scans were performed in immediate succession, I 
confirmed that most of this delay (6 minutes) was attributable to acquiring the extra 
angiography. The steep time dependency of alteplase effects on outcome mean that 
even this small delay could reduce the potential benefit of treatment,
16
 particularly on 
a population level if angiography is performed non-discriminately in all ischaemic 
stroke patients. Efforts should be directed at minimising delays attributable to 
obtaining angiography in stroke; some IST-3 centres were able to perform CTA only 
one minute after non-contrast CT.   
Testing for interaction between the results of angiography and 
response to intravenous alteplase in IST-3 
In my analysis of CTA and MRA data from IST-3, I demonstrated that having a 
greater number of obstructed arterial segments or poor collateral supply was 
associated with poor six-month functional outcome, independent of stroke severity 
and alteplase treatment; in these patients, alteplase appeared less likely to improve 
outcome. Those with a greater number of obstructed segments may, therefore, have 
the most to gain from endovascular therapy, which several RCTs have recently 
shown to be superior to intravenous alteplase alone among patients with 
angiography-confirmed proximal intracranial arterial obstruction.
17
 Consistent with 
my results, post hoc analysis of one of these endovascular treatment trials 
demonstrated that patients with poor collateral supply had poorer outcomes than 
those with good collaterals.
18
 
Despite trends toward improved outcome after alteplase versus control among 
patients with abnormality in one of several angiographic characteristics, I was not 
able to demonstrate a significant treatment interaction between alteplase and CT/MR 
angiography results in IST-3. That is, there was no significant difference in the 
treatment response between patients with abnormal angiography versus those with 
normal angiography, no matter how angiography was assessed. However, the wide 
confidence intervals indicate imprecise estimates of angiography findings on 
alteplase effects and that the sample is underpowered. It is for this reason that the 
subsequent meta-analysis was performed. 
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Other strengths and weaknesses of this IST-3 analysis are as follows. Angiographic 
imaging was not a requirement of IST-3 but some centres performed baseline CT or 
MR angiography for ischaemic stroke routinely; therefore, this angiography 
subgroup analysis was pre-planned to make most use of all available data and 
maximise knowledge gained from an RCT. The results of angiography were not used 
to determine trial eligibility, and at the time of IST-3 enrolment, there were virtually 
no data on how angiography results should be used in this context. Therefore, clinical 
uncertainty as to whether treatment with alteplase would be beneficial existed even 
for patients with large artery obstruction. Angiography was however performed in 
only 10% of IST-3 centres, reflecting local practice at the time, and so is limited by 
small sample size, the potential for selection bias and reduced generalizability of the 
findings to all current stroke centres. Nevertheless, IST-3 angiography represents 
‘real world’ practice where approximately 50% had angiographic obstruction
19
 and 
with 300 patients, is the largest angiography dataset from an RCT of intravenous 
alteplase in ischaemic stroke. IST-3 used robust, validated methods for scan 
management and scoring angiograms,
4




Meta-analysis of angiography results from randomised-controlled trials 
testing intravenous thrombolytics to identify treatment interaction 
My meta-analysis of CTA and MRA data from five RCTs (including IST-3) of 
intravenous thrombolytics (alteplase and desmoteplase), and comprising 591 patients 
treated within six hours of stroke onset, indicates that patients with severe 
angiographic obstruction/ occlusion benefit significantly from intravenous 
thrombolytics (p=0.011) and this result was significantly different to the 
thrombolytic response of patients with patent arteries (p=0.017). Therefore, where 
endovascular therapy is not available,
21
 intravenous thrombolytics remain an 
important treatment option. The significant interaction between angiography 
appearance and intravenous thrombolytics does not mean that patients with normal 
baseline angiography gain no benefit from intravenous thrombolytics;
22
 the meta-
analysis was neutral in this group, showing neither benefit or harm, but the sample is 
too small to exclude modest benefit or harm. It is important to remember that patients 
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with normal angiograms may have arterial obstruction(s) too small to see on 
CTA/MRA, and intravenous thrombolytics may be beneficial in these patients. 
I could not confirm in the meta-analysis that patients with MCA versus ICA 
obstruction responded differently to thrombolytics, but the sample available for this 
comparison was very small. In general, I was unable to identify available comparable 
trial data for most of the other angiography characteristics assessed in IST-3. 
Similarly, it would have been interesting to test further the other non-significant 
trends toward improved outcome after alteplase hinted at by several of the other 
angiography features assessed in IST-3 as discussed above. It is possible that control 
arm data from the recently published endovascular treatment trials,
23-33
 when pooled, 
could elucidate further the associations between baseline angiography and outcome 
after ischaemic stroke but only among patients treated with intravenous 
thrombolytics (since all patients in these trials received intravenous alteplase as the 
standard medical therapy).  To better understand thrombolysis–angiography 
interactions, future RCTs of acute stroke therapy with CTA or MRA should examine 
location, extent, completeness of arterial obstruction, and adequacy of collaterals, to 
refine how these findings could help treatment decisions. 
I used dichotomies of better versus worse angiography scoring to simplify scalar data 
in IST-3. I acknowledge that different dichotomies of the same scalar data could 
provide different results, but I felt that this approach nevertheless provided a 
meaningful and useable summary. For the meta-analysis, slight inconsistencies in 
angiogram scoring between trials mean that there is some overlap between categories 
(e.g. TIMI=2 is included in the better category for EPITHET but the worse category 
for the desmoteplase trials). Efforts to standardize angiogram rating in future trials 





Among patients presenting acutely with stroke, identification of angiographic 
obstruction at baseline helps to correctly classify those with ischaemic aetiology and 
independently predicts poor functional outcome at six months.  
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Intravenous thrombolytic therapy is significantly more effective in improving 
functional outcome in patients with ischaemic stroke who have arterial obstruction 
than in those with apparently patent arteries on CTA or MRA. Intravenous 
thrombolytics, therefore, remain an important treatment option. The data are too 
sparse to determine, in this analysis, whether patients without apparent arterial 
obstruction benefit from intravenous thrombolytics, bearing in mind that these 
patients may have obstruction too small to detect on CTA or MRA. 
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Chapter 10 Summary and Discussion 
 
10.1 Basics of Ischaemic Stroke, Imaging & 
Treatment 
In Chapter 1, I described that stroke is a major global health concern affecting both 
developed and under-developed nations. The majority of strokes are ischaemic and 
occur following a disruption of arterial blood supply to the brain, while a minority 
are secondary to brain haemorrhage. Emboli from the heart or thrombotic obstruction 
at the site of an atheromatous plaque in an artery supplying the brain are the 
commonest underlying causes of ischaemic stroke. Patients with hypertension, atrial 
fibrillation, severe carotid stenosis, hypercholesterolaemia, diabetes or a history of 
smoking are at most risk of stroke. 
The clinical presentation of stroke can be highly variable but a neurological deficit 
with an abrupt onset is commonest. To be differentiated from a transient ischaemic 
attack (TIA), stroke symptoms must last more than 24 hours. Since the clinical 
presentation of ischaemic and haemorrhagic strokes can be identical but treatment 
options for the two stroke subtypes are very different, an early non-contrast CT scan 
of the brain is usually performed (MRI is sometimes infrequently used instead but 
CT has many practical advantages in this context) as an effective means of 
identifying acute haemorrhage (and other structural mimics, e.g. tumour). Treatment 
for ischaemic stroke can begin even in the absence of positive evidence for ischaemia 
(changes indicative of ischaemia in the brain parenchyma, hyperattenuation within an 
artery suggesting acute thrombus or embolus i.e. the hyperattenuation artery sign or 
HAS); in fact the lack of an acute abnormality on CT is common for patients 
presenting to hospital within a few hours of stroke symptom onset.      
If an early non-contrast CT of the brain excludes haemorrhage or another structural 
mimic, then treatment to restore arterial blood flow is considered. Note that it has not 
been common practice to routinely image the major arteries supplying the brain 
before initiating treatment with an intravenous thrombolytic such as alteplase. 
However, with the advent of mechanical thrombectomy (physical removal of the clot 
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via a catheter) as an additive means of restoring arterial blood supply in some 
patients,
1
 routine use of CT angiography (or MR angiography, CTA and MRA, 
respectively) for this purpose will increase. New guidance aimed at delivering 
effective thrombectomy services clearly advocates arterial imaging. Both the 
American Heart Association guidelines for thrombectomy and a very recent 
commissioning statement from NHS England state that the treatment should be 
offered in the presence of a proximal arterial occlusion.
2;3
 Treatment for ischaemic 
stroke needs to be initiated as soon as possible to maximise benefit since there is an 
inverse relationship between time and the volume of potentially salvageable brain 
and therefore the likelihood of a given patient gaining benefit from treatment.      
After ischaemic stroke, approximately one third of patients return to normal or at 
least retain their independence, one third are disabled in the long term and one third 
die. A worse long-term outcome is more likely if: stroke severity is worse at baseline 
(commonly measured using the National Institutes of Health Stroke Scale, NIHSS); 
if a large area of brain is affected (often directly correlated with stroke severity); or if 
patients suffer from symptomatic haemorrhagic transformation of infarct or 
significant brain swelling/ mass effect, or hydrocephalus in the short term (days to 
weeks). The modified Rankin Scale (mRS) provides an ordinal assessment of 
functional outcome after stroke and is commonly used in stroke trials.
4-6
    
 
10.2 The Third International Stroke Trial 
In recruiting 3035 patients, the Third International stroke trial (IST-3) was the largest 
single randomised-controlled trial which tested intravenous alteplase for ischaemic 
stroke.
7
 The trial recruited patients from 156 stroke centres in 12 different countries 
and data collection, including standard imaging for the trial, was reflective of routine 
stroke care at the time.  
The IST-3 dataset provided a unique and unparalleled opportunity to address 
questions relating to whether and how acute brain imaging appearances after stroke 
might affect functional outcome for patients given intravenous alteplase. As a 
randomised-controlled trial which compared patients given alteplase with controls 
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who did not receive alteplase, the IST-3 dataset provides a robust means of 
attempting to answer such questions with the minimum of bias. 
 
10.3 Background for HAS and CTA/MRA Research in 
Stroke 
In Chapter 2, I describe two literature reviews undertaken by me at the outset of this 
MD research project. The first looked at HAS and the second looked at CTA and 
MRA, both of which have been used to image arterial patency in ischaemic stroke. 
These reviews increased my understanding of HAS and CTA/MRA research and 
helped to direct subsequent analyses.  
Systematic review and meta-analysis of HAS 
In this review I summarised HAS prevalence in the published literature. I noted that 
HAS prevalence was affected by the location and size of the obstructed artery (most 
common in large, proximal vessels), was easier to identify on thin-slice CT and was 
naturally a transient phenomenon. I identified reasons for false positivity and 
techniques for improving accurate identification of the sign. 
I also identified research articles where results for HAS sensitivity, specificity, 
positive and negative predictive value were reported. Again these data were 
heterogeneous but in general less than half of all patients were reported to have the 
sign but if present, HAS was highly likely to indicate a genuine ischaemic stroke. 
However these data were limited by the lack of angiographic imaging to confirm 
arterial obstruction in some cases.  
Across several measures of short and long-term outcome after stroke, patients with 
HAS are likely to do poorly. Many of the studies identified in my search showed that 
associations between HAS and outcome occurred independently of other recognised 
prognostic factors such as age, sex and baseline stroke severity. However, these 
results were not always replicated and so it was not possible to be definitive in this 
regard.  
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While there was evidence that patients with HAS gain benefit from intravenous 
alteplase, the limited randomised-controlled trial data could not identify an 
interaction between alteplase treatment and HAS, i.e. patients with and without the 
sign did not respond differently. There was some evidence suggesting that HAS are 
predominantly composed of red blood cells (rather than white blood cells, platelets or 
fibrin). However given that clots with a high red blood cell composition are said to 
be more likely than other types of clot to respond to thrombolytics, this observation 
is in contrast with the limited evidence suggesting that patients with and without 
HAS respond similarly. I concluded that this might relate to the fact that many 
studies (especially older ones) have conflated the presence of HAS with large 
proximal arterial obstructions since HAS is more likely to be identified if it is large 
and proximal. Finally, it was not clear from the assembled evidence whether the 
presence of HAS meaningfully altered the risk of brain haemorrhage after 
intravenous alteplase. 
Review of CT and MR angiography 
In this review I identified that routine use of CTA for the acute assessment of 
ischaemic stroke has been increasing and is likely to continue to do so. This rise in 
CTA use will be compounded by the advent of endovascular thrombectomy as a 
major treatment option for ischaemic stroke.  
I noted that while CTA (and MRA) provide an accurate ‘snap-shot’ representation of 
arterial patency, these techniques do not indicate speed or directionality of arterial 
flow. Unfortunately, many of the scales used for grading CTA and MRA in research 
are therefore not fully appropriate in this context as they were originally developed 
for assessing catheter angiography which is a dynamic test. Greater standardisation is 
required. 
I identified very little data for two aspects worthy of consideration when using CTA 
or MRA for the acute assessment of ischaemic stroke. Firstly, the observer reliability 
for the assessment of angiographic imaging was poorly reported. Secondly, there was 
limited data on exactly how much extra time CTA adds to a conventional non-
contrast CT imaging protocol. 
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While there was evidence that CTA and MRA provide additional information over 
standard brain imaging alone, it was less clear whether this extra information can be 
used usefully for effective diagnosis, whether the information might help front-line 
clinicians make treatment decisions more effectively and ultimately be used to help 
provide more accurate prognostic information to patients and their families.     
Major observations from HAS and CTA/MRA reviews 
The follow points were identified as being inadequately addressed by the literature at 
the time of my HAS and CTA/MRA reviews: 
 The prevalence of HAS was likely to be higher than previously reported 
when thin-slice contiguous CT scans were routinely used for assessment 
 Data addressing the sensitivity and specificity of HAS as a surrogate of 
arterial obstruction in ischaemic stroke were heterogeneous and derived using 
different gold standards 
 The effect of HAS on stroke severity, response to intravenous alteplase and 
functional outcome after stroke was unclear 
 It was not clear how accurately CTA and/or MRA can be scored in an acute 
setting if and when these techniques are implemented as routine practice for 
the assessment of ischaemic stroke   
 How much extra time is needed to include CTA to a standard non-contrast 
CT protocol for imaging ischaemic stroke was under reported 
 It was not clear whether the extra information provided by angiography 
improves the diagnosis of ischaemic stroke or ability to provide prognostic 
information during the early hours after stroke onset 
 Clarity was needed whether specific features of angiography such as the 
presence or absence of obstruction, the location and extent of obstruction, or 
the adequacy of collateral supply alters the response to intravenous alteplase 
and therefore functional outcome after stroke. 
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10.4 Summary of Main Results Mapped to Thesis 
Aims 
This summary includes an up to date context for my results where substantial new 
data were available (to December 2016) and where possible explores the potential 
impact of my work.  
Thesis aims are provided as subheadings. 
Quantify the prevalence and observer reliability of HAS on CT 
performed for the initial imaging assessment of patients with suspected 
ischaemic stroke 
In my systematic review of prior HAS research (Chapter 2) I identified 54 relevant 
research articles dated between 1989 and 2012 and from over 20,000 non-contrast 
CT brain scans performed acutely for the assessment of ischaemic stroke, HAS was 
identified 21% of the time although the data were heterogeneous.  
In IST-3, HAS was present in 24% of all non-contrast CT brain imaging performed 
at baseline (Chapter 5). As anticipated this result is slightly higher than the 21% from 
my systematic review since IST-3 data were more recently collected (recruitment ran 
from the year 2000 to 2011). However, a large proportion of IST-3 imaging was still 
not based on thin-slice CT acquisition, particularly among patients recruited earlier 
in the trial. Unfortunately, it was not possible to perform an analysis of only the thin-
slice CT data from IST-3 since studies were never classified in this way. I have not 
identified any recently published results looking specifically at thin-slice CT in a 
large cohort or as an analysis of multiple datasets. 
In Chapter 8, I used data from the IST-3 expert panel’s assessment of imaging to 
derive observer reliability results for the identification of HAS. Somewhat 
surprisingly, inter-observer agreement was only fair (K-alpha = 0.37) while intra-
observer agreement was near perfect (K-alpha = 0.83). I think these results tell us 
that even among experts, the definition of what constitutes a true HAS varies but that 
for an individual reader, the sign (however defined) is readily and consistently 
identified. Greater consistency among readers is therefore required.  
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On the basis of HAS research performed for this MD, I was invited to contribute to 
an international collaborative discussing stroke imaging research priorities with the 
aim of developing a 5 year research plan. The STIR (Stroke Imaging Research) 
group’s Acute Stroke Imaging Research Roadmap II was published in 2013; in this 
context I conveyed the importance of using thin-slice CT for accurately detecting 
HAS.
8
   
Determine how intravenous alteplase affects HAS and whether the 
presence or absence of HAS influences the response to intravenous 
alteplase and outcome and whether the characteristics of HAS such as 
attenuation, location and extent are important 
In Chapter 5, I calculated that the presence of HAS on baseline non-contrast CT was 
strongly associated with increased stroke severity at baseline and worse 6-month 
outcome in IST-3. This association with outcome occurred independent of age, 
baseline stroke severity, time from stroke onset to scan, and treatment allocation (i.e. 
patients with HAS did worse in both the alteplase and control groups). I also found 
that outcome was even worse if HAS was more extensive (true on adjusted 
multivariable analyses) or if HAS was proximally located (true only on univariate 
analyses). In Chapter 6, I investigated the importance of assessing the baseline 
attenuation of arterial obstructions in ischaemic stroke. This included direct measures 
of attenuation (actual Hounsfield Units, HU or as a derived ratio compared with a 
coincidentally normal artery) and in a dichotomy of hyperattenuating versus iso-
attenuating obstructions. Neither method of assessing the attenuation of arterial 
obstructions was independently predictive of functional outcome at 6 months. 
Treatment with alteplase in IST-3 was associated with shrinkage and/or 
disappearance of HAS (and similarly, a non-significant greater reduction in 
attenuation of the obstruction in the alteplase versus control groups). This association 
between alteplase and HAS removal was independent of age, baseline stroke 
severity, and time between baseline and follow-up scans. In addition, I demonstrated 
that alteplase was associated with HAS removal both for those with large and 
proximal HAS and for those with small and distal HAS. Nevertheless, complete 
clearance of small and distal HAS was more common, as others have also now 
demonstrated.
9
 Associations between alteplase and short term changes in HAS are 
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important as I also showed that functional outcome is improved when HAS shrinks 
or disappears. My analyses also offer an important counter argument to a widely held 
view that alteplase is ineffective against more extensive HAS; a previous report by 




I tested for a variety of HAS-alteplase treatment interactions using different 
subgroups; namely, presence versus absence of HAS, proximal versus distally sited 
HAS, more versus less extensive HAS and finally the measured attenuation of 
arterial obstructions in the treatment versus control groups. I did not demonstrate a 
differential response to alteplase in any of these comparisons, i.e. for each HAS 
characteristic, both subgroups responded similarly to treatment with alteplase. In 
other words, there was no treatment interaction between alteplase and HAS. This 
indicates that on the basis of one of the largest randomised-controlled datasets, HAS 
should not be used to select patients with ischaemic stroke for treatment with 
intravenous alteplase.  
My work should therefore provide confidence that while complete removal of more 
extensive HAS is less likely, such patients can still benefit from treatment with 
alteplase.  
Calculate the sensitivity and specificity of HAS for arterial obstruction 
In a first-of-its-kind meta-analysis incorporating data from 17 research articles 
including IST-3 and incorporating data from 1175 patients, I calculated that HAS is 
95% specific and 52% sensitive for true arterial obstruction (as demonstrated using 
angiography) during the acute phase of ischaemic stroke (Chapter 7). HAS was more 
commonly identified if proximally sited and there was a trend for greater 
identification of HAS if it was more versus less extensive. Sensitivity was improved 
if thin-slice CT was used.  
My meta-analysis was highlighted by the EvidenceUpdates service provided by the 
BMJ Group and McMaster University (https://plus.mcmaster.ca/EvidenceUpdates) 
and scored as 6/7 for Relevance to Practice and 6/7 for Is this News? An extract from 
the site is included as Appendix 15 (Chapter 11.6). 
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Using IST-3 data alone, I showed that while use of thin-slice CT improved 
sensitivity and there was a non-significant trend for improved specificity of HAS,  
other features of the obstruction (its location or extent) or of the patient (time from 
stroke onset to scan or patient age) did not significantly alter sensitivity or specificity 
results.  
A recent analysis of over 11,000 patients with baseline angiography from the SITS 
(Safe Implementation of Treatments in Stroke) International Stroke Thrombolysis 
Register (http://www.sitsinternational.org/), investigated whether thresholds of 
NIHSS could be used to predict arterial occlusion at baseline. They found that 
NIHSS = 11 optimally predicted arterial occlusion.
11
 This aligns well with my 
assessment of IST-3 imaging where there were no false positive HAS and far fewer 
true negative HAS with NIHSS greater than 11-15 (Figure 7-1).    
Most arterial segments with HAS in IST-3 (90%) were not completely occluded on 
angiography, rather they were obstructed; i.e. contrast (and thrombolytic agent) could 
bypass the obstruction to reach more distally occluded vessels and there was 
therefore an increased surface area of clot for thrombolytic action. This is counter to 
conventional thinking that the presence of HAS indicates occlusion and might help to 
explain the observation discussed above that alteplase does appear to work for these 
patients even when HAS is extensive. Some very recent analyses using data from the 
MR CLEAN (Multicenter Randomized CLinical trial of Endovascular treatment of 
Acute ischemic stroke in the Netherlands) thrombectomy trial
12
 and from the Dutch 
Acute Stroke Study (DUST)
13
 would seem to support my observations from IST-3. 
These secondary analyses of MR CLEAN and DUST tested whether correlative non-
contrast CT and CTA can be used to assess the perviousness of obstructions (that is 
the extent to which they can be penetrated by fluid) by measuring the change in the 
attenuation of obstructions before and after the administration of intravenous 
contrast; obstructions which show an increase in attenuation on the latter scan, are 
presumed to be more permeable to contrast.
14;15
 Their results showed that 
perviousness is strongly associated with higher recanalisation rate, smaller infarct 
volume at follow-up and better outcome. Data from MR CLEAN showed that these 
results were independent of treatment allocation; in other words, improved outcome 
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was demonstrated similarly in both the intravenous alteplase and thrombectomy 
groups.
14
 Finally, DUST data showed that the effect of perviousness on outcome 
occurred independent of recanalisation status; i.e. also demonstrating that even a 
partial reduction in the extent of obstruction is beneficial.
15
 
Quantify observer reliability for the assessment of CTA performed 
routinely as part of the initial CT imaging assessment of patients 
presenting with ischaemic stroke 
In my analysis of observer reliability for the assessment of CTA (Chapter 8), I found 
moderate to substantial agreement between expert readers for all CTA measures 
except identification of parenchymal hypoperfusion on CTA source images. 
Agreement was less between non-expert readers but those with extra relevant 
training (i.e. neuroradiology trainees) were more comparable with the expert group. 
Reassuringly, imaging features that are likely to have the most clinical impact were 
reported with the most reliability (for example, the presence and extent of arterial 
obstruction). 
My own personal inter- (me versus a variable member of the expert panel) and intra-
observer reliability scores were consistent with those of the expert panel. In addition, 
my results seemed to be platform independent. This provides confidence that other 
work in this thesis derived from those results (Chapters 6, 7 and 9) is meaningful. 
There remains very little published data assessing the reader reliability of non-
invasive angiography performed for the assessment of stroke with which to compare 
my results. One recent analysis demonstrated that the inter-observer agreement for 
detection of occlusion increased when multiphase CTA (synonymous with time-
resolved or 4-D CTA; imaging is performed intermittently during the entire phase of 
the contrast bolus as it flows in and out of brain, it is therefore more like catheter 
angiography) was compared with standard CTA.
16
  
Determine if the addition of CTA to standard plain CT improves 
ischaemic stroke detection, and prognosis prediction, by CT when 
performed as part of the initial imaging assessment and determine how 
much extra time is needed to perform CTA in this context 
In order to predict the presence of infarct on 24-48 hour follow-up imaging among 
IST-3 stroke patients (Chapter 9), I determined that combining results of non-
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contrast CT and CTA at baseline provided the best means of improving the 
sensitivity (if either non-contrast CT or CTA were abnormal) and specificity (if both 
non-contrast CT and CTA were abnormal) over non-contrast CT alone. However, I 
did not find a corresponding improvement in the prediction of stroke severity or 
outcome for these patients.  
In a recent very similar analysis testing whether CTA or CT perfusion improve the 
prediction of infarct presence and infarct volume on follow-up imaging, van Seeters 
et. al. found that the addition of baseline CTA to non-contrast CT was superior for 
predicting both the presence and the volume of infarct over non-contrast CT alone.
17
 
Their study also plans to model outcome prediction for non-contrast CT alone versus 
non-contrast CT plus CTA but the results are not yet published.
13
  
In IST-3, performing CTA in addition to non-contrast CT took an extra six minutes 
which corresponds well with the extra ten minutes from stroke onset to 
randomisation identified among the angiography subgroup compared with the full 
trial. Although this may not seem a significant delay, time is brain and every minute 
counts.
18;19
 It was clear from IST-3 data that some centres were able to minimise the 
delay attributable to CTA acquisition to around 1 minute. Such rapidity implies these 
centres are offering an efficient service that is fully protocol driven; one minute 
between scans does not allow for any deliberation over the need for CTA while a 
patient is still on the CT table. Notwithstanding, it is probably inappropriate to 
perform CTA on every patient suspected of having an ischaemic stroke. The ideal 
approach then must be to develop clear and robust (evidenced based) imaging 
protocols that allow the correct scanning to be performed in the correct patients 
without unnecessary delay.  
Determine whether the presence or absence of arterial obstruction on 
angiography performed acutely after ischaemic stroke influences the 
response to intravenous alteplase and outcome and whether 
characteristics of obstruction such as location, completeness and 
extent are important     
In my analyses of the IST-3 angiography expert panel data (Chapter 9), both the 
extent of arterial obstruction and a poor collateral supply at baseline were 
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independently associated with poor functional outcome at 6 months. This association 
with collateral supply has since been replicated elsewhere.
20;21
  
There were trends in the IST-3 angiography data for different treatment responses 
across subgroups with and without a variety of angiographic abnormalities, but none 
of these differences were significant, i.e. there was no treatment interaction with 
angiography in IST-3. However, when I combined IST-3 data with data from four 
other randomised-controlled trials in a meta-analysis, I found that patients with 
severe angiographic obstruction or occlusion responded differently to intravenous 
thrombolytics compared to those with minimally obstructed or normal arteries. The 
former group with severe arterial obstruction showed benefit with improved outcome 
after treatment (versus control) while the latter group with normal arterial patency 
showed neither treatment benefit nor harm. Therefore while the difference in 
response between these two groups was significant, their responses to treatment are 
not necessarily conflicted; it may simply be that one group achieved a greater benefit 
than the other, i.e. there is no evidence from my analyses that patients with patent 
arteries do not benefit from alteplase (a common assumption). Indeed in my earlier 
analyses, patients without HAS demonstrated conclusive benefit from alteplase 
(Figure 5-4). However as discussed above, perhaps 50% of these patients would still 
have an arterial obstruction on angiography. But similarly, a ‘normal’ angiogram 
cannot exclude obstruction of arteries with a calibre below the spatial resolution of 
the scanner on which it was obtained (0.6 mm is a current standard minimum 
resolution for CT). I therefore have to assume there is an acute arterial obstruction at 
some level in every ischaemic stroke patient; hence there is always the potential for 
benefit from intravenous alteplase even in the presence of a ‘normal’ angiogram. 
Arguably if this is the case, such patients with ‘small and distal’ obstructions may 
actually have the most to gain from alteplase. It is also worth noting that the 
significant result from my HAS analyses in Figure 5-4 is powered by a much larger 
number of patients (2245 versus 154 with a normal angiogram).  
I could not confirm in the meta-analysis that patients with proximal versus distal 
arterial obstruction responded differently to intravenous thrombolytics. 
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On the basis of these results, which as a meta-analysis of randomised-controlled trial 
data represent the best currently available evidence, I conclude that angiography is 
not necessary to select patients for intravenous thrombolytic therapy.    
10.5 Strengths and Limitations of My Work 
IST-3 used robust and validated methods for scoring imaging data which I replicated 
in my own analyses of IST-3 imaging. All image analysis was performed blind to 
other imaging (except if the other imaging was required; for example when 
measuring the attenuation of arterial obstructions on non-contrast CT using CTA as a 
guide to target attenuation measurements), to all other clinical information and to 
treatment allocation. 
I adopted best practice statistical analysis techniques where possible, particularly by 
using multivariable ordinal regression analyses to assess for associations with six-
month functional outcome and other ordinal scalar data, and to look for imaging 
interactions with alteplase. Similarly I used a relatively unknown but significantly 
more appropriate method (than Kappa) for assessing observer reliability when there 
are more than two observers and data types are mixed.  
I have secured peer reviewed publication as first author for six discrete articles 
(published between July 2014 and December 2016) 
22-27
 and three scientific abstracts 
(two were presented at the European Stroke Conference in London, May 2013; one 
was presented at the International Stroke Conference in San Diego, Jan 2014) 
28-30
 
which form the backbone of this thesis. Some of my results were also presented at 
the American Society of Neuroradiology meeting in San Diego, May 2013 and at the 
British Society of Neuroradiology meeting in Oxford, September 2013. In addition, I 
am a co-author on two further peer reviewed publications directly as a consequence 
of this work.
8;31
 I have thereby demonstrated that my work is clinically relevant and 
scientifically robust.  
Several of my analyses were probably underpowered, evidenced by wide confidence 
intervals. The full IST-3 trial was powered to detect outcome differences in the 
groups given alteplase versus control. Therefore any subgroup analyses using 
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reduced numbers of patients are likely to be underpowered to demonstrate 
differences in the alteplase treatment effect.  
For some of my analyses (particularly, measuring the attenuation of arterial 
obstruction) thin-slice CT acquisition for all patients would have been ideal but it 
was available in only a minority.   
A recent analysis concluded that manual measurements of attenuation in arterial 
obstruction in patients with ischaemic stroke probably oversimplify the true 
heterogeneity of attenuation within these obstructions by sampling in only a few 
discrete locations.
32
 That analysis was based on a comparison with an automated 
method of assessing the attenuation of obstructions in their entirety. However the 
same authors separately concluded, in an analysis of observer variability for 
measuring the attenuation of obstructions that the greatest observer agreement was 
obtained by taking three manual region-of-interest measurements (the approach I 
adopted) rather than only one.
33
 
A recent analysis by Seker et. al. concluded that the collateral score developed by 
Miteff et. al.
34
 (as used in IST-3) correlated less well with the extent of infarct core 
and penumbral volume on perfusion imaging than other scores.
35
 Nevertheless, inter-
observer reliability for Miteff collateral scoring was moderate in IST-3 and I was 
able to demonstrate a robust association between Miteff collateral scoring and 
outcome for patients with arterial obstruction on angiography. 
Other limitations of IST-3 have been previously discussed but include:
7
 the open 
design of the trial (treating physicians and patients were aware of their allocation to 
treatment or control) could have led to bias; in order to achieve the best rate of 
enrolment, IST-3 did not unduly restrict scanning protocols and allowed centres to 
use MRI rather than CT for example (although this was uncommon), and to include 
advanced imaging with angiography or perfusion if that was routine local protocol. 
While this approach led to variability in the imaging dataset, this is offset by the fact 
that the imaging represented ‘real-world’ practice and any results are therefore more 
widely applicable.  
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10.6 Residual Unanswered Questions or Where More 
Work is Needed 
In my analyses investigating treatment interaction between alteplase and imaging 
features of arterial obstruction, many of the subgroups were underpowered. IST-3 
data have nevertheless allowed me to provide robust recommendations that imaging 
evidence of arterial obstruction should not be used to influence alteplase treatment 
decisions. Further randomised-controlled trial data would be required to more 
adequately power these analyses, but those data are currently not available. Future 
randomised-controlled trials of intravenous thrombolytics should also include 
validated scoring for imaging characteristics of arterial obstruction. I plan to update 
my angiography meta-analysis (and perhaps derive a similar meta-analysis for HAS) 
in future if this becomes possible. See Table 10-1 for the future research implications 
of my work. 
 
Table 10-1 Implications for future research 
Although I have been able to draw conclusions from some underpowered analyses, it is 
possible that with larger RCT datasets, the end results would be different.  
Future RCTs of ischaemic stroke should robustly assess brain and vascular imaging using 
validated assessment methods similar to those in IST-3 which will allow more powerful 
meta-analyses to be subsequently performed. 
All of the imaging features I have investigated in this thesis may also be important for 
selecting patients most suitable for thrombectomy.  
Future thrombectomy trials should aim to standardise the collection and assessment of brain 
and vascular imaging. In particular, those undertaking thrombectomy trials should agree 
upon the most appropriate CTA/MRA grading system to avoid the same heterogeneity I 
encountered when meta-analysing CT and MR angiography among patients treated with 
intravenous thrombolytics (Chapter 9.3). 
There is continued interest in the use of automated systems for image analysis.  
IST-3 data, including some of my own image assessments, are already being used to test the 
performance of such systems against the ‘expert human rater’ gold standard. Carefully 
collected and rigorously human-reader assessed datasets such as IST-3 are likely to continue 
to provide ‘ground truth’ for future developments in computational image analysis.  
Footnote: RCT = randomised controlled trial. 
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There were insufficient numbers of patients in IST-3 with haemorrhagic 
transformation of infarct after alteplase to perform analyses exploring associations 
between HAS or angiographic obstruction and haemorrhagic transformation. Recent 
work has shown that the presence of HAS can independently predict haemorrhagic 
transformation
36
 but not necessarily symptomatic haemorrhage;
37;38
 and the latter is 
arguably more important. 
IST-3 had only limited data with which to assess whether an arterial obstruction or 
HAS was more likely embolic or thrombotic, for example embolic obstructions are 
probably more common in the presence of atrial fibrillation.  Recently in a large 
retrospective analysis of patients treated with alteplase, those with HAS due to large 
artery atherosclerosis were associated with lower rates of HAS disappearance 
compared with HAS secondary to cardio-embolic stroke.
39
 There were insufficient 
data in IST-3 for a robust analysis of ischaemic stroke aetiology and any potential 
associations with brain imaging appearances. However in Chapter 6 I found no 
difference in the CT attenuation of arterial obstruction among patients with and 
without atrial fibrillation, one of the primary causes of cardio-embolic stroke. 
Another recent analysis has suggested that use of antiplatelets may increase the 
likelihood of an arterial obstruction being hyperattenuating;
40
 this is something I 
could have tested using IST-3 data. 
Certain assumptions have been made about the composition of arterial clots in 
ischaemic stroke based on minimal pathological data and evidence from ex-vivo 
phantom studies using blood products.
41-45
 But a recent systematic review did 
conclude that HAS are more likely to be rich in red blood cells.
46
 In this new stroke 
treatment era of thrombectomy, it should be possible to get better information on the 
true pathological composition of a large number of clots, I suspect this might become 
more common in the near future as neuro-interventionalists strive for a better 
understanding of whether the imaging characteristics of arterial obstruction should 
alter their decision to offer treatment. Whether it is feasible to consistently collect 
arterial clots after thrombectomy and then to provide an accurate histological 
analysis of those clots remains uncertain. The findings I describe here between HAS, 
composition of obstruction, response to treatment with intravenous alteplase and 
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outcome might also be applicable to patients being considered for mechanical 
thrombectomy, but this has so far been largely untested.
47-49
 Unfortunately, due to the 
standard design of the major thrombectomy trials, it will not be possible to address 
similar issues for patients with angiographic obstruction using these trial data since 
patients without proximal obstruction were not enrolled in the major trials. 
10.7 Conclusions 
When identified on non-contrast CT performed soon after stroke onset, the presence 
of a hyperattenuated artery is a powerful surrogate indicator for arterial obstruction. 
However, when HAS is absent approximately 50% of patients may still have an 
unrecognised arterial obstruction.  
Angiography does provide more confirmatory evidence of an ischaemic stroke 
diagnosis (by identifying the other 50% with an arterial obstruction but no HAS) but 
does not alter prognosis prediction. That is, it does not improve our ability to identify 
those patients most likely to do well or poorly following treatment; severely affected 
individuals are rarely those that require a CTA for confirmation of stroke. 
My data provide confidence that CTA can be interpreted consistently by a range of 
individuals who differ in their experience level and that the reader reliability for CTA 
is similar to that for non-contrast CT. Delays inherent in the process of adding CTA 
to standard imaging can and should be minimised through the development of robust 
imaging protocols, these in turn should be derived from clear evidence that the 
addition of CTA is beneficial to any given patient.  
I showed that arterial obstruction on baseline angiography (or its imaging surrogate 
on non-contrast CT – HAS – described in a much larger, more powerful dataset) is 
associated with more severe stroke at baseline and worse functional outcome at six-
months independent of other known outcome predictors. I also showed that alteplase 
works to remove HAS regardless of its location or extent (but small distal HAS are 
more likely to be removed completely following treatment) and that HAS 
disappearance is associated with a better outcome. Unfortunately, IST-3 did not 
contain sufficient follow-up angiograms to check for the alteplase effect on 
Imaging Arterial Patency and Thrombolysis in Ischaemic Stroke 
10 - Discussion 240 
angiographic recanalisation, however it is plausible and likely that HAS clearance is 
a surrogate for recanalisation.  
Despite these associations with stroke severity and outcome, I did not identify any 
interactions between imaging appearances of arterial obstruction at baseline (either 
HAS on non-contrast CT or obstruction on CT/MR angiography) and response to 
intravenous alteplase in IST-3. It was only after combining IST-3 results in meta-
analysis that I identified a significant treatment interaction (with severity of arterial 
stenosis). While it is reassuring to discover that patients with severe arterial 
obstruction do benefit from intravenous thrombolytics, the lack of a significant 
outcome (i.e. neither benefit nor harm) in the subgroup with patent arteries means 
that even these results are non-contributory for alteplase treatment decision making. 
In other words, these data suggest that angiography results should not be used to 
decide whether patients do or do not receive intravenous alteplase. See Table 10-2 
for a summary of my major findings and the clinical practice implications of my 
work. 
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Table 10-2 Summary of main findings and their implications for clinical practice  
Summary of main findings Implications for clinical practice 
 HAS is a highly specific surrogate for arterial 
obstruction on non-contrast CT, present in 
around 25% of all patients presenting acutely 
with ischaemic stroke 
 The presence of HAS indicates that the patient 
is likely to be suffering a severe stroke and is 
likely to have poor functional outcome 
If clinicians are mindful of these findings 
they can more effectively diagnose, 
correctly triage and provide evidenced-
based prognosis to patients with  
ischaemic stroke 
 The use of CTA for the acute assessment of 
ischaemic stroke is rising (and is likely to 
continue rising now that thrombectomy has 
been proven effective in the presence of a 
proximal arterial obstruction)  
 CTA can be added to a standard stroke 
imaging protocol with around 6 minutes of 
extra time in the scanner 
 The addition of CTA at baseline makes it 
more likely that ischaemic stroke is correctly 
diagnosed 
 Angiographic abnormalities are associated 
with severe strokes and poor functional 
outcomes 
 CTA can be assessed consistently by a range 
of users if they are adequately trained  
Increased use of CTA will improve the 
recognition of ischaemic stroke 
My results provide confidence that CTA 
can be used efficiently and effectively 
 The majority of arterial obstructions causing 
ischaemic stroke are not fully occluded, which 
might explain how intravenous alteplase is 
able to reduce and remove even large and 
proximally sited arterial obstructions 
 Shrinkage or removal of arterial obstructions 
improves functional outcome 
 Using the best currently available evidence 
(meta-analysis of RCT data), there is no proof 
that the presence versus absence of arterial 
obstruction (or specific characteristics of the 
obstruction) materially alters the beneficial 
effect of intravenous alteplase   
 Therefore, neither the presence/absence of 
arterial obstruction on CTA nor the 
presence/absence of a HAS should be used to 
select patients for treatment with intravenous 
alteplase 
My results should provide stroke 
physicians with confidence to use 
intravenous alteplase even for patients 
with obstruction of large proximal 
arteries 
This might prove to be most relevant 
when thrombectomy is unavailable or 
contra-indicated 
Footnote: RCT = randomised controlled trial. 
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While associations between imaging findings of arterial obstruction (however 
assessed), stroke severity, outcome and interaction with alteplase may seem 
contradictory, they can be explained by consideration of the statistical tests used in 
these analyses. Ordinal regression analyses of alteplase treatment effect on outcome 
look for step-wise shifts along the outcome scales compared between treatment and 
control groups. In this way, a patient who moves one point down the severity scale is 
considered improved no matter where on the scale this movement occurred; i.e. in 
these analyses a change from death to severe disability (mRS 6 to 5) is considered an 
improvement no different to a change from dependent to independent living (mRS 3 
to 2). However, clinically and socio-economically we must acknowledge that these 
alternative ‘improved’ outcomes are not similar. Therefore, the correct interpretation 
of these results is that while alteplase offers benefit equally to different imaging 
subgroup patients (e.g. those with and without proximal arterial obstruction), those 
that have a severe stroke at outset remain likely to have a poor outcome, only this 
outcome is less poor following treatment.   
Therefore my analyses provide evidence from a large randomised-controlled trial, 
counter to some popular opinion, that alteplase is effective across all of these 
different subgroups of ischaemic stroke patients and therefore should not be denied 
(or delayed) on the basis of imaging. Where a thrombectomy service is available, 
alteplase is the first step in this treatment pathway. Where thrombectomy is 
unavailable or contra-indicated, alteplase remains an effective means of improving 
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Chapter 11 Appendices 
 
11.1 Appendix 1 - IST-3 Collaborative Group 
For a complete list of all committees, please see the IST-3 primary publication in The 
Lancet (The benefits and harms of intravenous thrombolysis with recombinant tissue 
plasminogen activator within 6 h of acute ischaemic stroke (the third international 
stroke trial [IST-3]): a randomized controlled trial. Lancet 2012;379:2352-63). 
IST-3 was conceived by the co-chief investigators, Peter Sandercock (University of 
Edinburgh, Scotland), Richard I Lindley (Sydney Medical School – Westmead 
Hospital and The George Institute for Global Health, University of Sydney, 
Australia), and Joanna M Wardlaw (University of Edinburgh, Scotland). 
 
11.1.1 CT and MRI reading panel 
Joanna M Wardlaw, Andrew Farrall (University of Edinburgh, Scotland), Zoe Morris 
(University of Edinburgh, Scotland), Rüdiger von Kummer (Dresden University 
Stroke Centre, Germany), Lesley Cala (University of Western Australia, Crawley, 
Australia), Anders von Heijne (Dandyred Hospital, Stockholm, Sweden ), 
Alessandro Adami (Sacro Cuore-Don Calabria Hospital, Verona, Italy), Andre 
Peeters (Cliniques Universitaires Saint-Luc, Bruxelles, Belgium), Gillian Potter 
(Salford Royal NHS Foundation Trust, England), Nick Bradey (Neuroradiology, 
James Cook University Hospital, South Tees Hospital NHS Trust, Middlesborough, 
UK). 
 
11.1.2 Angiography reading panel 
Joanna M Wardlaw, Rüdiger von Kummer, Andrew Farrall, Robin Sellar (University 
of Edinburgh, Scotland), Alessandro Adami, Philip White (Newcastle University, 
UK), Andrew Demchuk (University of Calgary, Canada), Matthew Adams (Great 
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Ormond Street Hospital, London, UK), Grant Mair (University of Edinburgh, 
Scotland), Bernard Yan (The Royal Melbourne Hospital, Parkville, Australia). 
 
11.1.3 Trial steering committee 
Independent chairmen: Colin Baigent (University of Oxford, UK); David Chadwick 
(University of Liverpool, UK). Independent member: Pippa Tyrrell (University of 
Manchester, UK); Gordon Lowe (University of Glasgow, UK). Co-principal 
investigators: PS; RIL.  Chief investigator for Neuroradiology: JMW; Martin Dennis 
(University of Edinburgh, Scotland).  Statistician: Geoff Cohen (University of 
Edinburgh, Scotland). Trial Co-ordinator: Karen Innes (University of Edinburgh, 
Scotland).  Lay representative: Heather Goodare. 
 
11.1.4 National coordinators and associate national 
coordinators 
Australia: RIL, Graeme J Hankey (Royal Perth Hospital, Perth). Austria: Karl Matz 
(Landesklinikum Donauregion Tulln, Tulln), Michael Brainin. Belgium: AP. 
Canada: Gord Gubitz (Dalhousie University and Queen Elizabeth II Health Sciences 
Centre, Halifax), Stephen J Phillips (Dalhousie University and Queen Elizabeth II 
Health Sciences Centre, Halifax). Italy: Stefano Ricci (Department of Neurology 
ASL1, Ospedale, Citta’ di Castello). Mexico: Antonio Arauz (Instituto Nacional de 
Neurologia, Mexico City). Norway: Eivind Berge (Oslo University Hospital, Oslo), 
Karsten Bruins Slot (Oslo University Hospital, Oslo). Poland: Anna Czlonkowska 
(Institute of Psychiatry and Neurology, Warsaw, and Medical University of Warsaw, 
Warsaw), Adam Kobayashi (Institute of Psychiatry and Neurology, Warsaw, 
Poland). Portugal: Manuel Correia (Hospital Geral de Santo Antonio, Porto). 
Switzerland: Phillippe Lyrer (University Hospital Basel, Basel), Stefan Engelter. 
Sweden: Veronica Murray (Karolinska Institutet, Stockholm), Andreas Terent, Bo 
Norrving, Per Wester: UK: Graham Venables (Sheffield Teaching Hospitals NHS 
Foundation Trust, Sheffield, UK). 
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11.1.5 IST-3 collaborative group and participating 
hospitals in each country  
Figures in parentheses are the number of patients recruited in the country or by the 
centre.  
UK (1447) Royal Hallamshire Hospital (118): G Venables, C Blank, H Bowler, C 
Doyle, K Endean, K Harkness, E Parker, M Randall. University Hospital of North 
Staffordshire (97): C Roffe, N Ahmad, A Arora, S Brammer, J Chembala, B Davies, 
S Ellis, E Epstein, K Finney, C Jackson, C Jadun, R Kinston, H Maguire, I Memon, I 
Natarajan, M Poulson, R Sanyal, S Sills, A Vreeburg, E Ward. Western General 
Hospital (95): P Sandercock, R Al-Shahi Salman, R Davenport, M Dennis, P Hand, S 
Hart, I Kane, S Keir, M MacLeod, L McKinlay, H Milligan, E Sandeman, J Stone, C 
Sudlow, P Taylor, J Wardlaw, C Warlow, W Whiteley, A Williams. The National 
Hospital for Neurology & Neurosurgery (84): M Brown, B Athwal, V Bassan, N 
Bhupathiraju, J Bowler, C Davie, D Doig, R Erande, S Gilbert, L Ginsberg, R 
Greenwood, S Gregoire, N Harding, N Losseff, R Luder, N Passeron, R Perry, P 
Rayson, R Simister, S Stone, D Werring. Arrowe Park Hospital (83): J Barrett, H 
Aitken, S Cherian, R Davis, S Downham, L Godd, V Gott, D Jose, V Little, D Lowe, 
L Luxford, M McGrory, P Owings, N Price, J Richards, G Sangster, J Sherlock, S 
Vargese, I Wakefield, P Weir. Southend University Hospital (77): P Guyler, T 
Attygale, S Chandler, L Coward, S Feasey, C Khuoge, T Loganathan, S Martin, A 
O'Brien, D Sinha, V Thompson, S Tysoe, R Walsh. Norfolk and Norwich University 
Hospital (67): K Metcalf, J Cochius, R Fulcher, N Gange, C Green, J Jagger, M Lee, 
P Myint, J Potter, G Ravenhill, S Shields, N Shinh, T Staunton, E Thomas, W 
Woodward, P Worth, N Wyatt. Nottingham City Hospital (63): W Sunman, P Bath, 
P Berman, J Clarke, C Gaynor, F Hammonds, R Harwood, K Mitchell, S Munshi, S 
Pacey, A Shetty, N Sprigg, H Stear, G Subramanian, A Wills. Guy's & St.Thomas 
Hospital (60): A Rudd, H Audebert, A Bhalla, J Birns, R Chowdhury, G Cluckie, I 
Davies, C Gibbs, P Holmes, N Mitchell, F Schiavone, E White, M Yeung. 
Darlington and Bishop Auckland Hospitals (56): A Mehrzad, V Baliga, E Brown, L 
Burnside, B Esisi, J Kent, P Orr, D Stead, E Wayman. University Hospital Aintree 
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(46): R Durairaj, C Cullen, R Kumar, H Martin, D McDowell, A Sharma, V Sutton, 
R White. University Hospital of Wales (46): T Hughes, K Ali, J Anderson, K Baker, 
K Bethune, K Bethune, M Booth, M Cossburn, S Halpin, M Hourihan, E Marsh, K 
Peall, R Powell, H Shetty, M Wardle, M Williams. Derby Royal Hospital (37): K 
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11.1.6 Centres in IST-3 that performed angiography 
 
Australia 
Austin Health - Repatriation Campus: Prof Helen Dewey.  
Box Hill Hospital (Monash University): Prof Chris Bladin 
Gosford Hospital: Dr Jonathan Sturm 
John Hunter Hospital: Dr Chris Levi  
Nambour General Hospital: Dr Rohan Grimley 
Royal Brisbane and Women's Hospital: Dr Stephen Read  
Royal Perth Hospital: Dr Graeme J. Hankey 
Austria 
Landesklinikum Donauregion Tulln:  Dr Karl Matz 
Belgium 
Cliniques Universitaires St. Luc: Dr Andre Peeters 
Canada 
QEII Health Sciences Centre: Dr Gord Gubitz 
Italy 
Nuovo Ospedale Civile: Dr Federica Casoni 
Ospedale Citta di Castello: Dr Silvia Cenciarelli 
Ospedale di Branca (Ospedale di Gubbio): Dr Tatiana Mazzoli 
Ospedale di Cattinara – Trieste: Dr Fabio Chiodo Grandi 
Ospedale Maggiore: Dr Gaetano Procaccianti 
Ospedale Valduce di Como: Dr Nicoletta Checcarelli 
Universita degli Studi di Genova, Dipartimento di Neuroscienze Oftalmologia  e 
Genetica: Prof Carlo Gandolfo 
Norway 
Aalesund Sjukehus: Dr Yngve Müller Seljeseth  
Harstad Sykehus: Dr Odd Kildahl-Andersen 
St Olavs Hospital, University Hospital of Trondheim: Dr Bent Indredavik 
Ullevål University Hospital: Dr Eivind Berge 
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University Hospital Northern Norway: Dr Stein Harald Johnsen 
Poland 
2nd Department of Neurology: Prof Anna Czlonkowska 
Institute of Psychiatry & Neurology, Medical University of Gdansk: Prof Walenty 
Michal Nyka, Dr Dariusz Gasecki 
Military Medical Institute SPZZOZ w Sandomierzu: Prof A Stepien, Dr Piotr 
Sobolewski 
Portugal 
Centro Hospitalar de Trás-os-Montes e Alto Douro: Dr Mário Silva 
Sweden 
Danderyds Sjukhus: Dr Veronica Murray 
Hassleholm Hospital:  Dr Magnus Esbjornsson 
University Hospital of Northern Sweden: Prof Per Wester 
Uppsala University Hospital: Dr Erik Lundström 
Switzerland 
Universitätsspital Basel: Prof Philippe Lyrer 
Universitätsspital Zürich: Prof Andreas Luft 
United Kingdom 
Addenbrookes Hospital: Dr Liz Warburton 
City Hospital, Sandwell & West Birmingham Hospitals NHS Trust: Dr David 
Nicholl 
Countess of Chester Hospital: Dr K Chatterjee 
Guy's & St.Thomas' Hospital: Prof Anthony Rudd 
Hammersmith Hospitals & Imperial College: Dr Pankaj Sharma  
King's College Hospital: Professor Lalit Kalra 
Leeds General Infirmary: Dr Ahamad Hassan 
Norfolk and Norwich University Hospital NHS Trust: Dr Kneale Metcalf 
Nottingham City Hospital: Dr Wayne Sunman 
Queen Elizabeth the Queen Mother Hospital: Dr Gunaratnam Gunathilagan 
Queen's Hospital, Barking, Havering & Redbridge Hospitals NHS Trust: Dr Khaled 
Darawil 
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Royal Hallamshire Hospital: Prof Graham Venables 
Southend University Hospital: Dr Paul Guyler 
St George's Healthcare NHS Trust: Dr Geoffrey Cloud 
The National Hospital for Neurology & Neurosurgery: Prof Martin Brown 
The Royal London Hospital, Barts and The London NHS Trust: Dr Patrick Gompertz 
University Hospital Aintree: Dr Ramesh Durairaj 
University Hospital of North Staffordshire: Prof Christine Roffe 
University Hospitals Coventry & Warwickshire NHS Trust: Dr Anthony Kenton 
Western General Hospital: Prof Peter Sandercock 
William Harvey Hospital: Dr David Hargroves.  
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11.2 Appendix 2 - Funding for IST-3 
 
The start-up phase of IST-3 was supported by a grant from the Stroke Association, 
UK (TSA 04/99). The expansion phase was funded by the Health Foundation UK 
(2268/1282). The scan reading development was funded by Chest, Heart Stroke 
Scotland (R100/7).  
The main phase of the trial is funded by: UK Medical Research Council (MRC) 
(grant numbers G0400069 and EME 09-800-15) and managed by NIHR on behalf of 
the MRC-NIHR partnership; the Research Council of Norway; Arbetsmarknadens 
Partners Forsakringsbolag (AFA) Insurances Sweden; the Swedish Heart Lung Fund; 
The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council; 
Karolinska Institute Joint ALF-project grants Sweden, the Polish Ministry of Science 
and Education (grant number 2PO5B10928); the Australian Heart Foundation; 
Australian National Health and Medical Research Council (NHMRC);  the Swiss 
National Research Foundation; the Swiss Heart Foundation; the Foundation for 
Health and Cardio-/Neurovascular Research, Basel, Switzerland; the Assessorato alla 
Sanita, Regione dell'Umbria, Italy; and,  Danube University, Krems, Austria.  
Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the 
double-blind phase, but thereafter had no role whatsoever in the trial.   
The UK Stroke Research Network (SRN study ID 2135) adopted the trial in 
01/05/2006, supported the initiation of new UK sites, and in some centres, and, after 
that date, data collection was undertaken by staff funded by the network or working 
for associated NHS organisations.   
IST-3 gratefully acknowledges the extensive support of the NIHR Stroke Research 
Network, NHS Research Scotland (NRS), through the Scottish Stroke Research 
Network, and the National Institute for Social Care and Health Research Clinical 
Research Centre (NISCHR CRC).  
The central imaging work was undertaken at the Brain Imaging Research Centre 
(www.bric.ed.ac.uk), a member of the Scottish Imaging Network A Platform for 
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Scientific Excellence (SINAPSE) collaboration (www.sinapse.ac.uk), at the Division 
of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the 
Scottish Funding Council (SFC) and the Chief Scientist Office of the Scottish 
Executive (CSO).  
Additional support was received from Chest Heart and Stroke Scotland, DesAcc, 
University of Edinburgh, Danderyd Hospital R&D Department, Karolinska Institutet, 
Oslo University Hospital, and the Dalhousie University Internal Medicine Research 
Fund. 
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11.3 Articles Published in Peer Reviewed Journals 
 
All of the following articles are derived directly from work contained within this 
thesis. 
 
11.3.1 Appendix 3 - Article 1 
Mair G and Wardlaw JM. 
Imaging of acute stroke prior to treatment: Current practice and evolving techniques. 
British Journal of Radiology 2014;87:20140216. 
Accepted for publication on the 16
th
 June 2014. 
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11.3.2 Appendix 4 - Article 2 
Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, 
Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PAG, Lindley RI and Wardlaw 
JM for the IST-3 Collaborative Group.  
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic 
stroke.  
Neurology 2016;86:1-8. 
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11.3.3 Appendix 5 - Article 3 
Mair G, von Kummer R, Lindley RI, Sandercock PAG, Wardlaw JM.  
Effect of X-ray attenuation of arterial obstructions on intravenous thrombolysis and 
outcome after ischemic stroke.  
PLOS ONE 2015;10:e0145683. 
Accepted for publication on the 7
th
 December 2015. 
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11.3.4 Appendix 6 - Article 4 
Mair G, Boyd EV, Chappell FM, von Kummer R, Lindley RI, Sandercock P, 
Wardlaw JM, The IST-3 Collaborative Group.  
Sensitivity and specificity of the hyperdense artery sign for arterial obstruction in 
acute ischemic stroke.  
Stroke 2015;46:102-7. 
Accepted for publication on the 30
th
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11.3.5 Appendix 7 - Article 5 
Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B, Demchuk AM, 
Farrall AJ, Sellar RJ, Ramaswamy R, Mollison D, Boyd EV, Rodrigues MA, Samji 
K, Baird AJ, Cohen G, Sakka E, Palmer J, Perry D, Lindley R, Sandercock PAG, 
Wardlaw JM, The IST-3 Collaborative Group.  
Observer reliability of CT angiography in the assessment of acute ischaemic stroke: 
data from the Third International Stroke Trial.  
Neuroradiology 2015;57:1–9. 
Accepted for publication on the 22
nd
 September 2014. 
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11.3.6 Appendix 8 - Article 6 
Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B, Demchuk AM, 
Farrall AJ, Sellar RJ, Sakka E, Palmer J, Perry D, Lindley RI, Sandercock PAG and 
Wardlaw JM and for the IST-3 Collaborative Group. 
Arterial Obstruction on Computed Tomographic or Magnetic Resonance 
Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke. 
Stroke 2017;48:353-360. 
Accepted for publication on the 11
th
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11.4 Data Collection Forms 
 
11.4.1 Appendix 9 - CT rating form for IST-3 
The following form was developed by the IST-3 Chief Investigators, but primarily 
Joanna Wardlaw, and was used for assessing all CT brain imaging collected for 
patients included in the angiography and perfusion imaging substudies of IST-3.  
The questions on this form were replicated exactly within the SIRS-2 imaging 
analysis platform.   
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11.4.2 Appendix 10 - MRI rating form for IST-3 
The following form was developed by the IST-3 Chief Investigators, but primarily 
Joanna Wardlaw, and was used for assessing all MR brain imaging collected for 
patients included in the angiography and perfusion imaging substudies of IST-3.  
The questions on this form were replicated exactly within the SIRS-2 imaging 
analysis platform.   
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11.4.3 Appendix 11 - Spreadsheet for HAS and 
angiography assessment 
This spreadsheet was developed by me and was derived from the pre-validated IST-3 
CT rating form (see Appendix 9) but additionally includes sections for recording 
intra-arterial attenuation measurements. 
Patient/ Scan Details 
Patient ID  
Date & time of scan  
Date of reading  
Scan quality  
Normal or abnormal?  
Ischaemia/ Infarct 
Acute ischaemia?  
Side of affected brain  
IST-3 ischaemia score  
Mass effect  
ASPECTS  
Old infarcts?  
IST-3 ischaemia score for 
old infarcts 
 







Basilar 1  
Basilar 2  
Basilar 3  
Left MCA 1  
Left MCA 2  
Left MCA 3  
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Right MCA 1  
Right MCA 2  
Right MCA 3  
Angiography 
CTA or MRA?  
Abnormality on angio?  
Matching HAS location?  
Largest artery affected  
Middle artery  
Smallest artery  
TICI score  
IST-3 angiography score  
Clot Burden Score  
Collateral status  
Intra-arterial attenuation 
measures (2) – if CTA 
abnormal but no HAS 
Measure 1  
Measure 2  
Measure 3  
Follow-up scans  
As above, plus: 
Time interval  
Clearance of HAS?  
Haemorrhage?  
Size of haemorrhage  
Type of haemorrhage  




Footnote: ASPECTS = Alberta Stroke Program Early CT Score. MCA = middle cerebral artery. TICI 
= Thrombolysis in Cerebral Infarct. All variables were scored as per IST-3 image rating forms (see 
Appendices 9 & 10, Chapters 11.4.1 and 11.4.2).   
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11.4.4 Appendix 12 – Spreadsheet for HAS sensitivity 
and specificity meta-analysis 
This spreadsheet was developed by me, Joanna Wardlaw and Elena Boyd based on 
the inclusion criteria and main areas of interest in the systematic review of HAS 







CT slice thickness  
Angio type  
Totals 
Angio total (n)  
HAS total (n)  
Abnormal angio (n)  
HAS Accuracy 
True Positive  
True Negative  
False Positive  
False Negative  






1 segment  
2 or more segments  
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NOTES FOR COMPLETION 
CT SLICE THICKNESS - should relate to non-contrast scan on which hyperdense 
arteries were assessed 
ANGIO TYPE - CTA, MRA or catheter 
ANGIO TOTAL - all patients in article who had angiography 
HYPERDENSE TOTAL - all patients in article who had a hyperdense artery (in any 
intracranial location - i.e. group MCA mainstem and sylvian branches into one total) 
ABNORMAL ANGIO - i.e. 'occlusion', if abnormality is graded include all those 
with any luminal narrowing - e.g. group TICI 0,1,2a and 2b 
TRUE POS - from the total angiography group, number who had hyperdense artery 
and angiographic abnormality 
TRUE NEG - number who had neither hyperdense artery nor angiographic 
abnormality 
FALSE POS - hyperdense artery with normal angiography 
FALSE NEG - no hyperdense artery but angiographic abnormality 
HYPERDENSE LOCATION - number of hyperdense arteries/number of occlusions 
in proximal (ICA, MCA mainstem, vertebral arteries, basilar) and distal (ACA, MCA 
sylvian branch, PCA) vessels 
HYPERDENSE EXTENT - number of hyperdense arteries/number of occlusions 
where 1 or 2+ segments (named vessels as for location) are involved 
TIME FROM ONSET - number of hyperdense arteries/number of occlusions within 
a given time frame.  May need to provide 2 counts, i.e. for those more and those less 
than a given time point (e.g. <180min, >180mins).  
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11.5 Posters Presented at the European Stroke 
Meeting in London 28-31 May 2013  
 
11.5.1 Appendix 13 – Poster 1 
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11.5.2 Appendix 14 – Poster 2 
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11.6 Appendix 15 – Extract from EvidenceUpdates 
 
